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 Summary 
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Summary 
Several members of the Src family of non-receptor protein tyrosine kinases (e.g. Yes), as 
well as Leishmania hydrophilic acylated surface protein B (HASPB) harbor a short 
N-terminal motif called the Src homology 4 (SH4) domain, which undergoes tandem 
modification with the saturated acyl chains myristate and palmitate. SH4 domains are 
responsible for stable anchoring of these otherwise soluble proteins to the cytoplasmic 
leaflet of cellular membranes, mediate their targeting to the plasma membrane, and 
moreover, confer affinity for cholesterol- and sphingolipid-enriched membrane 
microdomains, that is lipid rafts. N-terminal myristoylation occurs in the cytosol, 
concurrently with translation of the protein, and is a prerequisite for subsequent 
palmitoylation. The latter is thought to occur at perinuclear (most probably Golgi) 
membranes. It has been hypothesized that doubly acylated SH4 domain proteins 
partition into lipid rafts soon after being palmitoylated at the Golgi, and that these 
microdomains are necessary for the transport of SH4 proteins to the plasma membrane, 
by playing a role in their sorting and/or formation of transport carriers at the trans-Golgi 
network.  
 
The aim of the first part of this study was to characterize membrane (both lipid and 
protein) environment of diacylated SH4 domain proteins residing in lipid rafts. The 
approach was to analyze lipid and protein components of immunoaffinity-purified 
detergent-resistant membranes (DRMs) containing SH4 domain reporter fusion proteins. 
DRMs immunoisolated using a HASPB SH4 domain fusion protein as bait differed in lipid 
composition from the total DRM pool, being enriched in sphingomyelin, and depleted in 
phosphatidylcholine and phosphatidylethanolamine, and therefore seem to be a subset 
of total DRMs. This may suggest that in vivo, the protein associates with a specific subset 
of lipid rafts, thus indicating that the heterogeneity of lipid rafts can be appreciated also 
using the detergent method. Our immunoaffinity purification approach seemed to 
enrich for bona fide raft proteins, as suggested by an increase compared to total DRMs 
in the proportion of plasma membrane and lipid-anchored proteins, as well as proteins 
whose association with DRMs is sensitive to cholesterol depletion. We estimated 
relative amounts of proteins in immunoisolated SH4 DRMs and total DRMs, with the use 
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of label-free mass spectrometry-based quantification, which was validated for a subset 
of proteins by quantitative Western blotting. We could observe a lack of enrichment of 
endogenous Yes kinase in immunoisolated SH4 DRMs, which may indicate that the 
identity of lipid rafts into which SH4 domain proteins partition, is determined not only 
by the dual fatty acylation with myristate and palmitate, but also by interactions 
conferred by domains distal from the SH4 domain.  
 
In the second part of this study, we intended to investigate the previously reported role 
of the COPI coatomer complex, as well as of the secretory pathway in general, in the 
plasma membrane transport of diacylated SH4 domain proteins. Conditions that 
disrupted the structure and function of the Golgi apparatus, i.e. siRNA-mediated 
knockdown of the β subunit of the COPI complex, expression of constitutively active 
mutant (Q71L) of the small GTPase Arf1, as well as brefeldin A treatment, resulted in 
increased intracellular accumulation of a HASPB SH4 fluorescent fusion protein, pointing 
out to the role of the Golgi in its transport to the plasma membrane. None of the above 
treatments, however, blocked the appearance of the SH4 reporter protein at the plasma 
membrane, suggesting the existence of an alternative trafficking pathway that does not 
require the Golgi complex. 
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Zusammenfassung 
Mehrere Mitglieder der Src-Familie der Nicht-Rezeptor-Tyrosinkinasen (z.B. Yes), wie 
auch das hydrophile acylierte Oberflächenprotein B (HASPB) von Leishmania besitzen 
ein kurzes aminoterminales Motiv, die Src-Homologiedomäne 4 (SH4), die mit den 
beiden gesättigten Acylketten Myristinsäure und Palmitinsäure modifiziert ist. 
SH4-Domänen sind für die stabile Verankerung dieser ansonsten löslichen Proteine in 
der zytoplasmatischen Lipidschicht zellulärer Membranen verantwortlich, bewirken den 
gerichteten Transport zur Plasmamembran und vermitteln Affinität zu mit Cholesterin 
und Sphingolipid angereicherten Membranmikrodomänen, den sogenannten „lipid 
rafts“. Aminoterminale Myristoylierung geschieht während der Translation im Zytosol 
und ist Voraussetzung für die nachfolgende Palmitoylierung an perinukleären 
Membranen (wahrscheinlich am Golgi-Apparat). Vermutlich segregieren diacylierte 
SH4-Domäne-Proteine sofort nach der Palmitoylierung noch am Golgi in „lipid rafts“. 
Diese Mikrodomänen sind wahrscheinlich für den Transport der SH4-Proteine zur 
Plasmamembran verantwortlich, wobei sie eine Rolle beim Sortieren und/oder der 
Bildung von Transportmodulen am trans-Golgi-Netzwerk spielen. 
 
Das Ziel des ersten Teils dieser Arbeit war die Charakterisierung der Membranumgebung 
(Lipide und Proteine) von in „lipid rafts“ residierenden diacylierten SH4-Domäne-
Proteinen. Der experimentelle Ansatz bestand in der Analyse von Lipid- und 
Proteinkomponenten immunaffinitätsgereinigter detergensresistenter Membranen 
(DRMs), welche SH4-Domäne-Reporter-Fusionsproteine enthalten. Die mittels des 
HASPB SH4-Fusionsproteins immunaffinitätsgereinigten DRMs unterschieden sich 
hinsichtlich ihrer Lipidzusammensetzung von der DRM-Ausgangszusammensetzung 
dahingehend, dass sie Sphingomyelin-angereichert und Phosphatidylcholin- sowie 
Phosphatidylethanolamin-abgereichert waren. Dies deutet darauf hin, dass das Protein 
in vivo mit einer spezifischen „lipid raft“ Subpopulation assoziiert ist, was 
wiederum darauf schließen lässt, dass die Heterogenität von „lipid rafts“ mit der 
Detergens-Methode abgebildet werden kann. Unser Immunaffinitätsreinigungsansatz 
führt offensichtlich zur Anreicherung von bona fide Raft-Proteinen, da im Vergleich zu 
gesamt-DRMs der Anteil von Plasmamembran- und Lipidanker-Proteinen anstieg, wie 
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auch von Proteinen deren Assoziierung mit DRMs gegen Cholesterin-Abreicherung 
empfindlich ist. Wir bestimmten die relativen Proteinmengen in gesamt-DRMs und in 
immungereinigten SH4-DRMs mittels markierungsfreier Massenspektrometrie-basierter 
Quantifizierung. Diese Ergebnisse wurden für eine Reihe ausgewählter Proteine mittels 
quantitativem Western Blot validiert. Wir sahen allerdings keine Anreicherung 
endogener Yes Kinase in immungereinigten SH4-DRMs. Das mag daran liegen, dass die 
Identität von „lipid rafts“, in welche die SH4-Domäne-Proteine segregieren, nicht nur 
durch die duale Fettsäureacylierung mit Myristat und Palmitat bestimmt wird, sondern 
auch durch Interaktionen, welche von Domänen distal von den SH4-Domänen vermittelt 
werden. 
 
Im zweiten Teil dieser Arbeit wollten wir die Rolle des COPI-Coatomer-Komplexes, sowie 
des sekretorischen Weges im Allgemeinen beim Plasmamembrantransport diacylierter 
SH4-Domäne-Proteine studieren. Bedingungen die zur Zerstörung von Struktur und 
Funktion des Golgi-Apparates führten, d. h. siRNA-vermitteltes Knockdown der 
β-Untereinheit des COPI-Komplexes oder Expression der konstitutiv aktiven (Q71L) 
Mutante der kleinen GTPase Arf1, wie auch die Behandlung mit brefeldin A, führten zur 
intrazellulären Anhäufung des fluoreszierenden HASPB SH4-Fusionsproteins, was auf 
eine Rolle des Golgi-Apparates beim Transport zur Plasmamembran hinweist. Allerdings 
konnte mit keiner dieser Behandlungen das Auftauchen des SH4-Reporterproteins an 
der Plasmamembran blockiert werden, was auf alternative, Golgi-Komplex-unabhängige 
Transportwege hindeutet. 
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1 Introduction 
1.1 The secretory pathway 
All eukaryotic cells use the secretory pathway for synthesizing and sorting proteins 
destined for secretion or membrane insertion. In mammalian cells, most of the proteins 
are targeted to the endoplasmic reticulum (ER) cotranslationally (Jungnickel et al., 
1994). During synthesis of a secretory protein on free ribosomes in the cytosol, an 
N-terminal 7- to 20-residue hydrophobic ER signal sequence (Schatz et al., 1996), as 
soon as it emerges from the ribosome, is recognized by the signal recognition particle 
(SRP). SRP is a complex of six proteins and an RNA, which binds not only to the ER signal 
sequence, but also to the ribosome, leading to arrest of polypeptide chain elongation 
(Walter et al., 1994; Halic et al., 2005). SRP targets the ribosome/nascent chain complex 
to the ER membrane by interaction with the SRP receptor (SR), a heterodimer formed by 
an SRα, and a smaller SRβ subunit. Formation of the SRP/SR complex requires GTP 
binding to both SRP and SR (Rapiejko et al., 1992; Miller et al., 1993). The 
ribosome/nascent chain complex is then transferred to the translocon (the Sec61 
complex), a protein-conducting channel within the ER membrane (Johnson et al., 1999). 
The SRP/SR complex dissociates from the ribosome and upon GTP hydrolysis, SRP is 
released from the SR to the cytosol (Connolly et al., 1991). Translation elongation 
resumes, and the nascent chain passes through the central pore of the translocon into 
the ER lumen, where the signal sequence is cleaved by a transmembrane signal 
peptidase (Dalbey et al., 1992). Afterwards, the polypeptide is released into the ER 
lumen (in the case of secreted proteins, and soluble luminal proteins of the ER, Golgi or 
lysosome) or transferred into the ER membrane (membrane proteins of the ER, Golgi, 
lysosome or the plasma membrane). In the ER, formation and rearrangement of 
disulfide bonds, folding of polypeptide chains and assembly of multimers take place 
(Zapun et al., 1999; Sevier et al., 2002). Moreover, here occurs the attachment and 
initial processing of N-linked glycans (Kornfeld et al., 1985). Export of newly synthesized 
proteins from the ER is mediated by COPII vesicles (Lee et al., 2004; Hughes et al., 2008). 
In mammalian cells, COPII vesicles fuse with each other, generating the vesicular-tubular 
clusters (VTCs), also known as the ER-Golgi intermediate compartment (ERGIC). ERGIC is 
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subsequently delivered in a microtubule-dependent manner to the cis-side of the Golgi 
apparatus (Klumperman, 2000; Duden, 2003). Retrograde transport from the 
cis-Golgi/ERGIC back to the ER is mediated by COPI vesicles (Barlowe, 2000; Lee et al., 
2004). 
 
Formation of coated vesicles is initiated through activation of small GTP-binding 
proteins, Sar1 for COPII and ADP-ribosylation factor 1 (Arf1) for COPI vesicles (Barlowe, 
2000; Lee et al., 2004). Both proteins cycle between inactive GDP-bound cytosolic and 
active GTP-bound membrane-associated forms. The exchange of bound GDP for GTP is 
catalyzed by guanine nucleotide exchange factors (GEFs). Upon exchange of bound GDP 
for GTP, catalyzed by an ER membrane GEF Sec12, Sar1 exposes an N-terminal 
amphipathic α-helix, which inserts into the lipid bilayer (Bielli et al., 2005). 
Membrane-associated Sar1 recruits the Sec23/Sec24 heterodimeric coat complex. Sec24 
interacts with transmembrane cargo proteins carrying di-acidic or 
di-hydrophobic/di-aromatic sorting signals in their cytoplasmic domains (Barlowe, 
2003). Subsequently, the heterotetrameric Sec13/Sec31 coat complex is recruited, 
which is responsible for coat polymerization and membrane deformation, yielding a 
COPII vesicle (Lee et al., 2004; Hughes et al., 2008). Upon budding, Sec23 acts as the 
GTPase-activating protein (GAP) for Sar1, stimulating Sar1-mediated GTP hydrolysis, 
which results in uncoating of vesicles (Duden, 2003). COPI coat formation is initiated by 
the exchange of bound GDP for GTP on Arf1, catalyzed by an Arf GEF. GBF1 is the GEF 
involved in COPI vesicle biogenesis at the cis-Golgi/ERGIC (Zhao et al., 2002). GTP 
binding by Arf1 exposes its myristoylated N-terminal amphipathic α-helix that provides 
stable membrane anchorage (Antonny et al., 1997). Membrane-associated Arf1 recruits 
the heptameric COPI coatomer complex, composed of α, β, β′, γ, δ, ε and ζ subunits 
(Palmer et al., 1993). This recruitment seems to be assisted by members of the p24 
family membrane proteins, which bind directly to coatomer, stimulating vesicle 
formation (Bremser et al., 1999). Uptake of cargo membrane proteins into COPI vesicles 
involves a direct interaction of di-lysine or arginine-based sorting signals on their 
cytoplasmic domains with subunits of the COPI coat, whereas soluble ER-resident 
proteins contain a C-terminal KDEL sequence, recognized by transmembrane adaptors, 
KDEL receptors, which in turn harbor a di-lysine motif (Beck et al., 2009; Popoff et al., 
 Introduction 
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2011). Recruitment of cargo by COPI vesicles was proposed to be regulated by a cycle of 
GTP exchange on Arf1 and Arf1-mediated GTP hydrolysis stimulated by Arf 
GTPase-activating proteins, Arf GAPs (Malsam et al., 1999; Pepperkok et al., 2000). 
Fusion of COPI vesicles with the target compartment requires uncoating, which also 
depends on GTP hydrolysis by Arf1 (Tanigawa et al., 1993). 
 
Delivery of secretory proteins to the cis-side of the Golgi apparatus is followed by their 
passage across the Golgi stack of cisternae, which contains enzymes involved in 
sequential processing of oligosaccharide chains on glycoproteins, and in proteolytic 
cleavage (Mellman et al., 2000). The favored model of anterograde intra-Golgi transport 
is the cisternal maturation and progression (Glick et al., 1998). It assumes that new 
cisternae form at the cis-Golgi, progress through the stack carrying anterograde cargo, 
and disassemble at the trans-Golgi. The cisternae would mature by retrograde transport 
of Golgi-resident proteins mediated by COPI vesicles. However, current evidence 
suggests that COPI vesicles may mediate also anterograde cargo transport between 
Golgi cisternae (Orci et al., 1997). Proteins are exported from the trans-Golgi network 
(TGN), a tubular network that emanates from the last two trans-Golgi cisternae (De 
Matteis et al., 2008). The TGN is the main sorting hub in the secretory pathway (Griffiths 
et al., 1986) that segregates cargo molecules into distinct pleomorphic tubular-vesicular 
carriers targeted to different compartments: the plasma membrane (apical or 
basolateral in polarized cells), or the endolysosomal compartment. In addition, the TGN 
receives traffic from the endosomal system (De Matteis et al., 2008). The first step in the 
formation of pleomorphic carriers is segregation of cargo molecules into distinct tubular 
TGN export domains, which is followed by their elongation along microtubules with the 
help of microtubule motors kinesins. The subsequent fission of the tubules is facilitated 
by the pulling force exerted by kinesins. Other proteins known to be involved in fission 
are dynamin-2, protein kinase D (PKD), and brefeldin A-ribosylated substrate (BARS) (De 
Matteis et al., 2008; Anitei et al., 2011). Apical sorting relies on the presence of N- or 
O-linked glycans, special properties of the transmembrane domain, or on the presence 
of the glycosyl-phosphatidylinositol (GPI) anchor, together with the ability of the protein 
to oligomerize (Schuck et al., 2004; Fölsch, 2008). The apical sorting signals act mainly by 
promoting the incorporation into clustered lipid rafts (Schuck et al., 2004; Schuck et al., 
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2006; see also sections 1.3.4 and 1.4.1). Until now there has been no evidence for an 
involvement of coat proteins in apical transport (Anitei et al., 2011). Basolateral and 
endosomal sorting depends on tyrosine-based or di-leucine-based motifs in the 
cytoplasmic domains of transmembrane cargo proteins, which are recognized by 
heterotetrameric adaptor protein complexes (APs) or by monomeric Golgi-localized, 
γ-ear-containing, Arf-binding proteins (GGAs), which (in most cases) bind clathrin, thus 
acting as adaptors for clathrin coats (De Matteis et al., 2008; Anitei et al., 2011). 
Recruitment of both APs and GGAs is promoted by Arf1-GTP (De Matteis et al., 2008; 
Donaldson et al., 2011). In epithelial cells, transport of basolateral cargo to the plasma 
membrane is mediated by AP-1B/clathrin (operating only at the recycling endosomes) 
and AP-4 coats, most probably supporting an indirect (via recycling endosomes) and a 
direct route to the basolateral plasma membrane, respectively. Sorting to the 
endosomal system is mediated by AP-1A, AP-3 or GGA, which interact with clathrin (De 
Matteis et al., 2008; Anitei et al., 2011). It is worth noting that apical and basolateral 
signals operate also in non-polarized cells, giving rise to different transport routes to the 
plasma membrane (Müsch et al., 1996).  
1.2 Cellular membranes 
Eukaryotic cells are separated from the external environment by the plasma membrane 
and partitioned into membrane-bounded structures (organelles), which 
compartmentalize metabolic functions. Physical properties of membranes are largely 
determined by their lipid components, while the proteins are responsible for the unique 
functions of a particular membrane. All biomembranes have a bilayer structure 
(Robertson, 1981), with polar head groups facing outward and hydrophobic tails forming 
a hydrophobic core, which is impermeable to hydrophilic solutes. The Singer-Nicolson 
fluid-mosaic model of the structure of biological membranes postulated a uniform fluid 
lipid matrix with randomly distributed proteins (Singer et al., 1972). This model has been 
revised to consider lateral heterogeneity of lipids and proteins in the membrane 
resulting from preferential packing of sphingolipids and cholesterol into lipid rafts 
(Simons et al., 1997; see also section 1.3). 
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Membrane proteins can be classified as transmembrane, lipid-anchored or peripheral. 
Transmembrane proteins possess membrane-spanning domains, which consist of one or 
more α-helices or of multiple β-strands. Lipid-anchored proteins are attached to one 
leaflet of the bilayer via covalently-bound lipid molecules (Levental et al., 2010a; see 
also section 1.4). And finally, peripheral proteins associate with membranes by 
noncovalent interactions with other membrane proteins or with the head groups of 
membrane lipids. 
 
Biological membranes are composed of three major classes of lipids: 
glycerophospholipids, sphingolipids and sterols (Holthuis et al., 2005). 
Glycerophospholipids are based on glycerol 3-phosphate, with two fatty acid chains 
esterified to its two hydroxyl groups, and a polar head group esterified to the phosphate 
group. The fatty acid chains commonly contain 16 or 18 carbons, and 0, 1 or 2 cis-double 
bonds. The head group can be either neutral (yielding phosphatidylserine (PS) or 
phosphatidylinositol (PI), and giving a net negative charge) or basic (forming 
phosphatidylcholine (PC) or phosphatidylethanolamine (PE), which carry no net charge). 
Sphingolipids are derivatives of a C18-C20 amino alcohol (C18 sphingosine in animals), 
containing a C16-C26 saturated fatty acid attached to the amine group through an 
amide bond (which forms ceramide (Cer)). In animals, the sphingolipid head group 
attached to the terminal hydroxyl group of sphingosine can be phosphocholine (yielding 
sphingomyelin (SM)), or in the case of glycosphingolipids, glucose or galactose (yielding 
glucosylceramide (GlcCer) and galactosylceramide (GalCer), respectively), to which 
further monosaccharides can be attached. Sterols (cholesterol in animals) contain a 
planar four-ring carbon structure, with a hydroxyl group on one ring (Holthuis et al., 
2005). Synthesis of major glycerophospholipids (PC, PE, PS and PI) takes place on the 
cytosolic face of the ER membrane (Sprong et al., 2001; Blom et al., 2011). Ceramide, 
the common precursor of mammalian sphingolipids, is synthesized on the cytosolic face 
of the ER (Blom et al., 2011), and then converted into SM on the luminal (exoplasmic) 
face of the trans-Golgi, or to GlcCer on the cytosolic face of the cis-Golgi. GlcCer is then 
translocated to the exoplasmic leaflet to be converted into complex glycosphingolipids 
in the lumen of distal Golgi compartments (De Matteis et al., 2008; Blom et al., 2011). 
The main site of cholesterol synthesis is the ER (Blom et al., 2011). 
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The ER membrane is composed mainly of glycerophospholipids. For example, the ER 
membrane of rat liver contains 50-60 mol% PC, 25 mol% PE, 10 mol% PI, and 5 mol% 
cholesterol (Holthuis et al., 2005). The transbilayer lipid distribution in the ER membrane 
is nearly symmetric, as a result of equilibration of newly synthesized 
glycerophospholipids between leaflets, catalyzed by scramblase, an energy-independent 
transporter (Daleke, 2003). The lipid composition changes gradually along the secretory 
pathway to that of the plasma membrane, with cholesterol and sphingolipids being 
gradually enriched (Holthuis et al., 2005). For example, the plasma membrane of rat 
liver contains 30-40 mol% cholesterol, 25 mol% PC, 15 mol% PE, 10-15 mol% 
sphingolipids, 5 mol% PS, and 5 mol% PI (Holthuis et al., 2005). In addition, the 
distribution of lipids in the plasma membrane is highly asymmetric: PC, SM and 
glycosphingolipids are enriched primarily in the exoplasmic leaflet, whereas PE, PS and 
PI are preferentially located in the cytoplasmic leaflet (Sprong et al., 2001; Daleke, 
2003). Minor phospholipids, such as phosphatidic acid (PA), phosphatidylinositol-4-
monophosphate (PIP) and phosphatidylinositol-4,5-bisphosphate (PIP2) are enriched 
also in the cytoplasmic leaflet of the plasma membrane. The transbilayer distribution of 
cholesterol is not known (Sprong et al., 2001; Daleke, 2003). The asymmetric 
distribution of PS and PE is maintained by an aminophospholipid flippase, which 
translocates these lipids from the outer to the inner leaflet of the plasma membrane in 
an ATP-dependent manner (Daleke, 2003). During platelet activation and apoptosis, the 
distribution of plasma membrane phospholipids is randomized by a nonspecific 
Ca2+-activated scramblase, resulting in the exposure of PS at the exoplasmic leaflet, 
which activates enzymes participating in blood clotting and functions as a signal for 
phagocytosis of apoptotic cells by macrophages (Daleke, 2003).  
1.3 Lipid rafts 
1.3.1 The concept of lipid rafts 
The lipid raft concept was introduced to explain the preferential apical delivery of newly 
synthesized glycosphingolipids in epithelial Madin-Darby canine kidney (MDCK) cells 
(Simons et al., 1988). It was proposed that glycosphingolipids form clusters in the 
exoplasmic leaflet of the trans-Golgi network, which is followed by inclusion of newly 
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synthesized apical proteins, and transport of both in common carrier vesicles to the 
apical surface. Over the years, the proposed roles for lipid rafts were expanded to 
include the involvement in various aspects of intracellular trafficking of lipids and 
proteins, cell signaling, immune response and the entry of viruses and toxins (Simons et 
al., 1997; Simons et al., 2010). A recently adopted definition of lipid rafts describes them 
as: ‘small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-
enriched domains that compartmentalize cellular processes; small rafts can sometimes 
be stabilized to form larger platforms through protein-protein and protein-lipid 
interactions’ (Pike, 2006). 
1.3.2 Detergent insolubility 
It has long been known that some membrane components, such as 
glycosyl-phosphatidylinositol (GPI)-anchored proteins (Vitetta et al., 1973; Hooper et al., 
1988), as well as sphingomyelin and glycosphingolipids (Yu et al., 1973; Hagmann et al., 
1982), are not solubilized by nonionic detergents, for example Triton X-100. Later, a 
GPI-anchored protein, placental alkaline phosphatase (PLAP), was found to become 
insoluble in Triton X-100 in the Golgi complex during its biosynthetic transport to the 
apical surface of MDCK cells (Brown et al., 1992). The insoluble fraction that contained 
PLAP floated to low density during centrifugation on sucrose density gradients, and was 
enriched in cholesterol and sphingolipids, leading to the concept of detergent-insoluble, 
cholesterol- and sphingolipid-rich membrane domains (rafts). 
 
In model membranes containing high fractions of cholesterol, the cholesterol-poor 
liquid-disordered (ld) phase can coexist with the cholesterol-dependent liquid-ordered 
(lo) phase (Ipsen et al., 1987; Ahmed et al., 1997). Lipid acyl chains in the former phase 
are kinked and loosely packed, whereas in the latter, tightly packed and highly extended. 
In both phases the lipid molecules exhibit high degree of lateral diffusion (Simons et al., 
2004). Model membranes in the lo state were shown to be completely detergent 
insoluble (Schroeder et al., 1994). Furthermore, the detergent insolubility of cholesterol-
containing model membranes correlated well with the amount of the lo phase, as 
detected by fluorescence quenching (Ahmed et al., 1997). Consequently, the detergent 
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insolubility of the cholesterol- and sphingolipid-rich membrane domains was attributed 
to their existence in the lo state (London et al., 2000). 
 
Isolation of detergent-resistant membranes (DRMs) became the most widely used 
method for the identification of lipid raft components, its usefulness being confirmed by 
the fact that most proteins that have a substantial fraction in DRMs associate with rafts 
also when analyzed by other methods (Simons et al., 2004). Extraction of cells or 
isolated membranes with nonionic detergent on ice is followed by equilibrium density 
gradient centrifugation, usually in sucrose or OptiPrep gradients, during which DRMs, 
due to high lipid/protein ratio, float to low density (Brown et al., 1992; Schuck et al., 
2003). A comprehensive proteomic analysis of DRMs isolated from HeLa cells was 
performed by Mann and co-workers (Foster et al., 2003). Here, the isolation of Triton 
X-100 DRMs was combined with treatment with the cholesterol-extracting drug, 
methyl-β-cyclodextrin (MβCD), and a SILAC (stable isotope labeling with amino acids in 
cell culture)-based quantitative proteomic approach. As a result, 154 proteins were 
identified whose presence in DRM fractions was highly sensitive to cholesterol depletion 
by MβCD, and termed as ‘raft proteins’. Moreover, 92 proteins exhibited medium 
sensitivity to MβCD, and were referred to as ‘raft-associated proteins’. There was also a 
group of proteins whose presence in DRMs was not drastically affected by cholesterol 
depletion, denoted as nonspecific (i.e. non-raft) proteins. 
1.3.3 Phase separation in model and plasma membranes 
Model monolayers and bilayers mimicking the composition of the outer leaflet of the 
plasma membrane can phase separate into microscopically observable lo and ld domains 
(Dietrich et al., 2001a; Dietrich et al., 2001b). Sphingomyelin preferably partitions with 
cholesterol into lo phase domains, segregating from phosphatidylcholine, the main 
component of ld phase domains (Simons et al., 2004). Recent studies showed that 
microscopic phase separation into two liquid domains can be induced also in 
membranes containing native lipids and proteins. Plasma membrane blebs produced by 
cells upon treatment with N-ethylmaleimide or with formaldehyde and DTT, so-called 
giant plasma membrane vesicles (GPMVs), were induced to phase separate into lo-like 
and ld-like phases, when cooled below room temperature (Baumgart et al., 2007). 
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Similarly, plasma membrane spheres (PMS) produced using a cell-swelling procedure, 
separated into large-scale domains at 37°C, upon crosslinking of the raft ganglioside 
GM1 with pentavalent cholera toxin B subunit (Lingwood et al., 2008). Those results 
suggest that plasma membranes exhibit liquid-liquid immiscibility, and thus coexistence 
of domains in different (lo and ld) phase states. The nanoscale lo domains (rafts) can be 
induced to coalesce into large-scale domains. Such domains, formed as a result of 
incubation of live cells with primary antibodies against PLAP (which is embedded via its 
GPI-anchor in the outer leaflet of the plasma membrane), followed by crosslinking with 
secondary antibodies, were shown to accumulate the Src family kinase Fyn, which is 
attached via its acylations to the inner leaflet (Harder et al., 1998). This indicates that 
rafts exist in both the outer and the inner leaflet of the plasma membrane, with a 
transbilayer coupling between them. This coupling between the leaflets was proposed 
to be mediated by transmembrane raft proteins or by the interdigitation of long fatty 
acid chains of sphingolipids with the cytoplasmic leaflet of the bilayer (Simons et al., 
1997; Simons et al., 2004). The preferential packing of sphingomyelin and cholesterol 
can explain only the formation of lo phase domains in the outer leaflet of the bilayer, as 
sphingolipids are almost absent from the inner leaflet of cellular membranes. Studies 
using asymmetric planar bilayers demonstrate, however, that the formation of lo phase 
domains in a phosphatidylethanolamine and phosphatidylserine-containing leaflet can 
be induced by lo phase domains in the opposite leaflet (Kiessling et al., 2006), suggesting 
that lipid rafts in the outer leaflet of the plasma membrane could induce the formation 
of ordered lipid domains in the inner leaflet. 
1.3.4 Role of lipid rafts in post-Golgi trafficking 
Post-Golgi transport vesicles carrying a transmembrane raft protein, immunoisolated 
from the yeast Saccharomyces cerevisiae, were found to be enriched in ergosterol (the 
major yeast sterol) and sphingolipids, and to exhibit a higher membrane order, as 
compared to the donor organelle (Klemm et al., 2009). Thus, it was directly shown for 
the first time that the trans-Golgi network (TGN) is able to sort membrane lipids, as 
hypothesized from the study on apical transport in epithelial cells that introduced the 
concept of lipid rafts (Simons et al., 1988). More recently, a more detailed model of 
apical trafficking was put forward (Schuck et al., 2004). Sorting of apical from basolateral 
Introduction 
 
 
14 
cargo was proposed to occur in the TGN and be based on clustering of rafts through the 
oligomerization of raft components and subsequent recruitment of further proteins to 
the clustered rafts. Several proteins were proposed to induce raft clustering at the sites 
where sorting takes place. One such protein might be VIP17/MAL, a raft-associated 
transmembrane protein with the ability to oligomerize, shown to be involved in apical 
transport in polarized MDCK cells (Cheong et al., 1999). The clustering may also be 
induced by annexin-13b and annexin-2, both cytosolic proteins, which preferentially 
associate with cholesterol-rich membranes, have a tendency to oligomerize, and are 
involved in apical trafficking in polarized MDCK cells (Lafont et al., 1998; Jacob et al., 
2004). The galectin family of lectins might cluster rafts by crosslinking of glycoproteins 
and glycolipids, due to their ability to engage in multivalent protein-carbohydrate 
interactions. For example, galectin-4 was shown to associate with DRMs and play a role 
in apical sorting in enterocyte-like HT-29 cells (Delacour et al., 2005; Stechly et al., 
2009). Similarly, galectin-9 was shown to be a critical factor in apical membrane 
biogenesis (Mishra et al., 2010). Raft clustering could also play a role in the generation 
of transport carriers. Growth of the clustered raft domain beyond a critical size should 
result in budding driven by the line tension at the phase boundaries, followed by fission 
and the formation of TGN-derived secretory vesicles strongly enriched in raft 
components (Schuck et al., 2004; Rajendran et al., 2005). It seems that not only in 
epithelial cells, but also in fibroblasts (Yoshimori et al., 1996) and neurons (Ledesma et 
al., 1998), lipid rafts serve as platforms for the delivery of raft-associated cargo to the 
plasma membrane. As most of the proteins identified in epithelial cells as components 
of the apical sorting machinery have tissue-specific distributions, other proteins must 
perform analogous functions in the other cell types (Cheong et al., 1999). 
1.4 Lipid modifications of proteins 
1.4.1 Glycosyl-phosphatidylinositol (GPI) anchor 
Numerous proteins in protozoa, fungi, plants, and animals are attached to the cell 
surface via the glycolipid structure called glycosyl-phosphatidylinositol (GPI) anchor. 
GPI-anchored proteins (GPI-APs) mediate diverse cellular functions, such as adhesion, 
immune signaling, and nutrient uptake (Levental et al., 2010a). All GPI anchors contain 
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an identical backbone, consisting of phosphoethanolamine linked to a glycan comprising 
(mannose)3-glucosamine (Manα1-2Manα1-6Manα1-4GlcNH2), which in turn is linked to 
the position 6 of the myo-inositol ring of phosphatidylinositol (PI) (McConville et al., 
1993; Fujita et al., 2010). The GPI anchor is attached to the C-terminus of a protein via 
phosphoethanolamine. GPI anchors are structurally heterogeneous: the tetrasaccharide 
backbone may be substituted with mannose and/or galactose residues and with an 
additional phosphoethanolamine, the inositol ring can be acylated, and the nature of 
aliphatic chains of the PI is variable (McConville et al., 1993; Fujita et al., 2010). Proteins 
destined to be modified with the GPI anchor contain an N-terminal ER signal sequence, 
and a C-terminal GPI signal sequence, commonly a stretch of 12-20 hydrophobic 
residues (McConville et al., 1993). The GPI is assembled by sequential addition of 
monosaccharides and phosphoethanolamine to PI (McConville et al., 1993; Fujita et al., 
2010). The initial steps of GPI biosynthesis occur on the cytosolic face of the ER 
(Vidugiriene et al., 1993). A biosynthetic intermediate is then flipped into the ER lumen, 
where a complete GPI precursor is synthesized and transferred on the protein, replacing 
the GPI signal sequence in a transamidation reaction (Gerber et al., 1992), and attaching 
the protein to the exoplasmic leaflet through two (sometimes three) acyl or alkyl chains 
of the PI. GPI anchor undergoes lipid and/or glycan remodeling in the ER and Golgi, and 
afterwards the protein is transported to the plasma membrane (Fujita et al., 2010). 
 
GPI anchors act as lipid raft-targeting signals (Levental et al., 2010a). GPI-APs were the 
first proteins found to associate with DRMs (Brown et al., 1992). More recently, they 
were shown to preferentially partition into the lo-like phase in both plasma membrane 
spheres (PMS; Lingwood et al., 2008) and giant plasma membrane vesicles (GPMVs; 
Baumgart et al., 2007; Johnson et al., 2010) with liquid/liquid phase coexistence. 
Moreover, fluorescence resonance energy transfer (FRET)-based experiments revealed 
that GPI-APs are present in nanoscale cholesterol-dependent clusters on the surface of 
living cells (Sharma et al., 2004). GPI anchor was shown to serve as a signal for transport 
to the apical membrane of polarized epithelial cells (Brown et al., 1989; Lisanti et al., 
1989). Later, a GPI-AP was found to become associated with sphingolipid-rich 
detergent-resistant membranes during its transport through the Golgi (Brown et al., 
1992), supporting the model that sphingolipids form transport platforms (rafts) in the 
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Golgi, the association with which is responsible for apical targeting (Simons et al., 1988). 
Subsequently it became clear, however, that raft association is insufficient to direct 
apical targeting. The original model was refined to take into account the requirement for 
oligomerization or lectin-mediated crosslinking of GPI-APs in their association with, and 
possibly also in the formation of, clustered rafts, which then facilitate direct apical 
delivery of their components (Schuck et al., 2004; Schuck et al., 2006; see also section 
1.3.4). 
1.4.2 Prenylation 
Prenylation is a posttranslational modification that involves the attachment of a 
15-carbon farnesyl or a 20-carbon geranylgeranyl isoprenoid to a cysteine residue of the 
target protein via a covalent thioether bond. Modified in this way are, for example, 
many members of the Ras superfamily of small GTPases (Wennerberg et al., 2005). 
Prenylation is catalyzed by a cytosolic prenyltransferase (Casey et al., 1996), and occurs 
at a cysteine located within the C-terminal CaaX box, where ‘a’ is an aliphatic amino 
acid, and ‘X’ is an amino acid that determines whether the prenyl group that is added is 
a farnesyl or a geranylgeranyl isoprenoid. Upon prenylation, the three C-terminal amino 
acids (-aaX) are removed by prenylcysteine endoprotease, and the resulting C-terminal 
prenylated cysteine is carboxyl methylated by a prenylcysteine carboxyl 
methyltransferase. The last two modifications take place at the cytosolic surface of the 
ER (Romano et al., 1998; Schmidt et al., 1998). Cysteine residues immediately upstream 
of the prenylated cysteine can be then palmitoylated, as in the case of H-Ras and N-Ras 
(Hancock et al., 1989). Prenylation provides only weak membrane association, and thus 
a second signal (palmitate or a cluster of basic amino acids) is required for stable 
membrane attachment (Resh, 2006; see also section 1.4.4). It is expected that the bulky 
branched structure of prenyl groups should not fit well into the lo phase of lipid rafts. In 
agreement, peptides dually modified with a palmitoyl and a prenyl group show very low 
affinities for lo domains in model bilayers with coexisting ld and lo phases (Wang et al., 
2001), and DRMs isolated from cells contain few prenylated proteins (Melkonian et al., 
1999). However, it seems that this raft-disfavoring tendency of prenyl groups can be 
overcome, as in the case of doubly palmitoylated H-Ras, which is excluded from rafts in 
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its GTP-bound active state, but raft-associated when in the GDP-bound inactive state 
(Prior et al., 2001). 
1.4.3 Myristoylation 
Protein N-myristoylation refers to the attachment of a 14-carbon saturated fatty acid 
myristate to eukaryotic and viral proteins. Proteins that are destined to become 
myristoylated begin with the sequence: methionine-glycine (Met-Gly). The initiating 
methionine residue is removed cotranslationally by methionine aminopeptidase. 
Myristate is linked to the resulting N-terminal glycine via an irreversible amide bond, 
which also occurs cotranslationally in the cytosol (Wilcox et al., 1987), and is catalyzed 
by N-myristoyltransferase, NMT (Johnson et al., 1994; Farazi et al., 2001). In addition to 
the key glycine, the ability of a protein to be recognized by NMT depends also on other 
N-terminal residues: serine or threonine is preferred at position 6, and lysine or arginine 
at positions 7 and/or 8 (Resh, 1999). 
 
Myristoylation can play a role in stabilizing three-dimensional protein conformation, as 
in the case of the VP4 capsid protein of picornaviruses (Chow et al., 1987), or the 
catalytic subunit of cAMP-dependent protein kinase (Zheng et al., 1993). In the case of 
many cytoplasmic proteins myristoylation provides weak and reversible membrane 
attachment, with a second signal being required for stable anchoring to the lipid bilayer 
(the ‘two-signal hypothesis’; Resh, 1994; Resh, 1999; Resh, 2006). For some proteins, 
stable membrane binding is mediated by myristoylation in combination with an 
N-terminal cluster of basic amino acids that form electrostatic interactions with 
negatively charged phospholipids, primarily PS and PI, enriched in the cytoplasmic 
leaflet of cellular membranes (Resh, 1993; Resh, 1994; Resh, 2006). Examples of such 
proteins include Src kinase (Sigal et al., 1994), HIV-1 Gag and HIV-1 Nef proteins (Zhou et 
al., 1994; Welker et al., 1998), and the myristoylated alanine‐rich C kinase substrate 
(MARCKS; Taniguchi et al., 1993). For endothelial nitric-oxide synthase (eNOS), 
Leishmania hydrophilic acylated surface protein B (HASPB), many α subunits of 
heterotrimeric G proteins, as well as most members of the Src family of protein tyrosine 
kinases, stable membrane attachment is mediated by modification with both myristate 
and palmitate at the N-terminus (Resh, 1994; Resh, 1999; Resh, 2006; see also section 
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1.4.4). Membrane binding of myristoylated proteins can be subject to regulation. Some 
myristoylated proteins exist in two conformations in which the myristoyl chain is either 
sequestered in a hydrophobic pocket within the protein, or exposed and available for 
membrane binding. The trigger for the conformational change can be ligand binding or 
proteolytic cleavage. In the case of GDP-bound Arf1, its myristoylated N-teminal α-helix 
is buried in a hydrophobic pocket, from which it is displaced by GTP binding, which 
results in membrane association of Arf1 (Goldberg, 1998). Proteolytic cleavage of HIV-1 
Gag precursor, Pr55(gag), causes a conformational change that sequesters myristate 
within the proteolytic product, p17MA, resulting in its release from the membrane 
(Hermida-Matsumoto et al., 1999). 
1.4.4 Palmitoylation  
Protein S-palmitoylation involves the attachment of a 16-carbon saturated palmitic acid 
to the sulfhydryl group of cysteine residues of eukaryotic and viral proteins via a 
reversible thioester bond, and takes place posttranslationally in the membrane fraction 
(Paige et al., 1993). There is no clear sequence requirement for palmitoylation other 
than the presence of a cysteine residue (Smotrys et al., 2004). Palmitoylated proteins 
can be categorized into four types (Resh, 1999). Type I consists of membrane proteins 
that are palmitoylated on one or several cysteine residues located close to or within the 
transmembrane domain. This group is exemplified by transferrin receptor, influenza 
hemagglutinin (HA), vesicular stomatitis virus glycoprotein (VSVG), and a large number 
of G protein-coupled receptors (GPCRs). Type II proteins include members of the Ras 
family (H-Ras and N-Ras) that are farnesylated within their C-terminal CaaX box. 
Farnesylation is a prerequisite for subsequent palmitoylation of cysteines in the 
C-terminal region (Hancock et al., 1989). The third group includes proteins palmitoylated 
at cysteine residues near the N- or C-terminus, such as GAP-43 and PSD-95. Type IV 
proteins are dually fatty acylated with myristate and palmitate, and nearly all (apart 
from, for example, eNOS and HASPB) contain the consensus sequence Met-Gly-Cys at 
their N-termini. Myristoylation of glycine 2 is a prerequisite for subsequent 
palmitoylation (Alland et al., 1994; Galbiati et al., 1994; Koegl et al., 1994; Mumby et al., 
1994; Shenoy-Scaria et al., 1994; van’t Hof et al., 1997; Wolven et al., 1997). 
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Palmitoylation is catalyzed by a large family of palmitoyl transferases (PATs) containing a 
conserved aspartate-histidine-histidine-cysteine (DHHC) cysteine-rich (CR) domain 
(Putilina et al., 1999). Seven DHHC proteins are expressed in the yeast S. cerevisiae, 
whereas more than 20 DHHCs are encoded by mammalian genomes (Greaves et al., 
2011). DHHCs localize to cellular membranes, and are predicted to contain 4-6 
transmembrane domains, with the N- and C-terminus and the DHHC-CR domain in the 
cytosol (Greaves et al., 2011). Subcellular localization of GFP-tagged human DHHCs was 
analyzed in transfected HEK 293 cells. Most isoforms localized to the ER (DHHC-1, -6, 
-10, -11, -13, -14, -16 and -19), ER/Golgi (DHHC-2, -9, -12, -22), or the Golgi complex 
(DHHC-3, -4, -7, -8, -15, -17, -18). A few of them, however (DHHC-5, -20 and -21), 
exhibited a plasma membrane localization (Ohno et al., 2006). As for the specificity of 
interaction between DHHC proteins and their substrates, it can be controlled not only by 
sequences adjacent to the palmitoylated cysteines, but also by more distant regions of 
the substrate protein. The yeast DHHC protein Pfa3 palmitoylates the vacuolar protein 
Vac8 within its N-terminal Src homology 4 (SH4) domain, both in vitro and in vivo. In in 
vitro palmitoylation experiments, the isolated SH4 domain of Vac8, fused to GFP, was 
still palmitoylated by Pfa3. Unlike the full-length protein, however, it was also 
palmitoylated by each of the other four yeast DHHCs tested. This suggested that regions 
C-terminal to the SH4 domain are important for restricting specificity of palmitoylation 
to a particular enzyme (Nadolski et al., 2009).  
 
Palmitoylation can act as a secondary signal for membrane attachment of proteins 
synthesized on soluble ribosomes, such as Gα subunits, Src family kinases, and Ras 
proteins, which were brought to the membrane by primary signals, i.e. myristoyl or 
prenyl groups (Resh, 1994; Resh, 1999; Resh, 2006). Moreover, in many cases, 
palmitoylation is necessary for trafficking of these proteins from intracellular 
membranes of the secretory pathway to the plasma membrane (Apolloni et al., 2000; 
Sato et al., 2009; Tournaviti et al., 2009; see also section 1.5). According to the ‘kinetic 
bilayer trapping’ hypothesis (Shahinian et al., 1995), myristoylated or prenylated 
proteins transiently interact with (‘sample’) multiple intracellular membranes until they 
encounter a membrane with an appropriate PAT, which results in their palmitoylation 
and stable membrane association. Localization of the partner DHHC protein may thus 
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determine the sorting of a substrate protein. For example, palmitoylation by a 
Golgi-localized PAT would lead to enhanced membrane binding, allowing the protein to 
associate more efficiently with plasma membrane-directed transport vesicles (Greaves 
et al., 2007). Palmitoylation can play a role in regulating the sorting also of 
transmembrane proteins. In the case of δ opioid receptor, a GPCR, palmitoylation is 
required for its efficient biosynthetic delivery to the plasma membrane (Petäjä-Repo et 
al., 2006). Conversely, palmitoylation of a ligand-gated cation channel, 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, promotes its 
retention in the Golgi (Hayashi et al., 2005). Moreover, palmitoylation was shown to 
influence protein stability and aggregation (Linder et al., 2007). Palmitoylation of 
transmembrane proteins affects their stability by limiting access to E3 ubiquitin ligases, 
thus preventing their ubiquitylation-dependent targeting to the vacuole or lysosome, 
and degradation. It occurs either by stabilizing an interaction of the protein with the 
lipid bilayer, thus evading the quality-control machinery (as for Tlg1, a t-SNARE in 
S. cerevisiae; Valdez-Taubas et al., 2005), or by segregating the palmitoylated protein 
and the E3 ubiquitin ligase into different membrane subdomains (as for the anthrax 
toxin receptor; Abrami et al., 2006). Palmitoylation was also shown to inhibit the 
aggregation of polyglutamine-expanded mutant forms of huntingtin (Yanai et al., 2006). 
In addition, palmitoylation can serve as a lipid raft-targeting signal (see section 1.3). It 
has been proposed that the presence of multiple saturated acyl chains targets proteins 
to lipid rafts due to their high affinity for the ordered lipid environment (Melkonian et 
al., 1999). Indeed, peptides dually modified with a myristoyl and one or two palmitoyl 
groups, or with two palmitoyl groups, preferentially partition into lo domains in model 
bilayers exhibiting coexisting ld and lo phases (Wang et al., 2001). Diverse cytoplasmic 
proteins modified with multiple saturated acyl chains were found to be enriched in 
DRMs (Shenoy-Scaria et al., 1994; Wolven et al. 1997; Melkonian et al., 1999), and to 
co-cluster with raft-associated proteins (Harder et al., 1998). Moreover, FRET 
measurements revealed that variants of GFP, dually modified with myristate and 
palmitate, exhibit cholesterol-dependent clustering in the plasma membrane of living 
cells, consistent with their partitioning into lipid rafts (Zacharias et al., 2002). 
Palmitoylation seems to be necessary also for raft partitioning of the majority of 
transmembrane raft proteins (Levental et al., 2010b). It is still an open question whether 
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palmitoylated proteins associate with lipid rafts already on intracellular membranes, 
which would facilitate their sorting to the plasma membrane (Smotrys et al., 2004; 
Greaves et al., 2007).  
 
Many proteins undergo cycles of palmitoylation and depalmitoylation throughout their 
lifetime, which provides a mechanism to regulate their membrane association and/or 
sorting. This palmitate turnover can occur constitutively or in response to signals. For 
example, the palmitoylation/depalmitoylation cycle of Gα subunits is accelerated by the 
activation of GPCRs (Mumby et al., 1994; Wedegaertner et al., 1994; Bhamre et al., 
1998). Palmitoylation of farnesylated Ras at the Golgi promotes its transport to the 
plasma membrane, whereas depalmitoylation releases the protein from the plasma 
membrane into the cytosol, allowing it to be repalmitoylated at the Golgi membranes. 
This dynamic acylation cycle not only regulates the trafficking of H-Ras and N-Ras, but 
also is essential for maintaining their appropriate subcellular distribution (Rocks et al., 
2005). Depalmitoylation is catalyzed by acyl-protein thioesterases. To date only one 
enzyme has been shown to remove palmitate from proteins on the cytoplasmic surface 
of membranes, namely acyl-protein thioesterase 1 (APT1), a cytosolic protein that can 
depalmitoylate Gαi1, Gαs, eNOS and H-Ras in vitro, and Gαs and eNOS in vivo (Duncan et 
al., 1998; Yeh et al., 1999).  
1.5 SH4 domain proteins 
1.5.1 Src family kinases 
Src family kinases (SFKs) are non-receptor protein tyrosine kinases, which play key roles 
in signal transduction by diverse cell surface receptors, thus regulating many cellular 
processes including cell proliferation, differentiation, survival, migration, adhesion and 
cell-shape changes (Thomas et al., 1997). The family is composed of nine highly 
homologous proteins: c-Src, Fyn, c-Yes, Yrk, Lyn, Hck, c-Fgr, Blk and Lck. C-Src, Fyn, c-Yes 
and Yrk are expressed in a variety of cell types, whereas Lyn, Hck, c-Fgr, Blk and Lck are 
found primarily in hematopoietic cells. Both Lyn and Lck are also expressed in neurons 
(Thomas et al., 1997). All members of the family are composed of six distinct functional 
regions: (1) the N-terminal Src homology 4 (SH4) domain, (2) poorly conserved unique 
region, (3) the SH3 domain, (4) the SH2 domain, (5) the SH1 tyrosine kinase catalytic 
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domain, and (6) a short negative regulatory tail for autoinhibition (Thomas et al., 1997). 
The SH4 domains of all SFKs are responsible for targeting to cellular membranes and 
contain a myristoylated N-terminal glycine (glycine 2), as well as either a palmitoylated 
cysteine(s) or, in the case of Src and Blk, a basic stretch of amino acids (Paige et al., 
1993; Resh, 1993; Alland et al., 1994; Koegl et al., 1994; Resh, 1994; Shenoy-Scaria et al., 
1994). The SH3 and SH2 domains are protein-binding domains: SH3 binds to specific 
proline-rich sequences, and SH2, to sequences containing phosphotyrosine. 
Intramolecular interactions of the SH3 domain with the SH2-SH1 linker, and the SH2 
domain with the tyrosine phosphorylated C-terminal tail, stabilize the inactive 
conformation of SFKs (Sicheri et al., 1997; Xu et al., 1997).  
1.5.1.1  C-Src 
C-Src is a non-palmitoylated SFK (Koegl et al., 1994). Its interaction with cellular 
membranes is mediated by N-terminal myristate, in conjunction with lysines at positions 
5, 7, and 9 (Silverman et al., 1993). C-Src was found to localize to the plasma membrane 
of human platelets (Ferrell et al., 1990), and to endosomal membranes of rat fibroblasts 
(Kaplan et al., 1992). Src-GFP, transiently expressed in COS-1 cells (simian fibroblasts), 
was shown to rapidly move between late endosomes or lysosomes and the plasma 
membrane, possibly through its cytosolic release (Kasahara et al., 2007). 
1.5.1.2  Fyn 
Apart from N-terminal myristoylation, Fyn undergoes reversible (Wolven et al., 1997) 
palmitoylation at cysteine 3 and cysteine 6 (Alland et al., 1994). Fyn is expressed 
ubiquitously, and in T lymphocytes it is required for signal transduction via the T cell 
antigen receptor (TCR), thus regulating the development and activation of T cells 
(Thomas et al., 1997). Newly synthesized Fyn appears to associate directly with the 
plasma membrane, rather than to sample intracellular membranes first. Metabolic 
labeling of transfected NIH-3T3 (mouse embryo fibroblasts) or COS-1 cells with [35S] 
methionine, followed by subcellular fractionation, showed that the association of Fyn 
with the plasma membrane is rapid, taking place within 5 minutes after biosynthesis, 
and is followed by a slower acquisition of detergent resistance, which occurs 10-20 
minutes after binding to the plasma membrane (van’t Hof et al., 1997). Neither the 
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kinetics nor the extent of membrane binding of newly synthesized Fyn was affected by 
brefeldin A (BFA), an inhibitor of protein secretion (van’t Hof et al., 1997). Incubation at 
19°C to block TGN exit did not cause perinuclear accumulation of Fyn, both in the case of 
endogenous Fyn in a human megakaryocyte cell line Dami, and full-length Fyn 
transiently overexpressed in COS-1 cells (Sato et al., 2009). All these results indicate that 
Fyn is targeted to the plasma membrane directly, with no requirement for the secretory 
pathway, and suggest that its palmitoylation occurs at the plasma membrane. 
1.5.1.3  Lck 
Lck is expressed primarily in T lymphocytes, and is required for signal transduction via 
the TCR, thus playing a role in T cell development and activation (Straus et al., 1992). Lck 
localizes predominantly to the cytosolic side of the plasma membrane, where it 
associates with cytoplasmic domains of CD4 and CD8 glycoproteins, coreceptors of the 
TCR on helper and cytotoxic T cells, respectively (Turner et al., 1990), with these 
interactions being important for T cell activation (Zamoyska et al., 1989; Glaichenhaus et 
al., 1991). Lck undergoes reversible (Paige et al., 1993) palmitoylation at cysteine 3 and 
cysteine 5 (Koegl et al., 1994; Shenoy-Scaria et al., 1994). In CD4-positive T cells, shortly 
after synthesis, palmitoylated Lck associates with CD4 at intracellular membranes, 
possibly of the ERGIC or cis-Golgi. Transport of CD4-bound Lck from intracellular 
membranes to the plasma membrane, but not its palmitoylation, is inhibited by BFA, 
indicating that CD4-associated Lck is transported via the secretory pathway (Bijlmakers 
et al., 1999). Plasma membrane targeting of Lck, however, requires neither CD4, nor 
other T cell-specific proteins, as shown in T cells and transfected NIH-3T3 fibroblasts 
(Bijlmakers et al., 1997). Lck was shown to associate with DRMs (Shenoy-Scaria et al., 
1993; Shenoy-Scaria et al., 1994). Its engineered form attached to membranes via a 
transmembrane domain does not associate with DRMs, and is impaired in transducing 
some of the late events in the T cell receptor signaling (Kabouridis et al., 1997), implying 
that raft association of Lck is required for it to function properly in signal transduction by 
the TCR. 
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1.5.1.4  Lyn 
Lyn is myristoylated at glycine 2 and monopalmitoylated at cysteine 3 (Resh, 1994). The 
kinase plays a role in initiating signal transduction by the B cell antigen receptor (BCR), 
thus being important for the development, activation and survival of B lymphocytes 
(Gauld et al., 2004). Lyn-GFP transiently expressed in COS-1 cells, was shown to 
associate with perinuclear membranes (possibly the Golgi apparatus) soon after 
biosynthesis. The subsequent trafficking to the plasma membrane was inhibited by 
N-ethylmaleimide (Kasahara et al., 2004), a reagent which blocks multiple vesicular 
fusion events. In addition, incubation at 19°C to block TGN exit caused increased levels 
of perinuclear Lyn, both in the case of transiently expressed Lyn in COS-1 and HeLa cells, 
and endogenous Lyn in the human megakaryocyte cell line Dami (Sato et al., 2009). 
These results indicate that Lyn is palmitoylated at the Golgi apparatus, and subsequently 
traffics to the plasma membrane via the secretory pathway. Overexpression of the 
dominant-negative Rab11 S25N mutant in COS-1 cells caused increased perinuclear 
localization of Lyn, suggesting an involvement of Rab11 in the exocytic transport of Lyn 
(Sato et al., 2009). Moreover, the trafficking of Lyn from the Golgi apparatus to the 
plasma membrane requires four negatively charged residues in the C-lobe of the kinase 
domain (Kasahara et al., 2004). 
1.5.1.5  C-Yes 
C-Yes is myristoylated at glycine 2 and monopalmitoylated at cysteine 3 (Koegl et al., 
1994). Yes transiently expressed in COS-1 and HeLa cells, initially associated with 
membranes in the perinuclear region, partially colocalizing with the Golgi marker GalT, 
and was found at the plasma membrane in the later phase of expression (Sato et al., 
2009). Incubation at 19°C to block TGN exit caused increased levels of perinuclear Yes, 
both in the case of endogenous Yes in Dami cells, and transiently expressed Yes in COS-1 
and HeLa cells (Sato et al., 2009). These results suggest that Yes is palmitoylated at the 
Golgi apparatus, and subsequently traffics to the plasma membrane via the secretory 
pathway. Overexpression of the dominant-negative Rab11 S25N mutant caused 
increased perinuclear localization of Yes in COS-1 cells, suggesting an involvement of 
Rab11 in the exocytic transport of Yes (Sato et al., 2009). 
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1.5.2 Heterotrimeric G protein α subunits 
Heterotrimeric G proteins, composed of α, β and γ subunits, transduce signals from G 
protein-coupled receptors (GPCRs). The ligands that bind to and activate these receptors 
include neurotransmitters, peptide hormones, chemokines, and lipids. Ligand binding to 
a GPCR induces exchange of bound GDP for GTP on Gα subunits present in Gαβγ 
heterotrimers, resulting in their dissociation into signaling-competent Gα and Gβγ 
(Marrari et al., 2007). Gγ subunits are subject to prenylation, whereas Gα subunits 
undergo myristoylation and/or palmitoylation. Subunits α of the Gαi family (αi, αz and αo 
subunits) carry both modifications (Linder et al., 1993; Parenti et al., 1993; Galbiati et 
al., 1994; Resh, 1994). Interaction with Gβγ is necessary for the palmitoylation of Gα, 
and thus for plasma membrane localization of the heterotrimer (Marrari et al., 2007). 
Gα, including those of the Gαi family, localize to lipid rafts (Moffett et al., 2000), which 
can serve as a means of modulating signaling specificity. Gαz, following synthesis and 
myristoylation, first associates with intracellular membranes and subsequently with the 
plasma membrane, which requires its association with Gβγ. BFA does not prevent αz 
from reaching the plasma membrane, suggesting that it does not travel to the plasma 
membrane through the secretory pathway, and that palmitoylation of Gαz does not 
occur on intracellular membranes. Gαz seems to sample intracellular membranes, and 
when it reaches the plasma membrane, association with Gβγ allows for its 
palmitoylation and stable membrane association (Fishburn et al., 1999). 
1.5.3 Hydrophilic acylated surface protein B (HASPB) 
Hydrophilic acylated surface proteins (HASPs) are components of the surface coat of 
protozoan parasites from the Leishmania genus, expressed exclusively in the infective 
stages of their life cycle (Flinn et al., 1994; Alce et al., 1999). The N-terminal SH4 domain 
of hydrophilic acylated surface protein B (HASPB) becomes dually fatty acylated, 
myristoylated at glycine 2 and palmitoylated at cysteine 5, with both modifications being 
necessary for the transport of the protein to the surface of Leishmania parasites (Denny 
et al., 2000). 18 N-terminal amino acids of HASPB are sufficient for the targeting of the 
heterologous Aequorea victoria GFP to the inner plasma membrane leaflet of both 
Leishmania and mammalian cells (Denny et al., 2000; Stegmayer et al., 2005), and for its 
subsequent translocation to the outer leaflet, possibly by a plasma membrane-resident 
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transporter (Stegmayer et al., 2005). The portion of the fusion protein that could be 
biochemically detected at the outer surface of L. major cells was 20-30% (Denny et al., 
2000). 
 
A model of HASPB transport in mammalian cells was proposed, based on the analysis of 
subcellular localization and DRM association of various mutants of HASPB SH4 domain, 
fused to GFP, heterologously expressed in either CHO or HeLa cells (Stegmayer et al., 
2005; Tournaviti et al., 2007; Ritzerfeld, 2009; Tournaviti et al., 2009; Ritzerfeld et al., 
2011). As in the case of other diacylated SH4 domain proteins, myristoylation of glycine 
2 is a prerequisite for subsequent palmitoylation: mutation of this residue results in the 
lack of both myristoylation and palmitoylation, and as a result, the protein accumulates 
in the cytosol. Non-palmitoylated mutant (cysteine 5 to alanine or serine) accumulates 
at intracellular membranes and, unlike the wild-type form, is not recovered in DRMs. All 
this suggests that myristoylation enables the protein to transiently associate with 
intracellular membranes, thus bringing it in proximity to a palmitoyl transferase, which 
was proposed to be Golgi-associated. Only upon palmitoylation can the protein be 
transported to the plasma membrane, hypothetically - associated with the cytosolic face 
of secretory vesicles. It was proposed that palmitoylation results in partitioning of 
HASPB into lipid rafts already at the Golgi, and furthermore, that lipid rafts are necessary 
for the transport of HASPB to the plasma membrane. In agreement, reduction of cellular 
cholesterol levels, either by siRNA-mediated down-regulation of the crucial enzyme in 
early cholesterol biosynthesis, mevalonate-diphospho-dehydrogenase (MVD), or by 
treatment with the cholesterol-extracting drug, methyl-β-cyclodextrin (MβCD), resulted 
in increased levels of perinuclear HASPB SH4-GFP, and also Yes SH4-mCherry. The effect 
of MβCD on the localization of the reporter proteins could be reversed upon 
replenishment with exogenous cholesterol (Ritzerfeld et al., 2011). Targeted 
mutagenesis of HASPB SH4 domain led to identification of a mutation (threonine 6 to 
glutamate) that caused the HASPB SH4-GFP reporter to be retained in intracellular sites, 
with a strong accumulation at perinuclear membranes. This mutation influenced neither 
acylation levels of the protein, nor its membrane binding, reduced however its 
association with DRMs. HASPB SH4 domain was shown to be phosphorylated at 
threonine 6 in vivo. SiRNA-mediated down-regulation of the threonine/serine-specific 
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phosphatases PP1 and PP2A or their pharmacological inhibition by calyculin A caused 
reversible accumulation of the wild-type form of HASPB SH4-GFP (but not the 
non-phosphorylatable threonine 6 to alanine mutant) at intracellular sites. These data 
led to a hypothesis that a regulatory mechanism exists, in which phosphorylation at 
threonine 6 induces redistribution of HASPB from the plasma membrane to perinuclear 
membranes (possibly endosomal recycling compartment), whereas its 
dephosphorylation by PP1 and PP2A is required for the protein to be recycled back to 
the plasma membrane (Tournaviti et al., 2009).  
1.6 Aims of this thesis 
The aim of the first part of this study (chapters 2 and 3) was to characterize membrane 
(both lipid and protein) environment of diacylated SH4 domain proteins residing in lipid 
rafts. The approach was to analyze lipid and protein components of detergent-resistant 
membranes (DRMs) immunoaffinity-purified from the total pool with the use of 
diacylated SH4 domain fusion proteins as bait. In the second part of this study (chapters 
4 and 5), we intended to investigate the previously reported (Ritzerfeld, 2009; Ritzerfeld 
et al., 2011) role of the COPI coatomer complex, as well as of the secretory pathway in 
general, in the plasma membrane transport of diacylated SH4 domain proteins. To this 
end we employed: siRNA-mediated knockdown of the β subunit of the COPI complex, 
expression of constitutively active mutant (Q71L) of the small GTPase Arf1, as well as 
treatment with brefeldin A.  
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2 Results I 
The aim of this part of the study was to characterize membrane (both lipid and protein) 
environment of diacylated SH4 domain proteins residing in cholesterol- and 
sphingolipid-enriched subdomains of cellular membranes, that is lipid rafts. We decided 
to define lipid raft components based on the detergent-resistant membrane (DRM) 
approach. We intended to isolate DRMs from a human cell line, and subsequently 
perform a specific immunoaffinity purification of DRMs that contain either of two 
diacylated SH4 domain fusion proteins, followed by an analysis of their lipid and protein 
components. 
2.1 Generation of human cell lines stably expressing SH4 domain fusion 
proteins 
Immunoisolation of DRMs that contain diacylated SH4 domain proteins required 
generating human cell lines stably expressing a SH4 domain fused to an affinity tag. We 
decided to use for this purpose green fluorescent protein (GFP), the fusion with which 
also allows selection for transduced cells using fluorescence-activated cell sorting 
(FACS), visualization of the fusion protein in live cells using fluorescent microscopy, 
analysis of its expression levels by flow cytometry and finally, detection using Western 
blotting. A tobacco etch virus (TEV) protease cleavage site was introduced in between 
the SH4 domain and GFP (Figure 1), to allow for specific elution of the immunoisolated 
DRMs from the affinity matrix. We designed fusion proteins containing SH4 domains 
derived either from Leishmania major hydrophilic acylated surface protein B (HASPB), or 
from human Src family kinase Yes. Both SH4 domains become myristoylated at glycine 2 
(which is the N-terminal residue after removal of the initiating methionine), and 
palmitoylated either at cysteine 5 (in the case of HASPB) or at cysteine 3 (in the case of 
Yes) (Figure 1, A and C, respectively). Apart from the two fusion proteins containing the 
wild-type SH4 domains, we designed also a palmitoylation-deficient mutant, HASPB SH4 
Δpal-TEV-GFP, in which cysteine 5 is replaced with serine (Figure 1 B), to be used as a 
control. 
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Figure 1 SH4 domain fusion proteins stably expressed in human cell lines generated in this study. SH4 
domains derived either from Leishmania major hydrophilic acylated surface protein B (HASPB), or from 
human Src family kinase Yes, are fused to the N-terminus of green fluorescent protein (GFP), with a 
tobacco etch virus (TEV) protease cleavage site in between. (A) HASPB SH4-TEV-GFP is myristoylated at 
glycine 2 (N-terminal residue after removal of the initiating methionine) and palmitoylated at cysteine 5. 
(B) HASPB SH4 Δpal-TEV-GFP is a palmitoylation-deficient mutant, in which cysteine 5 was replaced with 
serine. (C) Yes SH4-TEV-GFP is myristoylated at glycine 2 and palmitoylated at cysteine 3. Acylated amino 
acid residues are shown in bold type, acyl moieties are represented by the squiggly lines, and the mutated 
residue is highlighted in red. 
2.1.1 Construction of plasmids for the generation of human cell lines stably 
expressing SH4 domain fusion proteins 
Inserts encoding each of the SH4 domains and a TEV protease cleavage site, were 
formed by annealing of oligonucleotides, and contained BamHI and AgeI sticky ends and 
a Kozak sequence. Moloney murine leukemia virus (MMLV)-based retroviral expression 
vector pRevTRE2, harboring HASPB SH4-coding sequence flanked by BamHI and AgeI 
restriction sites, followed by GFP-coding sequence flanked by AgeI and NotI restriction 
sites (i.e. pRevTRE2/HASPB SH4-GFP; created by Julia Ritzerfeld; Ritzerfeld, 2009), was 
digested with BamHI and AgeI restriction enzymes to remove the HASPB SH4 insert. 
Each of the SH4-TEV inserts was ligated into thus obtained pRevTRE2/GFP, upstream of 
and in frame with the GFP-coding sequence. Sequences encoding HASPB SH4-TEV-GFP, 
HASPB SH4 Δpal-TEV-GFP and Yes SH4-TEV-GFP were thus located between the MMLV 5′ 
and 3′ long terminal repeat sequences (LTRs), downstream of the tetracycline-response 
element (TRE), which enables their stable insertion into the genome, and inducible 
expression of the fusion proteins. 
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2.1.2 Retroviral transduction 
The pRevTRE2-based constructs were transiently cotransfected into packaging cells (HEK 
293T) together with two vectors encoding viral proteins. As a result, retroviral particles 
carrying vector RNA encoding the SH4 domain fusion proteins were produced, and 
subsequently used to infect target cell lines: HeLa (human cervical epitheloid carcinoma) 
and HeLa S3 (a clonal derivative of HeLa cells, capable of suspension growth). The target 
cells were MCAT-TAM2 stable cell lines, i.e. stably expressing mouse cationic amino acid 
transporter 1 (MCAT1), which serves as a receptor for retroviral particles, and rtTA-M2, 
a Tet-On transactivator, which binds to the tetracycline-response element. 
2.1.3 Fluorescence-activated cell sorting 
Following retroviral transduction, cells expressing each of the SH4 domain fusion 
proteins in a doxycycline-inducible manner were selected by several rounds of 
fluorescence-activated cell sorting (FACS). During the first round of sorting, transduced 
cells were selected. The second round excluded cells that expressed the fusion protein 
in a constitutive manner. The final, third sort isolated pools and single cells, in which the 
transduced fragment was stably integrated into the genome. 
2.2 Characterization of human cell lines stably expressing SH4 domain 
fusion proteins 
2.2.1 Analysis of expression levels of SH4 domain fusion proteins by flow 
cytometry 
To characterize the inducibility and expression levels of HASPB SH4-TEV-GFP, HASPB SH4 
Δpal-TEV-GFP, and Yes SH4-TEV-GFP fusion proteins stably expressed in the generated 
HeLa (Figure 2) and HeLa S3 (Figure 3) cell lines, pools and clones were cultivated in the 
absence or presence of 4 μg/ml doxycycline for 16 hours and analyzed using flow 
cytometry, by detecting the fluorescence of GFP. Autofluorescence of the respective 
MCAT-TAM2 cell lines was adjusted to 101.  
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Figure 2 Analysis of expression levels of SH4-TEV-GFP fusion proteins stably expressed in HeLa cells. 
HeLa cell lines stably expressing HASPB SH4-TEV-GFP (A, B), HASPB SH4 Δpal-TEV-GFP (C, D), or Yes SH4-
TEV-GFP (E) in a doxycycline-inducible manner, were grown in the absence (blue profile) or in the 
presence (green profile) of 4 μg/ml doxycycline for 16 hours, detached, and analyzed by flow cytometry. 
Autofluorescence of HeLa MCAT-TAM2 cells was adjusted to 10
1
. 
All generated cell lines exhibited some level of constitutive SH4 domain fusion protein 
synthesis. Expression levels in the absence of doxycycline were lower for HeLa S3 cell 
lines than for HeLa cell lines. In all cases, upon induction with doxycycline, expression 
levels were significantly increased. For the immunoisolation procedure we decided to 
use clonal (i.e. obtained by sorting single cells) HeLa S3 cell lines. Clones were chosen in 
which the expression levels of HASPB SH4 and Yes SH4 fusion proteins were low without 
doxycycline, and were high and similar upon cultivation in its presence, that is: clone 7 
for HeLa S3 HASPB SH4-TEV-GFP (Figure 3 B), and clone 1 for HeLa S3 Yes SH4-TEV-GFP 
(Figure 3 F). 
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Figure 3 Analysis of expression levels of SH4-TEV-GFP fusion proteins stably expressed in HeLa S3 cells. 
HeLa S3 cell lines stably expressing HASPB SH4-TEV-GFP (A, B), HASPB SH4 Δpal-TEV-GFP (C, D), or Yes 
SH4-TEV-GFP (E, F) in a doxycycline-inducible manner, were grown in the absence (blue profile) or in the 
presence (green profile) of 4 μg/ml doxycycline for 16 hours, detached, and analyzed by flow cytometry. 
Autofluorescence of HeLa S3 MCAT-TAM2 cells was adjusted to 10
1
. 
2.2.2 Analysis of subcellular localization of SH4 domain fusion proteins by 
confocal microscopy  
Subcellular localization of HASPB SH4-TEV-GFP, HASPB SH4 Δpal-TEV-GFP, and Yes SH4-
TEV-GFP fusion proteins stably expressed in HeLa (Figure 4) and HeLa S3 (Figure 5) cells 
was examined by live-cell confocal microscopy, after cultivation of the stable cell lines in 
the presence of 1 μg/ml doxycycline for 24 hours in 8-well Lab-Tek Chambered 
Coverglass plates. 
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Figure 4 Analysis of subcellular localization of SH4-TEV-GFP fusion proteins stably expressed in HeLa 
cells. HeLa cell lines stably expressing HASPB SH4-TEV-GFP (A, B), HASPB SH4 Δpal-TEV-GFP (C, D), or Yes 
SH4-TEV-GFP (E) in a doxycycline-inducible manner, were grown in 8-well Lab-Tek Chambered Coverglass 
plates in the presence of 1 μg/ml doxycycline for 24 hours and imaged by live-cell confocal microscopy 
(objective 63x). Scale bar, 10 μm. 
At steady state, both wild-type fusion proteins, HASPB SH4-TEV-GFP (Figure 4, A, B; 
Figure 5, A, B), and Yes SH4-TEV-GFP (Figure 4 E; Figure 5, E, F), localized mainly to the 
plasma membrane of both HeLa and HeLa S3 cells, with a small amount in the 
perinuclear region. This is in agreement with what was previously reported for 
GFP-tagged HASPB and Yes SH4 domains stably expressed in CHO (Stegmayer et al., 
2005; Tournaviti et al., 2007) and in HeLa cells (Ritzerfeld, 2009; Ritzerfeld et al., 2011), 
as well as for HASPB and Yes SH4 domains fused to GFP-protein A, stably expressed in 
CHO and HeLa cells (Tournaviti et al., 2009).  
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Figure 5 Analysis of subcellular localization of SH4-TEV-GFP fusion proteins stably expressed in HeLa S3 
cells. HeLa S3 cell lines stably expressing HASPB SH4-TEV-GFP (A, B), HASPB SH4 Δpal-TEV-GFP (C, D), or 
Yes SH4-TEV-GFP (E, F) in a doxycycline-inducible manner, were grown in 8-well Lab-Tek Chambered 
Coverglass plates in the presence of 1 μg/ml doxycycline for 24 hours and imaged by live-cell confocal 
microscopy (objective 63x). Scale bar, 10 μm. 
The palmitoylation-deficient cysteine 5 to serine (C5S) mutant, HASPB SH4 
Δpal-TEV-GFP, was retained at intracellular membranes in both HeLa (Figure 4, C, D), 
and HeLa S3 cells (Figure 5, C, D), in agreement with what was previously reported for 
GFP-tagged C5S mutant of HASPB SH4 domain stably expressed in CHO cells (Stegmayer 
et al., 2005; Tournaviti et al., 2007), as well as for C5A and C3A mutants of HASPB and 
Yes SH4 domains, respectively, fused to GFP, stably expressed in HeLa cells (Ritzerfeld, 
2009; Ritzerfeld et al., 2011), and for C5A mutant of HASPB SH4 fused to GFP-protein A, 
stably expressed in CHO and HeLa cells (Tournaviti et al., 2009).  
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2.2.3  Analysis of detergent-resistant membrane association of SH4 domain 
fusion proteins 
We examined the degree of detergent-resistant membrane (DRM) association of HASPB 
SH4-TEV-GFP, HASPB SH4 Δpal-TEV-GFP, and Yes SH4-TEV-GFP stably expressed in HeLa 
(Figure 6) and HeLa S3 (Figure 7) cells. The cells, grown in 10 cm plates in the presence 
of 1 μg/ml doxycycline for 24-48 hours, were extracted on ice with 1% Triton X-100 in 
MBS buffer. The lysate was centrifuged, and the resulting post-nuclear supernatant 
(PNS) adjusted with OptiPrep (i.e. 60% iodixanol) to 40% iodixanol, overlayered with 
28% iodixanol in MBS buffer, and finally with MBS (0% iodixanol). After equilibrium 
density gradient centrifugation, eight fractions were collected from the top of the 
gradient, and analyzed by Western blotting. 
 
Figure 6 Analysis of detergent-resistant membrane (DRM) association of SH4-TEV-GFP fusion proteins 
stably expressed in HeLa cells. HeLa cell lines stably expressing (A) HASPB SH4-TEV-GFP, (B) HASPB SH4 
Δpal-TEV-GFP, or (C) Yes SH4-TEV-GFP in a doxycycline-inducible manner, were grown in 10 cm plates in 
the presence of 1 μg/ml doxycycline for 24-48 hours. The cells were extracted on ice with 1% Triton X-100 
in MBS buffer. Post-nuclear supernatant (PNS) was floated on an OptiPrep step density gradient 
(40/28/0% iodixanol). Eight fractions were collected from the top of the gradient, and an aliquot of each 
was analyzed by Western blotting, together with an aliquot of PNS (denoted as input). As DRM and 
non-DRM markers, flotillin-1 and transferrin receptor were used, respectively. 
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Both wild-type SH4-TEV-GFP fusion proteins were found in low-density, that is DRM 
fractions (fractions 1-3; Figure 6, A, C and Figure 7, A, C), which is in agreement with 
what was previously reported for HASPB SH4 domain fused to GFP-protein A, stably 
expressed in CHO cells (Tournaviti et al., 2009). Flotillin-1, which was used here as a 
DRM marker, exhibited a very similar distribution across the eight fractions of the 
density gradient as the wild-type SH4-TEV-GFP fusion proteins, whereas transferrin 
receptor, a non-DRM marker, was found exclusively in the bottom fractions of the 
gradient, which contain fully solubilized proteins (fractions 6-8; Figure 6 and Figure 7). In 
contrast to the wild-type fusion proteins, HASPB SH4 Δpal-TEV-GFP was not detected in 
DRM fractions (Figure 6 B; Figure 7 B), which is consistent with what was previously 
shown for GFP-protein A-tagged C5A mutant of HASPB SH4 domain, stably expressed in 
CHO cells, of which less than 1% was recovered in DRMs (Tournaviti et al., 2009). 
 
Figure 7 Analysis of detergent-resistant membrane (DRM) association of SH4-TEV-GFP fusion proteins 
stably expressed in HeLa S3 cells. HeLa S3 cell lines stably expressing (A) HASPB SH4-TEV-GFP, (B) HASPB 
SH4 Δpal-TEV-GFP, or (C) Yes SH4-TEV-GFP in a doxycycline-inducible manner, were grown in 10 cm plates 
in the presence of 1 μg/ml doxycycline for 24-48 hours. The cells were extracted on ice with 1% Triton 
X-100 in MBS buffer. Post-nuclear supernatant (PNS) was floated on an OptiPrep step density gradient 
(40/28/0% iodixanol). Eight fractions were collected from the top of the gradient, and an aliquot of each 
was analyzed by Western blotting, together with an aliquot of PNS (denoted as input). As DRM and 
non-DRM markers, flotillin-1 and transferrin receptor were used, respectively. 
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2.3 Immunoaffinity purification of detergent-resistant membranes 
containing SH4 domain fusion proteins 
2.3.1 Experimental workflow 
After having obtained human cell lines stably expressing either HASPB SH4-TEV-GFP or 
Yes SH4-TEV-GFP in a doxycycline-inducible manner (section 2.1), which was followed by 
the characterization of fusion protein expression levels and inducibility, as well as 
subcellular localization and DRM association (section 2.2), we could proceed to perform 
immunoaffinity purification of detergent-resistant membranes containing the SH4 
domain fusion proteins. To be able to obtain large amounts of cells easily, we decided to 
use HeLa S3 cells, a clonal derivative of adherent HeLa cells, capable of growing in 
suspension. Two clonal stable cell lines were used, HeLa S3 HASPB SH4-TEV-GFP clone 7, 
and HeLa S3 Yes SH4-TEV-GFP clone 1, which exhibited very similar expression levels and 
inducibility of the SH4 domain fusion proteins (Figure 3 B and Figure 3 F, respectively). 
As a control for nonspecific binding to the affinity matrix and nonspecific release of the 
bound material, the below-described immunoaffinity isolation procedure was 
performed using also HeLa S3 cells that do not express any SH4-TEV-GFP fusion protein 
(i.e. HeLa S3 MCAT-TAM2 cells).  
 
The subsequent steps of the immunoisolation procedure are presented in Figure 8. The 
three HeLa S3 cell lines were first grown adherently, followed by the establishment of 
suspension cultures. Expression of SH4 domain fusion proteins was induced by 
incubation in the presence of 1 μg/ml doxycycline for 48 hours. Afterwards, the cells 
were harvested by centrifugation, disrupted with the use of nitrogen cavitation, and the 
lysates were subjected to differential centrifugation to remove first the nuclei 
(centrifugation at 3000 g for 10 minutes), and then mitochondria (15000 g, 10 minutes). 
The final centrifugation (60 minutes at more than 100000 g) was performed to pellet 
microsomal membranes (membrane fragments derived from the plasma membrane, 
Golgi apparatus and endoplasmic reticulum). Microsomal pellets were then extracted on 
ice with 1% Triton X-100 in MBS buffer and floated on OptiPrep step density gradients 
(40/28/0%). 
Results I 
 
 
38 
 
Figure 8 Caption on page 39. 
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Caption for figure on page 38. Figure 8 Workflow of immunoaffinity purification of detergent-resistant 
membranes (DRMs) containing SH4 domain fusion proteins. Clonal HeLa S3 cell lines stably expressing 
HASPB SH4-TEV-GFP or Yes SH4-TEV-GFP in a doxycycline-inducible manner, and HeLa S3 cells that do not 
express any SH4-TEV-GFP fusion protein (control), were grown in suspension. Expression of the SH4 
domain fusion proteins was induced with 1 μg/ml doxycycline for 48 hours. Cells were harvested, 
disrupted with the use of nitrogen cavitation, and the lysates were subjected to differential centrifugation 
to remove nuclei and mitochondria, and to obtain pelleted microsomes, which were then extracted on ice 
with 1% Triton X-100 in MBS buffer and floated on OptiPrep step density gradients (40/28/0%). Eight 
fractions were collected from the top of each gradient. The second fraction of each gradient (denoted as 
total DRMs, represented in the figure by protein-containing lipid vesicles) was then incubated with 
anti-GFP antibodies coupled to protein G magnetic beads, to immunoisolate SH4-TEV-GFP fusion proteins, 
together with their associated DRMs, which were then eluted from the beads by tobacco etch virus (TEV) 
protease cleavage, and pelleted by ultracentrifugation. Lipids present in those pelleted immunoisolated 
DRMs were subjected to lipid extraction and analysis by mass spectrometry, and proteins were partially 
resolved by 1-dimensional polyacrylamide gel electrophoresis (1D-PAGE) and analyzed by mass 
spectrometry. 
 
After overnight centrifugation at more than 100000 g, eight fractions were collected 
from the top of each gradient. The low-density fraction from each gradient with the 
highest content of the SH4 domain fusion proteins, or the corresponding fraction from 
the control cells (fraction number 2, denoted from now on as total DRMs), was then 
incubated with protein G magnetic beads to which anti-GFP antibodies had been 
coupled, with the aim of immunoisolating SH4-TEV-GFP fusion proteins, together with 
their associated DRMs, which were then eluted from the beads by TEV protease 
cleavage, and pelleted by ultracentrifugation. The pellets were subjected to lipid 
extraction and analysis by mass spectrometry (see section 2.3.2), or dissolved in 1x gel 
loading buffer, and the proteins partially resolved by 1-dimensional polyacrylamide gel 
electrophoresis (1D-PAGE) and analyzed by mass spectrometry (see section 2.3.3). 
 
Figure 9 presents Western blot analysis of several steps of the immunoaffinity 
purification procedure. GM130 and ribophorin-1, non-raft membrane proteins localized 
in the Golgi and endoplasmic reticulum, respectively, as well as the non-raft plasma 
membrane marker transferrin receptor, were present in lysates, post-mitochondrial 
supernatants (PMS) and solubilized microsomal pellets, but not (or barely) detectable in 
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total DRMs, in contrast to lipid raft markers, Yes and flotillin-1, and the two 
SH4-TEV-GFP fusion proteins. Substantial amounts of both fusion proteins were bound 
to magnetic beads, and afterwards, the SH4 domains were efficiently cleaved off by TEV 
protease, as seen from the 2-kDa shift to higher electrophoretic mobility of the fusion 
proteins that remained bound to magnetic beads after incubation with the protease 
(Figure 9). 
 
Figure 9 Steps of immunoaffinity purification of detergent-resistant membranes (DRMs) containing SH4 
domain fusion proteins. The immunoisolation was performed from HeLa S3 cell lines stably expressing 
HASPB SH4-TEV-GFP (denoted as HASPB) or Yes SH4-TEV-GFP (denoted as Yes), as well as from control 
cells (HeLa S3 cells that do not express any SH4-TEV-GFP fusion protein, denoted as ctrl). PMS, 
post-mitochondrial supernatant; solubilized microsomes, microsomal pellet after solubilization with 
detergent (Triton X-100); total DRMs, fraction 2 from OptiPrep step density gradient; unbound, material 
unbound to magnetic beads after their incubation with total DRMs; MBs, material associated with 
magnetic beads after their incubation with tobacco etch virus (TEV) protease. GM130 was used as a Golgi 
marker, transferrin receptor as a non-DRM plasma membrane marker, ribophorin-1 was used for the 
endoplasmic reticulum, Yes and flotillin-1 were used as DRM markers.  
 
Samples from the different stages of immunoisolation performed from HASPB SH4-TEV-
GFP-expressing cells and from control cells were reanalyzed (Figure 10), this time 
including also the respective TEV eluates (i.e. material eluted from magnetic beads by 
TEV protease cleavage). We could detect the presence of lipid raft markers, Yes and 
flotillin-1, in TEV eluate obtained from HASPB SH4-TEV-GFP-expressing cells (while 
analyzing 5% and 50% of the sample), which were not detectable in 2% of TEV eluate 
from control cells. Upon cleaving off the SH4 domain from the HASPB SH4-TEV-GFP 
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fusion protein, GFP and any uncleaved HASPB SH4-TEV-GFP should remain bound to 
magnetic beads via anti-GFP antibodies. We could detect, however, the presence of the 
full-length fusion protein in HASPB TEV eluates, indicating that uncleaved protein 
detached from the beads, which suggests that some amount of HASPB DRMs was eluted 
from the affinity matrix not due to specific cleavage with the protease. This amount was, 
however, small, as can be seen by comparing the amount of cleaved protein remaining 
on magnetic beads to the amount of uncleaved protein in TEV eluate (compare Western 
blot band intensity for 0.6% of the material remaining on magnetic beads after TEV 
cleavage to the intensities for 5% and 50% of HASPB TEV eluate; Figure 10). 
 
 
Figure 10 Steps of immunoaffinity purification of detergent-resistant membranes (DRMs) containing 
SH4 domain fusion proteins. Analyzed were samples from the different stages of immunoisolation 
performed from HeLa S3 HASPB SH4-TEV-GFP (denoted as HASPB), and from control cells (denoted as 
ctrl). PMS, post-mitochondrial supernatant; solubilized microsomes, microsomal pellet after solubilization 
with detergent (Triton X-100); total DRMs, fraction 2 from OptiPrep step density gradient; unbound, 
material unbound to magnetic beads after their incubation with total DRMs; MBs, material associated 
with magnetic beads after their incubation with tobacco etch virus (TEV) protease; TEV eluate, material 
eluted from magnetic beads by TEV protease cleavage. GM130 was used as a Golgi marker, transferrin 
receptor as a non-DRM plasma membrane marker, Yes and flotillin-1 were used as DRM markers. The 
percentage of sample analyzed is indicated for total DRMs, unbound, MBs and TEV eluate. 
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2.3.2 Lipid components of immunoaffinity-purified detergent-resistant 
membranes containing SH4 domain fusion proteins 
Lipids present in solubilized microsomal pellets (i.e. the input for DRM gradients), total 
Triton X-100 DRMs, as well as in DRMs immunoprecipitated from the total pool using 
SH4-TEV-GFP as bait and subsequently eluted from the affinity matrix by TEV protease 
cleavage and pelleted (denoted further as TEV eluates), were subjected to lipid 
extraction in the presence of internal standards, and analyzed by nano-ESI-MS/MS using 
a triple quadrupole mass spectrometer (Dr. Britta Brügger, Research Group Prof. Dr. 
Felix Wieland/Dr. Britta Brügger, Heidelberg University Biochemistry Center). TEV 
eluates obtained from HeLa S3 cells expressing a SH4-TEV-GFP fusion protein contained 
on average 0.21% and 0.08% (in the case of HASPB SH4-TEV-GFP and Yes SH4-TEV-GFP-
expressing cells, respectively) of the lipids present in the total DRMs from which they 
were immunoprecipitated, as compared to 0.03% of the input in the case of control 
cells, i.e. HeLa S3 cells that do not express any SH4-TEV-GFP fusion protein (averaged 
data from three independent experiments). Moreover, TEV eluates obtained from cells 
expressing a SH4-TEV-GFP fusion protein contained on average 8.0 times (in the case of 
HASPB SH4-TEV-GFP) or 2.7 times (Yes SH4-TEV-GFP) more total lipid than the respective 
TEV eluates from control cells (data from three independent experiments), suggesting 
that DRMs that contain SH4 domains were successfully immunoisolated. However, the 
relatively low total lipid yields for Yes SH4 DRMs, on average only 2.7 times higher than 
the nonspecific lipid background present in control TEV eluates, and thus the possibility 
of substantial contribution of nonspecifically copurified lipids to the observed lipid 
composition of Yes SH4 DRMs, make the results less certain. 
 
The charts in Figure 11 A, as well as the table in Figure 11 B, depict lipid class 
composition of solubilized microsomes, total DRMs and immunoisolated SH4 DRMs (TEV 
eluates) from HeLa S3 cells expressing HASPB SH4-TEV-GFP (denoted as HASPB) or Yes 
SH4-TEV-GFP (denoted as Yes). The content of each lipid class is presented as a molar 
percentage of the total lipid (mean ± standard deviation from three independent 
experiments). The table in Figure 11 B presents also statistical significance of the 
differences in lipid composition between solubilized microsomes from HeLa S3 HASPB 
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SH4-TEV-GFP or HeLa S3 Yes-TEV-GFP cells and the respective total DRMs, and between 
total DRMs and the respective TEV eluates. 
 
A 
      
B 
                
Figure 11 Lipid class composition of solubilized microsomes, total Triton X-100 detergent-resistant 
membranes (DRMs), and immunoisolated SH4 DRMs (TEV eluates) from HeLa S3 cells expressing 
HASPB SH4-TEV-GFP (denoted as HASPB) or Yes SH4-TEV-GFP (denoted as Yes). (A) The charts show 
mean molar percentages (mol%) of the total lipid ± standard deviation from three independent 
experiments. The right chart has an expanded scale to show minor lipid classes. (B) The table shows mean 
mol% of the total lipid ± standard deviation (SD) from three independent experiments, and statistical 
significance of the differences in lipid composition of solubilized microsomes versus total DRMs, and total 
DRMs versus TEV eluates (*, p≤0.05; **, p≤0.01; ns, p>0.05, paired Student’s t-test). PS, 
phosphatidylserine; PE, phosphatidylethanolamine; PC, phosphatidylcholine; PI, phosphatidylinositol; 
Chol, cholesterol; SM, sphingomyelin; PG, phosphatidylglycerol; Cer, ceramide; HexCer, hexosylceramide. 
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The proportion of most lipid classes differed significantly between solubilized 
microsomal pellets and the respective total DRMs. Total DRMs, compared with 
solubilized microsomes, had significantly higher levels of cholesterol (1.5 and 1.6 fold 
higher for HASPB and Yes, respectively), sphingomyelin (SM; 1.9 fold higher for both 
HASPB and Yes), and hexosylceramide (HexCer; 2.5 and 2.4 fold higher for HASPB and 
Yes, respectively). Moreover, total DRMs, compared with the respective solubilized 
microsomes, were found to be significantly depleted in phosphatidylethanolamine (PE; 
2.3 and 2.4 fold for HASPB and Yes, respectively), phosphatidylcholine (PC; 1.6 and 1.5 
fold, respectively) and phosphatidylinositol (PI; 3.3 and 3.5 fold). Immunoprecipitated 
DRMs (TEV eluates) from both SH4-TEV-GFP-expressing cell lines had significantly lower 
levels of PE (1.6 fold for both HASPB and Yes) than the respective total DRMs. What is 
more, TEV eluates prepared from cells expressing HASPB SH4-TEV-GFP, as compared 
with total DRMs, were significantly enriched in SM (1.3 fold), and depleted in PC (1.2 
fold), whereas the differences between mean molar percentages of PS, PI, cholesterol, 
phosphatidylglycerol (PG), Cer or HexCer, were not statistically significant (p>0.05). The 
differences in mean molar percentages of the various lipid classes (except for PE) 
between total DRMs and immunoisolated SH4 DRMs prepared from Yes SH4-
TEV-GFP-expressing cells, were all not statistically significant (Figure 11 B). 
 
Figure 12 depicts relative proportions of saturated, monounsaturated, diunsaturated, as 
well as tri- and more unsaturated PC species in solubilized microsomes, total DRMs, and 
immunoisolated DRMs from HeLa S3 cells expressing HASPB SH4-TEV-GFP, presented as 
mean molar percentages of the total PC ± standard deviation from three independent 
experiments. Total DRMs, compared with the membranes from which they were 
isolated, had a significantly higher proportion of saturated PC species (3.2 fold), and 
moreover, were significantly depleted in diunsaturated, as well as in tri- and more 
unsaturated PC species (3.3 and 3.2 fold, respectively). In each of the three independent 
experiments, HASPB SH4 DRMs had a higher percentage of saturated, and a lower 
percentage of mono- and diunsaturated PC species than the total DRMs from which they 
were immunoprecipitated. However, these observed differences in the degree of PC 
saturation between HASPB SH4-containing DRMs and total DRMs were not statistically 
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significant (Figure 12 B). It seems likely, though, that this lack of significance could be 
overcome by performing more independent experiments. 
 
A 
                          
 
 
 
 
 
 
 
 
B 
Figure 12 Extent of phosphatidylcholine (PC) saturation in solubilized microsomes, total Triton X-100 
detergent-resistant membranes (DRMs), and immunoisolated DRMs (TEV eluates) from HeLa S3 cells 
expressing HASPB SH4-TEV-GFP (denoted as HASPB). (A) Values presented in the chart are mean molar 
percentages (mol%) of the total PC ± standard deviation from three independent experiments. (B) The 
table shows mean mol% of the total PC ± standard deviation (SD) from three independent experiments, 
and significance of the differences between solubilized microsomes versus total DRMs, and total DRMs 
versus TEV eluate (***, p≤0.001; ns, p>0.05, paired Student’s t-test). 
 
2.3.3 Protein components of immunoaffinity-purified detergent-resistant 
membranes containing SH4 domain fusion proteins 
Proteins present in total Triton X-100 DRMs and in pelleted immunoprecipitated DRMs 
(i.e. TEV eluates), were partially resolved by 1D-PAGE in precast 10% Bis-Tris gels, 
stained with Colloidal Coomassie, and then each lane was cut into three pieces, which 
were individually processed: subjected to reduction, alkylation and digestion with 
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trypsin, and analyzed by a nano-HPLC system coupled to a nano-ESI-LTQ-Orbitrap mass 
spectrometer (Dr. Thomas Ruppert, Core Facility for Mass Spectrometry and Proteomics, 
Heidelberg University Center for Molecular Biology). MS/MS spectra were analyzed 
using Mascot (Matrix Science; Perkins et al., 1999). Peptide and protein identifications 
were validated using Scaffold 3 (Proteome Software; Searle, 2010).  
 
Table S1 (Appendix) depicts a list of 177 proteins identified in at least three out of six 
preparations of total DRMs (i.e. fractions number 2 from OptiPrep DRM gradients), 
isolated from the three different HeLa S3 cell lines used in this study (two independent 
preparations for each cell line, all considered together). The table lists also primary 
subcellular localizations of the identified proteins, and their classification into raft, 
raft-associated and nonspecific, according to the sensitivity of their presence in Triton 
X-100 DRMs to cholesterol depletion, as determined for HeLa cells with the use of a 
SILAC (stable isotope labeling with amino acids in cell culture)-based quantitative 
proteomic approach, combined with methyl-β-cyclodextrin (MβCD) treatment (Foster et 
al., 2003; see also section 1.3.2). Out of these 177 proteins, 68% were identified also in 
Triton X-100 DRMs isolated from HeLa cells in the study by Foster et al., and 51% were 
among proteins whose degree of sensitivity to MβCD was established in the same study, 
resulting in their classification into the three above-mentioned groups. In turn, in the 
study by Foster et al., out of all non-contaminating proteins identified, 53% were 
classifiable. Out of these, 43% were classified as raft proteins (as compared to 46% in 
our study), 26% as raft-associated (25% in our study), and finally 31% as nonspecific (i.e. 
non-raft) proteins (29% in our study). Of the proteins identified by us in at least three 
out of six preparations of total Triton X-100 DRMs from HeLa S3 cells, 34% are reported 
to localize primarily to the plasma membrane (Figure 13 A; Table S1, Appendix). A 
substantial amount of the identified proteins localizes to the nucleus (24%) and to the 
cytosol (23%). Among the identified DRM proteins were also cytoskeletal (6.8%), 
mitochondrial (6.2%) and endoplasmic reticulum (4.5%) proteins. The remaining 
1.7% localize to lysosomes and peroxisomes (Table S1, Appendix). In the pie chart in 
Figure 13 B, all identified plasma membrane proteins are classified according to the type 
of membrane association. As much as almost 30% of them associate with the membrane 
via lipid anchors, which is a common property among lipid raft proteins (see section 1.4).  
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Table S2 (Appendix) lists 52 proteins that were identified (i.e. that met criteria for 
positive protein identification specified in Scaffold 3) in at least one TEV eluate sample 
out of six (two independent experiments, each performed using the three HeLa S3 cell 
lines: the control cells and the two SH4-TEV-GFP stable cell lines). The number of 
proteins identified in the immunoisolates from DRMs prepared from the control cells 
was 1 and 0 in two different experiments, suggesting that almost no protein was 
nonspecifically immunoprecipitated in the absence of a SH4-TEV-GFP bait, or that the 
amounts of the nonspecific proteins were below the sensitivity limit of the mass 
spectrometer used. In immunoisolates from HeLa S3 HASPB SH4-TEV-GFP DRMs, 12 and 
37 proteins were identified, with 9 proteins common for the two experiments. 
Immunoisolates from HeLa S3 Yes SH4-TEV-GFP DRMs contained 20 and 31 proteins, 
with 14 overlapping proteins between the two experiments. All of the 9 proteins present 
in immunoisolated HASPB SH4 DRMs in both experiments were also identified in both 
immunoisolates from HeLa S3 Yes SH4-TEV-GFP DRMs. Of the proteins identified in at 
least two out of four preparations of DRMs immunoprecipitated from the total pool 
using a SH4-TEV-GFP fusion protein as bait (two independent preparations for each HeLa 
S3 SH4-TEV-GFP cell line, all considered together), 39% are known to localize primarily to 
the plasma membrane (Figure 14 A; Table S2, Appendix). Out of these, as much as 40% 
associate with the membrane via lipid anchors (Figure 14 B). Among the proteins 
identified in at least two out of four preparations of immunoprecipitated SH4 DRMs, 
there were also cytoskeletal (23%), nuclear (19%), and cytosolic (19%) proteins. 
Furthermore, 88% of the identified proteins were detected also in Triton X-100 DRMs 
Figure 13 Classification of proteins identified in total Triton X-100 detergent-resistant membranes 
(DRMs) isolated from HeLa S3 cells (in at least three out of six preparations). Pie charts of the identified 
proteins classified according to: (A) their primary subcellular localization, and (B) subclasses of plasma 
membrane proteins. 
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isolated from HeLa cells (Foster et al., 2003), and 69% had their degree of sensitivity to 
MβCD determined. Among those, 67% were classified as raft proteins, 17% as 
raft-associated, and finally 17% as nonspecific (i.e. non-raft) proteins (Table S2, 
Appendix). 
 A                                                          B
 
 
We decided to compare the relative abundances of proteins in immunoprecipitated and 
total DRMs. We expected that proteins which preferentially associate with membrane 
environments of diacylated SH4 domain proteins would be enriched over total DRMs. 
Conversely, we would expect non-raft proteins nonspecifically copurifying with DRMs, to 
be depleted as compared to the total DRM pool. Finally, raft proteins which do not 
preferentially associate with membrane environments surrounding SH4 domain fusion 
proteins, should be either unchanged or depleted relative to total DRMs. To estimate 
relative amounts of the proteins identified in immunoprecipitated DRMs as compared to 
total DRMs, we employed two different methods of label-free mass spectrometry-based 
protein quantification. The first method entails calculating the exponentially modified 
protein abundance index (emPAI), equal to 10PAI–1, where PAI is defined as the number 
of peptides detected for a given protein, divided by the theoretical number of tryptic 
peptides for this protein (Ishihama et al., 2005). EmPAI was shown to be directly 
proportional to protein content, allowing for estimating both the absolute and relative 
protein abundance. The number of identified peptides for each protein in each sample 
was exported from Scaffold 3, and the number of theoretically observable tryptic 
peptides for each protein was calculated using Protein Digestion Simulator. The 
Figure 14 Classification of proteins identified in at least two out of four preparations of 
detergent-resistant membranes (DRMs) immunoprecipitated from the total DRM pool using a SH4-TEV-
GFP fusion protein as bait. Pie charts of the identified proteins classified according to: (A) their primary 
subcellular localization, and (B) subclasses of plasma membrane proteins. 
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calculated emPAI values were normalized for different protein amounts in each of the 
samples using data from mass spectrometry lipid analysis, assuming that the amounts of 
total lipid correspond to total protein amounts. Relative abundance of each protein in 
immunoisolated DRMs and the respective total DRMs was then calculated by comparing 
its normalized emPAI values in the two samples. In the other method used here, relative 
protein quantification is based on the integration of liquid chromatography-mass 
spectrometry (LC-MS) ion chromatograms. In each MS scan, peptide ions with a 
particular m/z (mass-to-charge ratio) values are detected with a particular signal 
intensity. Coupling MS with LC introduces a retention time dimension. Thus, during 
LC-MS experiments, peptide peaks are detected as three-dimensional objects in m/z, 
signal intensity and retention time space (Zhang et al., 2010). The intensities of these 
three-dimensional peptide peak hills in LC-MS ion chromatograms are integrated, and 
used as a measure of quantity, as the signal intensity from electrospray ionization 
corresponds to ion concentration (Voyksner et al., 1999), and therefore relative 
amounts of a peptide can be determined by comparing its integrated peak areas in 
different samples. Integrated areas of LC-MS peptide peaks were calculated with the use 
of MaxQuant software (Cox et al., 2008). For each protein, 2 or 3 most intense peptides 
were chosen, and their ratios between peak areas in TEV eluates and in the respective 
total DRMs were calculated and then averaged, to obtain protein ratios. To correct for 
unequal protein amounts between samples, based on the assumption that the 
lipid/protein ratio is constant across all of them, the calculated protein ratios were 
normalized using data on amounts of total lipid, acquired using lipid mass spectrometry. 
For each protein identified in at least one TEV eluate sample, enrichment factors relative 
to the respective total DRMs, calculated using the two above-mentioned label-free 
quantitative proteomic methods, are listed in Table S2 (Appendix). The direction of 
change (assuming: depleted, values ≤0.5; unchanged, between 0.5 and 2; enriched, ≥2) 
was consistent between the two methods of calculation for almost 60% of value pairs. 
For none of the pairs did one value indicate depletion, and the other, enrichment (Table 
S2, Appendix). As expected, proteins which were the most abundant in immunoisolated 
DRMs, were not necessary also the most enriched, as exemplified by actin, cytoplasmic 
2, the most abundant protein (i.e. with the highest emPAI value) in each preparation of 
immunoprecipitated SH4 DRMs, which, however, was not among the most enriched 
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proteins (as indicated by emPAI enrichment factors). Similarly, tubulin beta chain was 
more abundant than many other proteins, but was among proteins with the lowest 
enrichment factors (Table S2, Appendix).  
 
We decided to select a subset of proteins identified in immunoisolated SH4 DRMs, and 
validate their enrichment factors over total DRMs calculated by label-free quantitative 
proteomic methods, with the use of quantitative Western blotting. We chose proteins 
that were consistently present in total DRMs (i.e. that were identified in at least three 
out of six preparations of total DRMs; see Table S1 in Appendix). Three of the selected 
proteins: moesin, non-POU domain-containing octamer-binding protein (NONO), and 
splicing factor, proline- and glutamine-rich (SFPQ), were among the proteins identified in 
immunoisolated HASPB SH4-containing DRMs and Yes SH4-containing DRMs in both 
experiments (Table S2, Appendix). NONO and SFPQ were consistently enriched in the 
immunoisolated SH4 DRMs, having one of the highest enrichment factors (according to 
both methods of quantification; Table S2, Appendix). Most of the selected proteins are 
known to localize primarily to the plasma membrane, namely: brain acid soluble protein 
1 (BASP1), flotillin-1, moesin, Ras GTPase-activating-like protein (IQGAP1), and Yes 
(Table S1 and Table S2, Appendix). The remaining two proteins (NONO and SFPQ) 
localize primarily to the nucleus. Among the chosen proteins were those whose 
presence in DRMs was previously shown (Foster et al., 2003; see also section 1.3.2) to 
be highly sensitive to cholesterol depletion, termed as raft proteins (moesin, SFPQ, and 
the well-established lipid raft markers, flotillin-1 and Yes), or moderately sensitive, 
termed as raft-associated (IQGAP1) (Table S1 and Table S2, Appendix). Sensitivity of 
BASP1 and NONO was not determined in the study by Foster et al. There are, however, 
other studies which support lipid raft association of BASP1 (Khan et al., 2003). With the 
aim of performing quantitative Western blot analysis, two further immunoisolation 
experiments were carried out, each using the control HeLa S3 cells, and the two 
SH4-TEV-GFP cell lines. Figure 15 depicts the distribution of the selected proteins across 
DRM gradients, whose fractions number 2 were used for subsequent 
immunoprecipitation in one of the two experiments. The proportion of protein present 
in floating (i.e. DRM) fractions, in the case of SFPQ, moesin, NONO and BASP1, was 
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Figure 15 Distribution of selected proteins across DRM gradients. HeLa S3 cells (A) that do not express 
any SH4-TEV-GFP fusion protein, and stable cell lines expressing (B) HASPB SH4-TEV-GFP or (C) Yes 
SH4-TEV-GFP in a doxycycline-inducible manner, were grown in suspension. Expression of the fusion 
proteins was induced with 1 μg/ml doxycycline for 48 hours. Upon cell disruption with the use of nitrogen 
cavitation, and several rounds of differential centrifugation, microsomal membranes were obtained, 
which was followed by their extraction with 1% Triton X-100 in MBS buffer and flotation on OptiPrep step 
density gradients (40/28/0%). Eight fractions were collected from the top, and an aliquot of each was 
analyzed by Western blotting, together with an aliquot of solubilized microsomes (denoted as input). Yes 
and flotillin-1 were used as DRM markers, transferrin receptor was used as a non-DRM marker. IQGAP1, 
Ras GTPase-activating-like protein; SFPQ, splicing factor, proline- and glutamine-rich; NONO, non-POU 
domain-containing octamer-binding protein; BASP1, brain acid soluble protein 1. 
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much smaller than for the well-established lipid raft markers, flotillin-1 and Yes, and 
than for both SH4-TEV-GFP fusion proteins, with the proportion for IQGAP1 being 
intermediate (Figure 15).  
 
Figure 16 depicts one out of two Western blots used for calculating the abundance of 
the selected proteins in immunoisolated DRMs (TEV eluates) relative to total DRMs. 
Assuming a constant lipid/protein ratio across all samples, we used mass spectrometry 
data on amounts of total lipid in each sample to analyze equal amounts of lipid (and 
thus protein) from each sample (and also five times the amount for total DRMs).  
 
Figure 16 Western blot analysis of total Triton X-100 detergent-resistant membranes (DRMs) and 
immunoisolated DRMs (TEV eluates). DRMs were prepared from HeLa S3 cell lines stably expressing 
HASPB SH4-TEV-GFP (denoted as HASPB), Yes SH4-TEV-GFP (denoted as Yes), or from control cells (HeLa 
S3 cells that do not express any SH4-TEV-GFP fusion protein, denoted as ctrl), and served as input for 
immunoprecipitation with the use of anti-GFP antibodies coupled to magnetic beads, which was followed 
by tobacco etch virus (TEV) protease cleavage to elute bound SH4 DRMs (yielding TEV eluates). Assuming 
a constant lipid/protein ratio across all samples, we used mass spectrometry data on amounts of total 
lipid to analyze equal amounts of lipid (and thus protein) from each sample (and also five times the 
amount for total DRMs). Western blot band intensities were used for calculating enrichment factors of the 
indicated proteins in TEV eluates as compared to the respective total DRMs. IQGAP1, Ras 
GTPase-activating-like protein; SFPQ, splicing factor, proline- and glutamine-rich; NONO, non-POU 
domain-containing octamer-binding protein; BASP1, brain acid soluble protein 1. 
 
Enrichment factors were calculated as the ratio between Western blot band intensities 
(adjusted to equal lipid amounts) in TEV eluate and in the respective total DRMs, and 
are listed in Table 1, together with the enrichment factors calculated for the two 
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preceding experiments using the above-mentioned label-free quantitative proteomic 
methods. Moreover, the detected Western blot band intensities in TEV eluates were 
adjusted to the yield of total lipid in the whole sample amount, thus obtaining values 
that reflect the total amounts of each protein in each TEV eluate. For each protein, the 
values for SH4 TEV eluates were compared to the value for the control TEV eluate, 
obtaining ratios, which are listed in Table 1. Consistent with quantitative proteomic 
results, Western blot-based quantification showed depletion of BASP1, and lack of 
enrichment of flotillin-1 and Yes in the immunoisolated SH4 domain-containing DRMs, 
as well as enrichment of NONO and SFPQ in most samples of SH4 DRMs (Table 1). 
Enrichment factor values for moesin were not consistent either between experiments, 
or between HASPB and Yes SH4 DRMs, as already observed for mass 
spectrometry-based quantification. IQGAP1 seemed to be neither depleted nor 
enriched, unlike what we previously observed. Again, unlike for mass spectrometry 
results, most of the proteins probed for were detected also in TEV eluates from control 
cells, and were thus nonspecifically isolated in the absence of any SH4-TEV-GFP bait. As 
already mentioned, the results for NONO and SFPQ seem in agreement with their 
enrichment in the immunoprecipitated SH4 DRMs, as compared to total DRMs. 
However, their enrichment in the control immunoprecipitates is, in most cases, even 
higher than in the immunoisolated SH4 DRMs, which suggests that at least some 
amounts of both proteins bind to the affinity matrix nonspecifically, possibly as soluble 
contaminants of DRM preparations, and nonspecifically detach during TEV cleavage. 
Similar or even higher total amounts of NONO and SFPQ were recovered in the control 
TEV eluates, compared to SH4 TEV eluates (Table 1), which suggests that the apparent 
high enrichment of both proteins in SH4 TEV eluates may in fact be due to nonspecific 
isolation of the two proteins, and not due to their preferential association with 
membrane environments surrounding SH4 domain fusion proteins.  
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* in TEV eluates, Yes did not fulfill the criteria for positive protein identification specified in Scaffold 3, but was nevertheless included in quantitative Western blot analysis 
Table 1 Selected proteins identified in TEV eluates (i.e. immunoisolated detergent-resistant membranes, DRMs), together with their enrichment factors over total 
Triton X-100 DRMs. Total DRMs prepared from HeLa S3 cell lines stably expressing HASPB SH4-TEV-GFP (denoted as HASPB), Yes SH4-TEV-GFP (denoted as Yes), or from 
control cells (HeLa S3 cells that do not express any SH4-TEV-GFP fusion protein, denoted as ctrl), were incubated with anti-GFP antibodies coupled to magnetic beads, 
which was followed by tobacco etch virus (TEV) protease cleavage to elute bound SH4 DRMs (yielding TEV eluates). Listed are enrichment factors of the selected proteins in 
TEV eluates relative to the respective total DRMs, calculated using two label-free quantitative proteomic methods (based on the comparison of exponentially modified 
protein abundance index (emPAI) values, and on the comparison of integrated areas of liquid chromatography-mass spectrometry (LC-MS) peptide peaks between 
samples), and using quantitative Western blotting. To correct for unequal protein amounts between samples, based on the assumption that the lipid/protein ratio is 
constant across all of them, we used mass spectrometry data on amounts of total lipid in each sample either to normalize protein ratios calculated using label-free 
quantitative proteomic methods, or to analyze equal amounts of protein by Western blotting. Label-free quantification with both methods was performed using the same 
dataset (two experiments, each for the three cell lines), whereas for quantitative Western blotting two further experiments were used. For those proteins that were only 
detected in a TEV eluate (and not in the respective total DRMs), the missing emPAI values were replaced by minimal emPAI values (calculated for 1 observed unique 
spectrum), allowing us to calculate minimal enrichment factors (underlined). Listed are also ratios between total amounts of each protein in SH4 TEV eluates and in the 
control TEV eluate, calculated based on Western blot band intensities and data on the yield of total lipid in the whole sample amount. Blank cells indicate that values could 
not be calculated.  
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3 Discussion I 
3.1 Generation and characterization of human cell lines stably expressing 
SH4 domain fusion proteins 
With the aim of characterizing lipid and protein environment of diacylated SH4 domain 
proteins associated with lipid rafts, we decided to specifically immunoisolate from 
human cells detergent-resistant membranes (DRMs) that contain SH4 domain fusion 
proteins, and analyze their components. SH4 domains, derived either from Leishmania 
major hydrophilic acylated surface protein B (HASPB) or from human Src kinase Yes, 
were fused to the N-terminus of GFP (to be used as an affinity tag), with a TEV protease 
cleavage site in between (Figure 1), to allow for specific elution of the immunoisolated 
DRMs from the affinity matrix. Clonal cell lines of suspension HeLa (HeLa S3) cells were 
generated, stably and inducibly expressing HASPB SH4-TEV-GFP or Yes SH4-TEV-GFP. The 
expression level of the fusion proteins was low in the absence of doxycycline, and in its 
presence, high and very similar for both clonal cell lines (Figure 3, B and F). In agreement 
with what was previously reported for similar constructs expressed in HeLa or CHO cells 
(Stegmayer et al., 2005; Tournaviti et al., 2007; Ritzerfeld, 2009; Tournaviti et al., 2009; 
Ritzerfeld et al., 2011), both fusion proteins localized mainly to the plasma membrane of 
HeLa S3 cells, with smaller amounts in the perinuclear region (Figure 5, B and F), and 
were present in DRM fractions (Figure 7, A and C). Thus, the use of the two SH4 domain 
fusion proteins should allow for immunoisolation of DRMs derived from lipid rafts 
localized predominantly to the plasma membrane. In contrast, palmitoylation-deficient 
mutant, HASPB SH4 Δpal-TEV-GFP, was retained at intracellular membranes (Figure 
5, C, D), and was absent from DRM fractions (Figure 7 B), indicating that plasma 
membrane targeting of HASPB SH4-TEV-GFP and its association with DRMs, are 
dependent on palmitoylation, as reported previously for similar constructs expressed in 
HeLa or CHO cells (Stegmayer et al., 2005; Tournaviti et al., 2007; Ritzerfeld, 2009; 
Tournaviti et al., 2009; Ritzerfeld et al., 2011). 
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3.2 Immunoaffinity purification of detergent-resistant membranes 
containing SH4 domain fusion proteins 
The two clonal HeLa S3 SH4-TEV-GFP cell lines, as well as control HeLa S3 cells (HeLa S3 
cells that do not express any SH4-TEV-GFP fusion protein), were grown in suspension. 
Upon cell disruption and several rounds of differential centrifugation, microsomal 
membranes were obtained, which was followed by their extraction with 1% Triton X-100 
and flotation on OptiPrep step density gradients (Figure 8). The resulting floating (DRM) 
fractions were relatively enriched in lipid raft markers, and depleted in non-raft plasma 
membrane, Golgi and ER markers (Figure 9; Figure 10). The low-density fraction with the 
highest content of the SH4 domain fusion proteins, or the corresponding fraction from 
the control cells (denoted as total Triton X-100 DRMs), served as input for 
immunoprecipitation with the use of anti-GFP antibodies coupled to magnetic beads, 
which was followed by TEV protease cleavage, to elute the immunoisolated DRMs. Both 
the binding of the SH4-TEV-GFP fusion proteins to the affinity matrix, and their 
subsequent cleavage, were efficient (Figure 9; Figure 10), and the resulting SH4 TEV 
eluate contained lipid raft markers (analyzed only for HASPB; Figure 10), suggesting that 
SH4 DRMs were successfully immunoisolated and eluted from the affinity matrix.  
3.2.1 Lipid components of immunoaffinity-purified detergent-resistant 
membranes containing SH4 domain fusion proteins 
Total Triton X-100 DRMs from HeLa S3 cells, as compared to membranes from which 
they were isolated, were enriched in cholesterol, sphingomyelin (SM) and 
hexosylceramide (HexCer), and depleted in phosphatidylethanolamine (PE), 
phosphatidylcholine (PC) and phosphatidylinositol (PI) (Figure 11). Moreover, the former 
had a significantly higher proportion of saturated PC species, and a significantly lower 
proportion of diunsaturated, as well as tri- and more unsaturated PC species (Figure 12). 
This is consistent with previous studies, which reported the lipid composition of DRMs 
prepared by extraction of whole CHO or MDCK cells with 1% or 0.5% Triton X-100, 
respectively, and subsequent flotation on linear or step sucrose density gradients (Pike 
et al., 2005; Delaunay et al., 2008). Even though the protocols used were different than 
the one employed in our study, the floating fractions were also depleted in PE, PC and 
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PI, and more importantly, enriched in cholesterol, SM, and saturated phospholipids, 
relative to the starting material (PNS or lysate). DRMs immunoaffinity-purified using 
HASPB SH4-TEV-GFP as bait, exhibited statistically significant depletion in PE and PC, and 
enrichment in SM, with no significant difference in the amounts of phosphatidylserine 
(PS), PI, cholesterol, phosphatidylglycerol (PG), ceramide (Cer) and HexCer, relative to 
the input for immunoprecipitation, i.e. total DRMs (Figure 11). Thus, immunoisolated 
HASPB SH4 DRMs have a lipid composition that is distinct from that of the total 
population of detergent-resistant membranes, and therefore seem to be a subset of 
total DRMs. This may suggest that in vivo, HASPB SH4-TEV-GFP associates with a specific 
subset of lipid rafts. It seems likely that our inability to detect statistically significant 
differences in lipid composition between Yes SH4 DRMs and total DRMs (except for the 
depletion in PE in the case of the former), may be due to low total lipid yields for Yes 
SH4 DRMs, and the consequent high contribution of nonspecific lipid background to the 
observed composition. Nevertheless, our results for HASPB SH4 DRMs indicate that the 
heterogeneity of lipid rafts can be appreciated also using the DRM approach, which is in 
agreement with what was reported previously, however for a milder nonionic detergent, 
namely Brij 96 (Brügger et al., 2004). In the study by Brügger and co-workers, the total 
pool of DRMs prepared from the rat brain was used to immunoaffinity purify DRMs 
containing either of the two GPI-anchored proteins: prion protein (PrP) or Thy-1. Not 
only were the two proteins present in different domains on the neuronal surface, but 
also the immunopurified PrP and Thy-1 DRMs differed in lipid composition from each 
other, and from the total DRM pool. This suggested that the immunopurified DRMs 
contained specific lipid environments surrounding the two proteins, which indicates, in 
agreement with the results of our study, that the detergent approach does not preclude 
immunoisolation of specific membrane micro-environments.  
3.2.2 Protein components of immunoaffinity-purified detergent-resistant 
membranes containing SH4 domain fusion proteins 
Out of proteins present in at least half of the preparations of total Triton X-100 DRMs 
isolated from HeLa S3 cells (Table S1, Appendix), almost 70% were identified also in 
Triton X-100 DRMs from HeLa cells in the study by Mann and co-workers (Foster et al., 
2003). This high overlap is remarkable, considering the fact that the exact protocol for 
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the preparation of DRMs influences the identified proteome, and the two protocols 
were different, as were the cell lines used (suspension versus adherent HeLa cells). In 
our study, DRMs were isolated from pelleted microsomal membranes, using flotation on 
an OptiPrep step density gradient (40/28/0%), as compared to extraction of whole cells 
and subsequent flotation on a sucrose step density gradient (45/35/5%) in the other 
study. Out of the DRM proteins in both studies that were classifiable into raft, 
raft-associated and nonspecific (non-raft), similar proportions belonged to each of the 
three groups, namely about 45%, 25% and 30%, respectively, which suggests that the 
purity of DRM preparations was similar between our study and the benchmark study by 
Mann and co-workers. 
 
Lipid rafts are microdomains of the plasma membrane, believed to be assembled in the 
Golgi complex (Simons et al., 1997). Therefore, we would expect to identify in DRMs 
mainly proteins that localize to these two compartments. However, only 34% of the 
identified proteins localize primarily to the plasma membrane (Figure 13 A; Table S1, 
Appendix). The primary cellular locations of the remaining proteins (e.g. the nucleus, 
mitochondrion, ER) are not expected to contain lipid rafts. The presence of these 
proteins in DRMs may therefore solely reflect the well-known inability to purify 
membrane microdomains to homogeneity. However, among the identified proteins may 
also be ‘moonlighting’ proteins which reside in more than one subcellular location 
(having different functions at each one of them), the secondary localization being lipid 
rafts. In agreement with this, the presence in DRMs of some of the proteins whose 
primary localization is not the plasma membrane, is highly or moderately sensitive to 
cholesterol depletion (Table S1, Appendix), which suggests that they are bona fide raft 
components. The presence in DRMs of cytoskeletal proteins is in agreement with the 
previous finding that raft patches formed by the GPI-anchored protein CD59 or the 
ganglioside GM1 accumulate actin filaments, indicating an interaction of actin 
cytoskeleton with lipid rafts (Harder et al., 1999). This corresponds to the results by 
Mann and co-workers which showed moderate sensitivity of major cytoskeletal 
components to cholesterol depletion (Foster et al., 2003). 
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We analyzed the distribution of several of the identified proteins across DRM gradients. 
For most of them (SFPQ, moesin, NONO and BASP1), the proportion of protein present 
in floating (i.e. DRM) fractions was much smaller than for the well-established lipid raft 
markers, Yes and flotillin-1 (Figure 15). Triton X-100, the most commonly used nonionic 
detergent for isolating DRMs, is one of the most stringent, and therefore also one of the 
most reliable detergents (Schuck et al., 2003). It can however solubilize more loosely 
associated raft proteins. It is therefore possible that a significantly higher proportion of 
the above-mentioned proteins would be recovered in the floating fractions, if a less 
stringent detergent was used. Alternatively, the presence of only small amounts of a 
protein in DRM fractions may reflect its transient association with lipid rafts, or its 
primary residence in other subcellular locations, with rafts being the secondary 
localization. 
 
Among the proteins identified in at least half of the preparations of immunoprecipitated 
SH4 DRMs, 39% are known to localize primarily to the plasma membrane, as compared 
to 34% in the case of total DRMs (Figure 13 A; Figure 14 A; Table S1 and Table S2, 
Appendix). Moreover, out of the plasma membrane proteins in total DRMs and 
immunopurified SH4 DRMs, 28% and 40%, respectively, associate with the membrane 
via lipid anchors (Figure 13 B; Figure 14 B). Finally, out of the proteins in 
immunoprecipitated SH4 DRMs whose sensitivity to cholesterol depletion is known 
(Foster et al., 2003), 83% were highly or moderately sensitive, as compared to 71% in 
the case of total DRMs (Table S1 and Table S2, Appendix). These results suggest that our 
immunoaffinity purification approach enriches for bona fide raft proteins. 
 
To estimate relative amounts of the identified proteins in immunoprecipitated SH4 
DRMs, as compared to total DRMs, we employed two different methods of label-free 
mass spectrometry (MS)-based protein quantification: based on the comparison of 
exponentially modified protein abundance index (emPAI) values, and based on the 
comparison of integrated areas of liquid chromatography-mass spectrometry (LC-MS) 
peptide peaks between samples (Table S2, Appendix). We selected several proteins to 
validate their enrichment using quantitative Western blotting. The obtained values 
corresponded fairly well with the MS-based enrichment factors (Table 1). However, 
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whereas almost no proteins were identified by MS in the immunoisolates from control 
cells (Table S2, Appendix), we were able to detect the majority of proteins probed for by 
Western blotting (Figure 16; Table 1), which indicates their nonspecific isolation in the 
absence of a SH4-TEV-GFP bait. Total amounts of flotillin-1, IQGAP1 and Yes, recovered 
in the control immunoprecipitates, were much lower than in the immunoisolated SH4 
DRMs (Table 1), which may indicate their specific copurification with SH4 DRMs, and 
thus association with membrane environments of SH4 domain fusion proteins, however, 
not preferential, as indicated by their lack of enrichment in SH4 DRMs over the total 
DRM pool. For NONO and SFPQ, the total amounts of protein immunoisolated in the 
presence and absence of a SH4-TEV-GFP bait seemed similar, suggesting that their 
apparent enrichment in SH4 DRMs may be due to nonspecific isolation, which could 
explain their high enrichment factors observed also for the control. We thus did not 
confirm any of the selected proteins to be specifically enriched, and thus to 
preferentially associate with membrane environments of SH4 domain fusion proteins, 
which, however, does not preclude the presence of such proteins among all identified in 
SH4 DRMs. The absence of enrichment of endogenous Yes kinase in Yes SH4 DRMs may 
point out to the difference in raft partitioning of full-length Yes and Yes SH4-TEV-GFP. It 
seems conceivable that the identity of lipid rafts in which a protein resides could be 
controlled also by interactions conferred by domains distal from the SH4 domain. In our 
model system however, membrane micro-localization is determined only by dual fatty 
acylation with myristate and palmitate. 
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4 Results II 
In a whole-genome primary RNAi screen aimed at identifying factors involved in the 
transport of diacylated SH4 domain proteins to the plasma membrane, and 
subsequently in a validation screen, which used independent siRNAs (both performed by 
Julia Ritzerfeld; Ritzerfeld, 2009; Ritzerfeld et al., 2011), the most clear-cut hit 
phenotypes (increased perinuclear localization of HASPB SH4-GFP) were exhibited after 
knockdowns of α- and β-COP, two subunits of the heptameric coatomer (COPI) protein 
complex, which coats vesicles that mediate retrograde transport from the cis-Golgi to 
the ER, as well as retrograde and possibly anterograde transport across the Golgi stack 
(Beck et al., 2009; Popoff et al., 2011; see also section 1.1). The effect of 
down-regulation of the two coatomer subunits on the localization of Yes SH4-mCherry 
was less pronounced. Further analyses showed that knockdowns of other coatomer 
subunits, β′ and δ, also result in a pronounced increase in perinuclear accumulation of 
HASPB SH4-GFP, with a milder effect on the localization of Yes SH4-mCherry (Ritzerfeld, 
2009; Ritzerfeld et al., 2011). Moreover, microinjection of recombinant coatomer 
complex prevented the increased perinuclear accumulation of HASPB SH4-mCherry in 
β-COP knockdown cells (Ritzerfeld et al., 2011). We intended to investigate the apparent 
role of coatomer, as well as of the secretory pathway in general, in the plasma 
membrane transport of diacylated SH4 domain proteins. 
4.1 Analysis of subcellular localization of a HASPB SH4 domain fusion 
protein and a VSVG fusion protein upon β-COP knockdown 
We analyzed the subcellular localization of a HASPB SH4 domain fusion protein upon 
siRNA-mediated knockdown of the β subunit of the COPI coatomer complex, as 
compared to scrambled siRNA-transfected cells. HeLa cell line stably expressing HASPB 
SH4-mCherry in a doxycycline-inducible manner (Ritzerfeld, 2009; Ritzerfeld et al., 2011) 
was transfected with a scrambled siRNA or an siRNA targeting β-COP, using 
Oligofectamine. 48 hours upon transfection (20 hours upon the induction with 1 μg/ml 
doxycycline) the cells were imaged using live-cell confocal microscopy, by collecting Z 
stacks. Magnitude of perinuclear accumulation of HASPB SH4-mCherry upon the siRNA 
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transfections was determined by intensity quantification of sum intensity projections of 
Z stack images (Figure 17, A, B; each image represents a sum intensity projection of one 
Z stack). In agreement with what was previously reported for HASPB SH4-GFP 
(Ritzerfeld, 2009; Ritzerfeld et al., 2011), there was an increase in perinuclear 
localization of HASPB SH4-mCherry upon β-COP knockdown, which was highly 
statistically significant (p≤0.0001, unpaired Student’s t-test; Figure 17 C). 
 
Figure 17 Quantitative analysis of subcellular localization of a HASPB SH4 domain fusion protein (HASPB 
SH4-mCherry) upon siRNA knockdown of the β subunit of the COPI coatomer complex (β-COP). HeLa cell 
line stably expressing HASPB SH4-mCherry in a doxycycline-inducible manner was transfected with a 
scrambled siRNA or an siRNA targeting β-COP, using Oligofectamine. 48 hours upon transfection (20 hours 
upon the induction with 1 μg/ml doxycycline) the cells were imaged using live-cell confocal microscopy, by 
collecting Z stacks (objective 40x). (A, B) Each image represents a sum intensity projection of Z stack 
images. Scale bar, 10 μm. (C) Magnitude of perinuclear accumulation of HASPB SH4-mCherry upon 
transfection with a scrambled or β-COP siRNA, determined by intensity quantification of sum intensity 
projections of Z stacks. Perinuclear accumulation per cell is expressed as the percentage of perinuclear 
signal respective to the total signal per cell. Values for individual cells are depicted as triangles, horizontal 
bars represent arithmetic means for each condition; ****, p≤0.0001, unpaired Student’s t-test. 
Next, we analyzed the subcellular localization under control and β-COP knockdown 
conditions of a model transmembrane glycoprotein commonly used to study the 
transport through the secretory pathway, vesicular stomatitis virus glycoprotein (VSVG; 
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Tisdale et al., 1992), and compared it to the localization of a HASPB SH4 domain fusion 
protein. HeLa MCAT-TAM2 cells were transfected with a scrambled siRNA or an siRNA 
targeting β-COP, using Oligofectamine. 24 hours later the cells were cotransfected with 
pEGFP-N1/VSVG-SP (Keller et al., 2001; courtesy of Prof. Dr. Kai Simons, Max Planck 
Institute of Molecular Cell Biology and Genetics, Dresden; SP, long spacer arm between 
VSVG and GFP) and pRevTRE2/HASPB SH4-mCherry (Ritzerfeld, 2009), using FuGENE HD 
transfection reagent. 45 hours upon siRNA transfection (18 hours upon the induction 
with 1 μg/ml doxycycline) the cells were imaged using live-cell confocal microscopy.  
 
Figure 18 Analysis of subcellular localization of a vesicular stomatitis virus G protein fusion protein 
(VSVG-SP-GFP) upon siRNA knockdown of the β subunit of the COPI coatomer complex (β-COP), as 
compared to the localization of a HASPB SH4 domain fusion protein (HASPB SH4-mCherry). HeLa 
MCAT-TAM2 cells were transfected with a scrambled siRNA or an siRNA targeting β-COP, using 
Oligofectamine. 24 hours later the cells were cotransfected with pEGFP-N1/VSVG-SP and 
pRevTRE2/HASPB SH4-mCherry, using FuGENE HD transfection reagent. 45 hours upon siRNA transfection 
(18 hours upon the induction with 1 μg/ml doxycycline) the cells were imaged using live-cell confocal 
microscopy (objective 63x). Scale bar, 10 μm. 
In scrambled siRNA-transfected cells, both VSVG-SP-GFP and HASPB SH4-mCherry 
localized to the plasma membrane and perinuclear membranes (Figure 18, A-C). In 
β-COP-depleted cells, however, we could observe complete intracellular retention of 
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VSVG-SP-GFP (Figure 18 D), in contrast to HASPB SH4-mCherry, which as previously 
observed (Figure 17 B; Ritzerfeld, 2009; Ritzerfeld et al., 2011), except for exhibiting 
increased perinuclear localization, was also found at the plasma membrane (Figure 
18 E). 
4.2 Analysis of subcellular localization of a HASPB SH4 domain fusion 
protein and a VSVG fusion protein upon coexpression with Arf1 Q71L 
We decided to examine whether the subcellular localization of a HASPB SH4 domain 
fusion protein is dependent not only on β-COP, but also on ADP-ribosylation factor 1 
(Arf1), a small GTPase that controls the biogenesis of COPI vesicles by playing a role in 
recruitment of coatomer, uptake of cargo proteins, and finally, in scission and uncoating 
of the vesicles (Beck et al., 2009; Popoff et al., 2011). We analyzed the subcellular 
localization of HASPB SH4-mCherry upon its coexpression with the wild-type (WT) Arf1, 
or its trans-dominant constitutively active (i.e. GTP-bound) mutant (Q71L), known to 
cause stable association of coatomer with the Golgi complex (Dascher et al., 1994; Teal 
et al., 1994), and to inhibit transport through the secretory pathway, both ER to 
medial-Golgi and intra-Golgi (Dascher et al., 1994; Zhang et al., 1994). HeLa MCAT-TAM2 
cells were cotransfected in the presence of 4 μg/ml doxycycline, using FuGENE HD 
transfection reagent, with pRevTRE2/HASPB SH4-mCherry and pIRES2-EGFP/Arf1 (WT or 
Q71L; courtesy of Prof. Dr. Felix Wieland, Heidelberg University Biochemistry Center), a 
bicistronic vector coexpressing Arf1 and GFP. The cells were imaged 18 hours after 
transfection using live-cell confocal microscopy (Figure 19 A). We analyzed also the 
subcellular localization of a VSVG fusion protein (VSVG-SP-mRFP) upon its coexpression 
with the wild-type Arf1, or its Q71L mutant. HeLa MCAT-TAM2 cells were cotransfected 
with pIRES2-EGFP/Arf1 (WT or Q71L) and pmRFP-N1/VSVG-SP (courtesy of Prof. Dr. Kai 
Simons) using FuGENE HD transfection reagent, and imaged 20 hours after transfection 
with the use of live-cell confocal microscopy (Figure 19 B). Both HASPB SH4-mCherry and 
VSVG-SP-mRFP when coexpressed with Arf1 WT localized to the plasma membrane and 
perinuclear membranes (Figure 19 A, b; Figure 19 B, b). Upon coexpression with Arf1 
Q71L, VSVG-SP-mRFP exhibited complete intracellular retention (Figure 19 B, e), which is 
in striking contrast to what we observed for HASPB SH4-mCherry, which under these 
conditions was able to reach the plasma membrane (Figure 19 A, e).  
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Figure 19 Analysis of subcellular localization of a HASPB SH4 domain fusion protein (HASPB SH4-
mCherry) and a vesicular stomatitis virus G protein fusion protein (VSVG-SP-mRFP) upon their 
coexpression with the wild-type (WT) Arf1, or its constitutively active mutant (Q71L). (A) HeLa 
MCAT-TAM2 cells were cotransfected with pIRES2-EGFP/Arf1 (WT or Q71L) and pRevTRE2/HASPB SH4-
mCherry using FuGENE HD transfection reagent, in the presence of 4 μg/ml doxycycline. The cells were 
imaged 18 hours after transfection using live-cell confocal microscopy (objective 40x). (B) HeLa 
MCAT-TAM2 cells were cotransfected with pIRES2-EGFP/Arf1 (WT or Q71L) and pmRFP-N1/VSVG-SP using 
FuGENE HD transfection reagent, and imaged 20 hours after transfection with the use of live-cell confocal 
microscopy (objective 63x). Scale bar, 10 μm. 
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Upon coexpression with Arf1 Q71L, apart from plasma membrane localization, HASPB 
SH4-mCherry exhibited also perinuclear localization, the magnitude of which was 
significantly increased as compared to cells expressing Arf1 WT (p≤0.001, unpaired 
Student’s t-test; Figure 20 C), which was determined by intensity quantification of sum 
intensity projections of Z stack images (Figure 20, A, B; each image represents a sum 
intensity projection of one Z stack). 
 
Figure 20 Quantitative analysis of subcellular localization of a HASPB SH4 domain fusion protein 
(HASPB SH4-mCherry) upon its coexpression with the wild-type (WT) Arf1, or its constitutively active 
mutant (Q71L). HeLa MCAT-TAM2 cells were cotransfected with pIRES2-EGFP/Arf1 (WT or Q71L) and 
pRevTRE2/HASPB SH4-mCherry using FuGENE HD transfection reagent, in the presence of 4 μg/ml 
doxycycline. The cells were imaged 18 hours after transfection using live-cell confocal microscopy, by 
collecting Z stacks (objective 40x). (A, B) Each image represents a sum intensity projection of Z stack 
images. Scale bar, 10 μm. (C) Magnitude of perinuclear accumulation of HASPB SH4-mCherry upon its 
coexpression with Arf1 WT or Arf1 Q71L, determined by intensity quantification of sum intensity 
projections of Z stacks. Perinuclear accumulation per cell is expressed as the percentage of perinuclear 
signal respective to the total signal per cell. Values for individual cells are depicted as triangles, horizontal 
bars represent arithmetic means for each condition; ***, p≤0.001, unpaired Student’s t-test. 
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4.3 Analysis of subcellular localization of a HASPB SH4 domain fusion 
protein and a VSVG fusion protein upon their expression in the 
presence of brefeldin A 
We analyzed the subcellular localization of HASPB SH4-mCherry and VSVG-SP-GFP, 
transiently coexpressed in the presence of brefeldin A (BFA), a drug known to inhibit 
protein trafficking in the secretory system of mammalian cells (Misumi et al., 1986; 
Lippincott-Schwartz et al., 1989; Miller et al., 1992), by preventing Arf1 activation and 
thus also the Arf1-dependent recruitment of coatomer to membranes (Donaldson et al., 
1990; Donaldson et al., 1991). HeLa MCAT-TAM2 cells were cotransfected with 
pEGFP-N1/VSVG-SP and pRevTRE2/HASPB SH4-mCherry using FuGENE HD transfection 
reagent, in the presence of 1 μg/ml doxycycline and 100 μg/ml cycloheximide. 4 hours 
later, cycloheximide was washed out, followed by incubation in the presence of 1 μg/ml 
doxycycline and BFA (0.1 μg/ml) or methanol as a mock control, for 16 hours. The cells 
were imaged using live-cell confocal microscopy. In mock-treated cells, both 
VSVG-SP-GFP (Figure 21 A) and HASPB SH4-mCherry (Figure 21 B) localized to the 
plasma membrane and perinuclear membranes. Upon expression in the presence of 
BFA, VSVG-SP-GFP exhibited complete intracellular retention (Figure 21 D), whereas 
HASPB SH4-mCherry under these conditions reached the plasma membrane (Figure 
21 E).  
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Figure 21 Analysis of subcellular localization of a HASPB SH4 domain fusion protein (HASPB 
SH4-mCherry) and a vesicular stomatitis virus G protein fusion protein (VSVG-SP-GFP), coexpressed in 
the presence of brefeldin A (BFA). HeLa MCAT-TAM2 cells were cotransfected with pEGFP-N1/VSVG-SP 
and pRevTRE2/HASPB SH4-mCherry using FuGENE HD transfection reagent, in the presence of 1 μg/ml 
doxycycline and 100 μg/ml cycloheximide. 4 hours later, cycloheximide was washed out, followed by 
incubation in the presence of 1 μg/ml doxycycline and BFA (0.1 μg/ml) or methanol as a solvent control 
(mock), for 16 hours. The cells were imaged using live-cell confocal microscopy (objective 40x). 
Magnitude of perinuclear and intracellular accumulation of HASPB SH4-mCherry upon 
expression in the presence of BFA or methanol was determined by intensity 
quantification of sum intensity projections of Z stack images (Figure 22, A, B; each image 
represents a sum intensity projection of one Z stack). Expression in the presence of BFA 
resulted in increased perinuclear localization of HASPB SH4-mCherry as compared to 
mock-treated cells (p≤0.05, unpaired Student’s t-test; Figure 22 C), as well as in 
increased intracellular localization (p≤0.001, unpaired Student’s t-test; Figure 22 D). The 
increase in intracellular localization was more pronounced (1.50x versus 1.27x when 
comparing arithmetic means of percentages of accumulated protein in relation to total 
protein per cell), and more homogeneous across the cell population than the increase in 
perinuclear localization.  
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Figure 22 Quantitative analysis of subcellular localization of a HASPB SH4 domain fusion protein 
(HASPB SH4-mCherry) expressed in the presence of brefeldin A (BFA). HeLa MCAT-TAM2 cells were 
transfected with pRevTRE2/HASPB SH4-mCherry using FuGENE HD transfection reagent, in the presence 
of 1 μg/ml doxycycline and 100 μg/ml cycloheximide. 4 hours later, cycloheximide was washed out, 
followed by incubation in the presence of 1 μg/ml doxycycline and BFA (0.1 μg/ml) or methanol as a 
solvent control (mock), for 16 hours. The cells were imaged using live-cell confocal microscopy, by 
collecting Z stacks (objective 40x). (A, B) Each image represents a sum intensity projection of Z stack 
images. Scale bar, 10 μm. Magnitude of perinuclear (C) and intracellular (D) accumulation of 
HASPB SH4-mCherry upon expression in the presence of BFA or methanol (mock), determined by intensity 
quantification of sum intensity projections of Z stacks. Perinuclear/intracellular accumulation per cell is 
expressed as the percentage of perinuclear/intracellular signal respective to the total signal per cell. 
Values for individual cells are depicted as triangles, horizontal bars represent arithmetic means for each 
condition; * p≤0.05; ***, p≤0.001, unpaired Student’s t-test. 
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4.4 Immunogold electron microscopy analysis of subcellular localization 
of a HASPB SH4 domain fusion protein upon transfection with a 
scrambled or β-COP siRNA 
We analyzed the subcellular localization of a HASPB SH4 domain fusion protein (HASPB 
SH4-TEV-GFP) upon transfection with a scrambled or β-COP siRNA with the use of 
immunogold electron microscopy, conducted in collaboration with Dr. Jacomine 
Krijnse-Locker from the Electron Microscopy Core Facility (EMCF), BioQuant, University 
of Heidelberg. The aim was to establish the identity of the perinuclear membranes on 
which HASPB SH4 fusion protein accumulates upon β-COP knockdown (see Figure 17 B 
and Figure 18 E), and thus determine at which step its transport is blocked under these 
conditions. HeLa cell line stably expressing HASPB SH4-TEV-GFP in a doxycycline-
inducible manner (HeLa HASPB SH4-TEV-GFP clone 4; Figure 2 B; Figure 4 B) was 
transfected with a scrambled siRNA (Figure 23, A, B) or a β-COP siRNA (Figure 23, C-F), 
using Oligofectamine. 48 hours upon transfection (24 hours upon the induction with 
2 μg/ml doxycycline) the cells were fixed, embedded in gelatin, which was followed by 
sucrose infiltration and cryosectioning. Cryosections were double labeled using anti-GFP 
and anti-GM130 antibodies (Figure 23, A, C, E), or anti-GFP and anti-TGN46 antibodies 
(Figure 23, B, D, F), and protein A-gold conjugates of different sizes. Subsequently, 
cryosections were imaged using a transmission electron microscope.  
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Figure 23 Caption on page 72. 
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Caption for figure on page 71. Figure 23 Immunoelectron microscopy analysis of subcellular localization 
of a HASPB SH4 domain fusion protein (HASPB SH4-TEV-GFP), upon transfection with a scrambled siRNA 
or an siRNA targeting the β subunit of the COPI coatomer complex (β-COP). HeLa cell line stably 
expressing HASPB SH4-TEV-GFP in a doxycycline-inducible manner (HeLa HASPB SH4-TEV-GFP, clone 4) 
was transfected with a scrambled siRNA (A, B) or a β-COP siRNA (C-F), using Oligofectamine. 48 hours 
upon transfection (24 hours upon the induction with 2 μg/ml doxycycline) the cells were fixed, followed 
by embedding in gelatin, sucrose infiltration and cryosectioning. (A, C, E) Cryosections were double 
labeled using anti-GFP antibodies and 15 nm protein A-gold, followed by anti-GM130 antibodies and 
10 nm protein A-gold. (B, D, F) Cryosections were double labeled using anti-GFP antibodies and 15 nm 
protein A-gold, followed by anti-TGN46 antibodies and 10 nm protein A-gold. Cryosections were imaged 
using a transmission electron microscope. Pictures were taken at magnifications of 20000-25000x. Scale 
bar, 250 nm. G, Golgi stack; V, vesiculated Golgi. Small and large arrowheads point to 10 nm and 15 nm 
gold particles, respectively. Arrows point to Golgi-derived vesicles labeled with both 10 nm and 15 nm 
gold particles. 
 
In the control cells (transfected with a scrambled siRNA), gold labeling for HASPB SH4-
TEV-GFP in the perinuclear region was localized mainly to the opposite side of the Golgi 
apparatus, as compared to the labeling for GM130 (a marker for cis-Golgi; Figure 23 A). 
Consistently, HASPB SH4-TEV-GFP was localized on the side of the Golgi labeled for 
TGN46 (a trans-Golgi network marker), mainly outside of the Golgi stack (Figure 23 B), 
and less commonly, within the stack (not shown). SiRNA-mediated knockdown of β-COP 
caused striking changes in the morphology of the Golgi apparatus, namely complete loss 
of Golgi cisternae and vesiculation of the Golgi apparatus, with HASPB SH4-TEV-GFP 
localizing to some of those vesicles (Figure 23, C-F). Labeling for HASPB SH4-TEV-GFP 
and GM130 in the β-COP knockdown cells was localized to distinct regions of the 
vesiculated Golgi, with GM130 being localized more centrally (Figure 23, C, E). On the 
other hand, HASPB SH4-TEV-GFP and TGN46 in the knockdown cells seemed to be less 
separated than HASPB SH4-TEV-GFP and GM130, and localized more to the perimeter of 
the vesiculated Golgi area (Figure 23, D, F). We could also observe the occurrence of 
labeling for both HASPB SH4-TEV-GFP and TGN46 on the same vesicles (Figure 23, D, F; 
arrows). 
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4.5 Immunogold electron microscopy analysis of subcellular localization 
of a HASPB SH4 domain fusion protein upon its coexpression with 
Arf1 WT or Arf1 Q71L 
We then analyzed the subcellular localization of HASPB SH4-mCherry upon its 
coexpression with the wild-type (WT) Arf1, or its constitutively active mutant (Q71L), 
with the use of immunogold electron microscopy, to establish the identity of the 
perinuclear membranes on which the fusion protein accumulates upon coexpression 
with Arf1 Q71L (Figure 19 A, e; Figure 20 B). HeLa cell line stably expressing HASPB SH4-
mCherry in a doxycycline-inducible manner was transfected with pIRES2-EGFP/Arf1 WT 
(Figure 24, A, B) or pIRES2-EGFP/Arf1 Q71L (Figure 24, C-F) using jetPRIME transfection 
reagent, in the presence of 2 μg/ml doxycycline. 15 hours later, the cells were fixed, 
which was followed by embedding in gelatin, sucrose infiltration and cryosectioning. 
Cryosections were double labeled using anti-mRFP and anti-GM130 antibodies (Figure 
24, A, C, E), or anti-mRFP and anti-TGN46 antibodies (Figure 24, B, D, F), and 
protein A-gold conjugates of different sizes. Subsequently, cryosections were imaged 
using a transmission electron microscope.  
 
Caption for figure on page 74. Figure 24 Immunoelectron microscopy analysis of subcellular localization 
of a HASPB SH4 domain fusion protein (HASPB SH4-mCherry) upon its coexpression with the wild-type 
(WT) Arf1, or its constitutively active mutant (Q71L). HeLa cell line stably expressing HASPB SH4-mCherry 
in a doxycycline-inducible manner was transfected with pIRES2-EGFP/Arf1 WT (A, B) or pIRES2-EGFP/Arf1 
Q71L (C-F) using jetPRIME transfection reagent, in the presence of 2 μg/ml doxycycline. 15 hours later, the 
cells were fixed, followed by embedding in gelatin, sucrose infiltration and cryosectioning. (A, C, E) 
Cryosections were double labeled using anti-GM130 antibodies and 10 nm protein A-gold, followed by 
anti-mRFP antibodies (diluted 1:50) and 15 nm protein A-gold. (B, D, F) Cryosections were double labeled 
using anti-mRFP antibodies (diluted 1:30) and 15 nm protein A-gold, followed by anti-TGN46 antibodies 
and 10 nm protein A-gold. Cryosections were imaged using a transmission electron microscope. Pictures 
were taken at magnifications of 20000-50000x. Scale bar, 250 nm. G, Golgi stack; V, vesiculated Golgi. 
Small and large arrowheads point to 10 nm and 15 nm gold particles, respectively. Arrow points to a 
Golgi-derived vesicle labeled with both 10 nm and 15 nm gold particles. 
Results II 
 
 
74 
 
Figure 24 Caption on page 73. 
 
 
 Results II 
 
75 
In the control cells (i.e. expressing Arf1 WT), gold labeling for HASPB SH4-mCherry was 
localized mainly to the opposite side of the Golgi apparatus, as compared to the labeling 
for GM130 (Figure 24 A). Consistently, HASPB SH4-mCherry was localized on the side of 
the Golgi labeled for TGN46, mainly outside of the Golgi stack, but also within the stack 
(Figure 24 B). Expression of Arf1 Q71L resulted in almost complete (Figure 24 C), or 
complete (Figure 24, D-F) loss of Golgi cisternae, which were replaced by a great 
quantity of vesicular structures. HASPB SH4-mCherry and GM130 in Arf1 Q71L-
expressing cells were localized to distinct regions of the vesiculated Golgi, GM130 being 
localized more centrally (Figure 24, C, E). HASPB SH4-mCherry and TGN46 in 
Arf1 Q71L-expressing cells seemed to be less separated than HASPB SH4-mCherry and 
GM130, and localized more to the perimeter of the vesiculated Golgi area (Figure 24, D, 
F). We could also observe the occurrence of labeling for both HASPB SH4-mCherry and 
TGN46 on the same vesicles (Figure 24 F; arrow). 
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5 Discussion II 
Previous result from our laboratory (Ritzerfeld, 2009; Ritzerfeld et al., 2011) suggested 
an involvement of the β subunit of the COPI coatomer complex in the subcellular 
trafficking of diacylated SH4 domain proteins. Namely, siRNA-mediated knockdown of 
β-COP resulted in an increased perinuclear localization of a SH4 domain reporter fusion 
protein (HASPB SH4-GFP) in HeLa cells. It was also shown that down-regulation of β-COP 
results in decreased levels of δ-COP, and vice versa (Ritzerfeld et al., 2011), indicating 
that depletion of one coatomer subunit inhibits the assembly of the whole complex. 
Moreover, also knockdowns of other coatomer subunits, α, β′ and δ, were shown to 
result in a pronounced increase in perinuclear accumulation of HASPB SH4-GFP 
(Ritzerfeld, 2009; Ritzerfeld et al., 2011). Furthermore, the targeting of HASPB SH4-
mCherry was unaffected in cells that were microinjected with recombinant coatomer 
complex prior to transfection with β-COP siRNA (Ritzerfeld et al., 2011). Thus, 
phenotypic changes induced by the β-COP knockdown result from depletion of the 
coatomer complex. We decided to examine in more detail the involvement of coatomer 
in the transport of diacylated SH4 domain proteins to the plasma membrane. 
5.1 Analysis of subcellular localization of a HASPB SH4 domain fusion 
protein and a VSVG fusion protein upon β-COP knockdown 
SiRNA-mediated knockdown of the β subunit of the COPI coatomer complex in a stable 
HeLa cell line expressing HASPB SH4-mCherry in a doxycycline-inducible manner, 
resulted in a statistically significant increase in perinuclear localization of the fusion 
protein. The protein, however, was also found at the plasma membrane (Figure 17, 
B, C). The seeming failure of β-COP knockdown to completely inhibit the transport of 
HASPB SH4-mCherry to the plasma membrane may reflect insufficient knockdown 
efficiency, but it is also possible that the stable cell line exhibits some level of 
constitutive expression of HASPB SH4-mCherry, and thus the fusion protein was 
localized to the plasma membrane already before siRNA transfection and subsequent 
induction with doxycycline, and a low turnover rate of the protein let it remain at the 
plasma membrane. 
Discussion II 
 
77 
In a different experiment, HeLa cells that do not stably express any reporter fusion 
protein (HeLa MCAT-TAM2) were first transfected with an siRNA targeting β-COP, and 
24 hours later cotransfected with constructs encoding VSVG-SP-GFP, a GFP-tagged 
version of a model transmembrane glycoprotein, vesicular stomatitis virus glycoprotein 
(VSVG; Keller et al., 2001), and HASPB SH4-mCherry (Figure 18, D-F). In contrast to the 
above experiment, in this experiment there was no fusion protein at the plasma 
membrane before the siRNA transfection. Similarly to the previous experiment, despite 
exhibiting increased perinuclear localization, HASPB SH4-mCherry was again found at 
the plasma membrane (Figure 18 E). On the other hand, the transport of VSVG-SP-GFP 
to the plasma membrane was totally abolished under β-COP knockdown conditions 
(Figure 18 D), and the protein accumulated, similarly as the intracellular pool of HASPB 
SH4-mCherry, within a perinuclear globular compartment. In agreement with our 
results, anterograde transport of VSVG-GFP in β-COP-depleted HeLa cells was previously 
shown to be arrested at the level of large globular structures, with no VSVG-GFP 
detectable at the plasma membrane (Styers et al., 2008). The complete block in the 
transport of VSVG-SP-GFP under β-COP knockdown conditions suggests that the 
knockdown was efficient and abolished transport via the secretory pathway. It implies 
that the presence of HASPB SH4-mCherry at the plasma membrane does not result from 
insufficient knockdown efficiency, but rather suggests that the transport of HASPB SH4-
mCherry to the plasma membrane is operational under β-COP knockdown conditions. 
The perinuclear accumulation of HASPB SH4-mCherry may reflect a transport block 
occurring at perinuclear membranes, pointing to their involvement in the transport of 
HASPB SH4-mCherry. The protein, however, seems to be able to reach the plasma 
membrane via an alternative pathway which bypasses the transport block. 
5.2 Analysis of subcellular localization of a HASPB SH4 domain fusion 
protein and a VSVG fusion protein upon coexpression with Arf1 Q71L 
Association of the COPI coatomer complex with membranes (and thus the formation of 
COPI vesicles) depends on its recruitment by the small GTPase Arf1, which in turn 
requires GTP binding by Arf1 and the resulting exposure of its myristoylated N-terminal 
amphipathic α-helix that provides stable membrane anchorage (Antonny et al., 1997; 
see sections 1.1 and 1.4.3). Hydrolysis of GTP by Arf1 was shown to be involved in the 
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uptake of cargo proteins into COPI vesicles (Malsam et al., 1999; Pepperkok et al., 2000), 
and in uncoating of the vesicles (Tanigawa et al., 1993). Replacement of glutamine 71 in 
Arf1 with leucine in the guanine nucleotide binding pocket results in a mutant (Q71L) 
which is unable to hydrolyze GTP and is thus constitutively active (Dascher et al., 1994; 
Teal et al., 1994; Zhang et al., 1994). Its trans-dominant effect is thought to result from 
the sequestration of Arf GTPase-activating proteins (Arf GAPs), thus preventing 
inactivation of endogenous Arf1 (Zhang et al., 1994). 
 
Either HASPB SH4-mCherry or VSVG-SP-mRFP was transiently coexpressed with Arf1 
Q71L in HeLa MCAT-TAM2 cells. Under these conditions, VSVG-SP-mRFP exhibited a 
complete intracellular retention, and accumulated at perinuclear structures (Figure 
19 B, e), indicating a complete block in the transport of the protein to the plasma 
membrane, and suggesting that transport via the secretory pathway was abolished. 
Similarly, Arf1 Q71L expressed in normal rat kidney (NRK) cells was shown to inhibit 
secretion of [35S] methionine-labeled proteins (Zhang et al., 1994), and its 
overexpression in HeLa cells resulted in the inhibition of ER to medial-Golgi and 
intra-Golgi transport of VSVG (Dascher et al., 1994). HASPB SH4-mCherry expressed in 
the presence of Arf1 Q71L exhibited an increased perinuclear accumulation (Figure 
19 A, e; Figure 20, B, C), but nevertheless localized also to the plasma membrane, 
indicating that the transport of HASPB SH4-mCherry is operational under these 
conditions. The perinuclear accumulation of HASPB SH4-mCherry may reflect a transport 
block occurring at perinuclear membranes, pointing to their involvement in the 
transport of HASPB SH4-mCherry. The protein, however, seems to be able to bypass the 
transport block and reach the plasma membrane via an alternative pathway. 
5.3 Analysis of subcellular localization of a HASPB SH4 domain fusion 
protein and a VSVG fusion protein upon their expression in the 
presence of brefeldin A 
Brefeldin A (BFA) is a fungal macrocyclic lactone (Härri et al., 1963), which stabilizes a 
non-productive complex between Arf1-GDP and Sec7 domain of BFA-sensitive Arf GEFs 
(Peyroche et al., 1999), thus sequestering Arf GEFs and acting as a noncompetitive 
inhibitor of Arf1 activation. BFA induces dissociation of Arf1 and β-COP from the Golgi 
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apparatus into the cytoplasm, thus inhibiting the formation of COPI vesicles (Donaldson 
et al., 1990; Donaldson et al., 1991), which is followed by the breakdown of the Golgi 
stacks into tubules that extend along microtubules and fuse with the endoplasmic 
reticulum, resulting in redistribution of cis-, medial- and trans-Golgi enzymes back to the 
ER (Lippincott-Schwartz et al., 1989; Chege et al., 1990; Sciaky et al., 1997). Transport 
out of the mixed Golgi-ER system is blocked (Misumi et al., 1986; Lippincott-Schwartz et 
al., 1989). The dissociation of β-COP, disruption of the Golgi apparatus, and inhibition of 
protein secretion, take place already at relatively low concentrations of BFA (0.05 μg/ml) 
(Klausner et al., 1992). It was proposed that upon inhibition of the formation of COPI 
vesicles by BFA, retrograde vesicle-associated SNARE proteins (v-SNARES) remain 
exposed on the Golgi, which underlies the direct and uncontrolled fusion of Golgi 
cisternae with the ER (Elazar et al., 1994). BFA was also shown to induce tubulation of 
endosomes, lysosomes and the trans-Golgi network (TGN), at the same concentrations 
that affect the Golgi apparatus (Lippincott-Schwartz et al., 1991). TGN-resident proteins, 
such as sialyltransferase and TGN38, were shown not to redistribute to the ER upon BFA 
treatment (Chege et al., 1990; Lippincott-Schwartz et al., 1991; Ladinsky et al., 1992), 
but rather mix with the early endosomal system (Lippincott-Schwartz et al., 1991). 
Moreover, BFA was shown to inhibit transport from distal Golgi compartments to the 
plasma membrane, via both constitutive and regulated pathways, for example, it 
blocked plasma membrane transport of VSVG accumulated at 20°C in the TGN of BHK-21 
cells (Miller et al., 1992). 
 
To test whether HASPB SH4-mCherry travels to the plasma membrane via the secretory 
pathway, we expressed the fusion protein in the presence of BFA. As a control for the 
effect of BFA, HASPB SH4-mCherry was coexpressed with VSVG-SP-GFP, a 
transmembrane protein, the transport of which should be inhibited by BFA at the level 
of the fused ER-Golgi compartment. Both proteins were expressed transiently to 
ascertain that none of the proteins was localized to the plasma membrane before the 
addition of BFA, and that the whole expression took place in the presence of the drug. 
Upon expression in the presence of BFA, VSVG-SP-GFP exhibited complete intracellular 
retention (Figure 21 D), accumulating most possibly in the fused ER-Golgi compartment. 
HASPB SH4-mCherry however, under these conditions reached the plasma membrane 
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(Figure 21 E), despite disruption of the structure and compromising the function of 
secretory organelles by BFA, as demonstrated by the inhibition of VSVG-SP-GFP 
transport. Thus, functional secretory pathway, and even properly organized secretory 
organelles, are dispensable for the transport of HASPB SH4-mCherry to the plasma 
membrane. When expressed in the presence of BFA, apart from plasma membrane 
localization, HASPB SH4-mCherry exhibited also highly significant increase in intracellular 
localization (Figure 22 D), possibly reflecting its accumulation in the ER-Golgi hybrid 
compartment. The quantified increase in perinuclear localization, which was much less 
significant (Figure 22 C), could be due to accumulation of HASPB SH4-mCherry in the 
perinuclear portion of the hybrid compartment. Accumulation of HASPB SH4-mCherry in 
the fused ER-Golgi compartment upon BFA treatment suggests that under control 
conditions the protein at one point associates with the ER, or more probably, with cis-, 
medial- or trans-Golgi, as these Golgi subcompartments, as already mentioned, are 
known to fuse back to the ER in the presence of BFA (Lippincott-Schwartz et al., 1989; 
Chege et al., 1990; Sciaky et al., 1997). What is more, the observed accumulation points 
out to the involvement of the secretory pathway in the plasma membrane transport of 
HASPB SH4-mCherry. However, there seems to exist an alternative pathway, which is 
independent from the secretory pathway, as suggested by the appearance of the HASPB 
SH4 domain fusion protein at the plasma membrane in the presence of BFA.    
5.4 Immunogold electron microscopy analysis of subcellular localization 
of a HASPB SH4 domain fusion protein upon transfection with a 
scrambled or β-COP siRNA 
Immunogold electron microscopy analysis of the perinuclear Golgi region of scrambled 
siRNA-transfected HeLa cells stably expressing HASPB SH4-TEV-GFP (Figure 23, A, B), 
indicates that the protein localizes mainly to the trans-Golgi network, an array of tubules 
and vesicles found on one side of the Golgi stack. In contrast, in β-COP-depleted cells 
there were no stacks, and the Golgi complex was fragmented into vesicular structures, 
which accumulated in the perinuclear region, with HASPB SH4-TEV-GFP localizing to 
some of those vesicles (Figure 23, C-F). This fragmented Golgi phenotype of β-COP 
knockdown cells is in agreement with what was previously observed (Guo et al., 2008; 
Saitoh et al., 2009), and indicates that depletion of COPI affects not only the function (as 
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indicated by complete intracellular retention of VSVG-SP-GFP and increased perinuclear 
accumulation of HASPB SH4-mCherry; Figure 17, B, C and Figure 18, D-F), but also the 
structure of the secretory pathway. Our results suggest that even though under β-COP 
knockdown conditions the Golgi is fragmented, its polarity is to some extent maintained, 
as HASPB SH4-TEV-GFP did not seem to localize to vesicular structures labeled for the 
cis-Golgi marker GM130, which were localized to the center of the vesiculated Golgi 
area (Figure 23, C, E), but was rather observed in the region containing vesicles labeled 
for the TGN marker TGN46, with the occurrence of labeling for HASPB SH4-TEV-GFP and 
TGN46 on the same vesicles (Figure 23, D, F). Similarly, it was previously shown using 
immunofluorescence that whereas ERGIC and cis-Golgi markers exhibit significant 
colocalization in β-COP knockdown cells, ERGIC and trans-Golgi markers do not 
significantly overlap under these conditions (Saitoh et al., 2009). 
 
It seems likely that the effect of COPI depletion on anterograde transport of both 
VSVG-SP-GFP and HASPB SH4-mCherry is not a direct consequence of the lack of 
formation of COPI vesicles (which are known to mediate primarily retrograde transport), 
but a result of changes in Golgi morphology due to the inhibition of retrograde transport 
or the lack of COPI coats on Golgi membranes. It seems reasonable to expect that upon 
the disruption of the Golgi stack and vesiculation of Golgi cisternae, the cisternal 
maturation and progression responsible for anterograde intra-Golgi transport cannot 
occur anymore, hence the observed transport block. It has been proposed that 
palmitoylation, and therefore also the initial stable membrane association of diacylated 
SH4 domain proteins occurs at the Golgi (Kasahara et al., 2004; Sato et al., 2009). If 
HASPB SH4-TEV-GFP was palmitoylated at the cis-Golgi, under β-COP knockdown 
conditions (i.e. in the absence of anterograde intra-Golgi transport) the protein would 
accumulate at cis-Golgi-derived fragments. The lack of HASPB SH4-TEV-GFP localization 
to vesicular structures labeled for GM130 (Figure 23, C, E) suggests that its initial stable 
membrane association (and thus also palmitoylation) does not take place at the 
cis-Golgi, but rather at more distal Golgi compartments. 
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5.5 Immunogold electron microscopy analysis of subcellular localization 
of a HASPB SH4 domain fusion protein upon its coexpression with 
Arf1 WT or Arf1 Q71L 
Immunogold electron microscopy analysis of the perinuclear Golgi region of HeLa cells 
stably expressing HASPB SH4-mCherry, transiently transfected with a plasmid encoding 
the wild-type (WT) Arf1 (Figure 24, A, B), indicates that HASPB SH4-mCherry localizes 
primarily to the trans-Golgi network, but also to the distal portions of the Golgi stack, 
which is in agreement with the localization of HASPB SH4-TEV-GFP, stably expressed in 
scrambled siRNA-transfected HeLa cells (Figure 23, A, B). In cells expressing Arf1 Q71L, 
the Golgi apparatus disassembled into vesicular structures accumulating in the 
perinuclear region (Figure 24, C-F), which is in agreement with what was previously 
reported for Arf1 Q71L overexpressed in NRK cells (Zhang et al., 1994).  
 
Apart from the coatomer complex, Arf1 has many other effectors at the Golgi (such as 
various coat proteins, lipid-modifying enzymes, lipid-transfer proteins and tethers; 
Donaldson et al., 2011). However, the similarity of the phenotypes (both with regard to 
protein localization and Golgi morphology) caused by Arf1 Q71L expression, to those 
upon β-COP knockdown, suggests that the effect of Arf1 Q71L on Golgi structure and 
function results primarily (if not completely) from interfering with COPI functions, and is 
not caused by the inhibition of other Arf1 effectors. It was previously shown that Arf1 
Q71L leads to stable association of COPI with the Golgi membranes (Dascher et al., 
1994; Teal et al., 1994), which may be what causes the Golgi to vesiculate. Thus, 
maintenance of the Golgi structure would require Arf1 to undergo cycles of membrane 
association and dissociation. Alternatively, the fragmentation of the Golgi could be 
caused by inhibition of COPI-dependent transport as a result of impaired cargo uptake 
into COPI vesicles, in agreement with the reported role of Arf1-mediated GTP hydrolysis 
in this process (Malsam et al., 1999; Pepperkok et al., 2000). In turn, the vesiculation of 
the Golgi complex may underlie the observed inhibition of transport through the 
secretory pathway (indicated by complete intracellular retention of VSVG-SP-mRFP, and 
increased perinuclear accumulation of HASPB SH4-mCherry; Figure 19 A, e and B, e; 
Figure 20, B, C). 
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In some cells, the disassembly of the Golgi apparatus was not complete, with only the 
trans-face transformed into vesicles, and the cis-face intact (Figure 24 C), which 
indicates that the vesiculation starts from the trans-side of the Golgi. Similarly as in the 
control cells (Figure 24 A), also upon partial or complete fragmentation of the Golgi in 
Arf1 Q71L-expressing cells, HASPB SH4-mCherry remained segregated from the cis-Golgi 
marker GM130 (Figure 24, C, E), indicating that the polarity of the Golgi was to some 
extent retained, which is similar to what we observed for β-COP knockdown conditions 
(Figure 23, C, E). The lack of accumulation of HASPB SH4-mCherry on cis-Golgi-derived 
fragments upon Arf1 Q71L expression, once again suggests that under control 
conditions HASPB SH4-mCherry does not pass through the cis-Golgi, but rather 
associates with more distal Golgi compartments, which is followed by Golgi-dependent 
transport of the protein to the plasma membrane.    
5.6 Concluding remarks 
The localization phenotypes of the HASPB SH4 fusion protein under conditions that 
disrupt the structure and function of the Golgi apparatus, i.e. β-COP knockdown, 
expression of Arf1 Q71L and BFA treatment, indicate that the initial stable membrane 
association of the fusion protein (most probably as a result of palmitoylation) could 
occur at medial/trans-Golgi (possibly also at the TGN), and what is more, point out to 
the role of the Golgi in the plasma membrane transport of SH4 reporter proteins. This 
apparent involvement of the secretory pathway is in agreement with what was observed 
by others for full-length diacylated Src family kinases Lyn and Yes, which associate with 
the Golgi complex in the initial phase of their expression, exhibit increased perinuclear 
localization upon incubation at 19°C, and whose Golgi to plasma membrane transport is 
inhibited by N-ethylmaleimide (Kasahara et al., 2004; Sato et al., 2009; see also sections 
1.5.1.4 and 1.5.1.5).  
 
We could observe that none of the treatments that disrupt the Golgi block the 
appearance of the SH4 reporter protein at the plasma membrane, suggesting the 
existence of an alternative trafficking pathway that does not require the Golgi complex. 
Palmitoyl transferases (PATs) are mostly known to localize to the ER/Golgi membranes, 
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and the Golgi apparatus was proposed to function as a hub for palmitoylation (Rocks et 
al., 2010). However, there exist PATs which exhibit plasma membrane localization (Ohno 
et al., 2006; see section 1.4.4), indicating that some of the palmitoylation events may 
occur at the plasma membrane, a possibility which was not excluded by Rocks et al. 
Proteins palmitoylated at the plasma membrane would not depend on a functional 
secretory pathway for their plasma membrane localization, unlike proteins 
palmitoylated at the ER/Golgi membranes. The SH4 domain reporter protein seems to 
reach the plasma membrane also via a secretory pathway-independent route, which 
could involve its palmitoylation directly at the plasma membrane, as proposed for the 
Src kinase Fyn (van’t Hof et al., 1997; Sato et al., 2009; see section 1.5.1.2). Although the 
SH4 domain alone was shown to be sufficient for palmitoylation to occur (McCabe et al., 
1999; Tournaviti et al., 2009), the specificity of interaction with the appropriate PAT may 
be controlled also by distal parts of the protein to be palmitoylated (Nadolski et al., 
2009; see section 1.4.4). Thus, our model system, consisting of a SH4 domain fused to a 
fluorescent protein, may in fact be an oversimplified one, allowing palmitoylation, but 
making it promiscuous, i.e. occurring at multiple subcellular locations, including the 
plasma membrane. For the palmitoylation to occur only at locations within the cell 
typical for endogenous diacylated SH4 domain proteins, interactions mediated by 
domains downstream of the SH4 domain would be required. As a heterologous protein, 
however, full-length HASPB may lack domains conferring specificity of interaction with 
human DHHCs, and thus its palmitoylation could still occur promiscuously. The presence 
of two alternative pathways in the plasma membrane transport of SH4 domain reporter 
fusion proteins may explain why during the whole-genome RNAi screen aimed at 
identifying factors involved in this process, down-regulation of none of the gene 
products caused complete intracellular retention of the reporter proteins (Ritzerfeld, 
2009; Ritzerfeld et al., 2011). 
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6 Materials and methods 
6.1 Materials 
6.1.1 Chemicals and consumables 
1 kb DNA Ladder New England Biolabs, Frankfurt, Germany 
2-(N-morpholino)ethanesulfonic acid (MES) Carl Roth GmbH, Karlsruhe, Germany 
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
5ml Polystyrene Round-Bottom Tubes with 
Cell-Strainer Cap 
BD Biosciences, Erembodegem, Belgium 
Acetic acid (CH3COOH) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Agar Becton Dickinson, Le Pont de Claix, France 
Agarose Invitrogen Ltd., Paisley, UK 
Ammonium acetate (CH3COONH4) Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
Ammonium persulfate (APS) Carl Roth GmbH, Karlsruhe, Germany 
Ampicillin sodium salt Gerbu Biotechnik GmbH, Gaiberg, Germany 
Aqua ad iniectabilia Braun AG, Melsungen, Germany 
BD Microlance 3 27G x 3/4", 0,4 mm x 19 mm 
needles 
Becton Dickinson, Drogheda, Ireland 
BD Plastipak 1 ml syringe Becton Dickinson S.A., Madrid, Spain 
BD Plastipak 50 ml syringe Becton Dickinson, Drogheda, Ireland 
Bovine serum albumin (BSA) Carl Roth GmbH, Karlsruhe, Germany 
Brefeldin A (BFA) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Bromophenol blue Na-salt Serva Electrophoresis GmbH, Mannheim, Germany 
BSA (100X)  New England Biolabs, Frankfurt, Germany 
Cell culture dishes Corning Inc., Corning, USA 
Cell Dissociation Buffer  Invitrogen Ltd., Paisley, UK 
Cell scraper 23 cm Orange Scientific, Braine-l’Alleud, Belgium 
Cell scraper 25 cm Sarstedt AG & Co., Nümbrecht, Germany 
Chloroform Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
Chloroquine diphosphate salt Sigma F and D, St. Louis, USA 
Collagen R Serva Electrophoresis GmbH, Heidelberg, Germany 
Complete Protease Inhibitor Cocktail Tablets, 
EDTA-free 
Roche Diagnostics, Mannheim, Germany 
COPB1 Silencer Pre-designed siRNA, ID: 24546 Ambion, Applied Biosystems, Darmstadt, Germany 
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CryoTubes Cryo.s Greiner Bio-One GmbH, Frickenhausen, Germany 
Cycloheximide Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
D(+)-saccharose Applichem GmbH, Darmstadt, Germany 
Diethylaminoethyl-dextran (DEAE-dextran) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Doxycycline Clontech Laboratories Inc., Mountain View, USA 
Dulbecco’s modiﬁed Eagle’s medium (DMEM) Biochrom AG, Berlin, Germany 
Dynabeads Protein G for Immunoprecipitation Invitrogen Dynal AS, Oslo, Norway 
EM copper grids, hexagonal 100 meshes, G2410C Plano GmbH, Wetzlar, Germany 
Eppendorf tubes 1.5 ml, 2 ml Sarstedt AG & Co., Nümbrecht, Germany 
Erlenmeyer (Fernbach design) cell culture flasks, 3 l  Corning Inc., Corning, USA 
Ethanol absolute Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Ethidium bromide Carl Roth GmbH, Karlsruhe, Germany 
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-
tetraacetic acid (EGTA) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Ethylenediaminetetraacetic acid (EDTA) disodium 
salt dihydrate 
Applichem GmbH, Darmstadt, Germany 
Fetal Calf Serum (FCS) gold PAA Laboratories GmbH, Cölbe, Germany 
Formaldehyde 16% 
Electron Microscopy Sciences, Science Services 
GmbH, Munich , Germany 
FuGENE HD Transfection Reagent Promega Corporation, Madison, USA 
Gelatin Merck KGaA, Darmstadt, Germany 
Gelatin from cold water fish skin Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Glass vials, 4 ml + Teflon lined screw caps Neolab, Heidelberg, Germany 
Glutaraldehyde 25% 
Electron Microscopy Sciences, Science Services 
GmbH, Munich , Germany 
Glycerol Carl Roth GmbH, Karlsruhe, Germany 
Glycine Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Hydrochloric acid (HCl) 37% Merck KGaA, Darmstadt, Germany 
Immobilon-FL Transfer Membrane Millipore Corporation, Bedford, USA 
Isopropanol Merck KGaA, Darmstadt, Germany 
JetPRIME transfection reagent Polyplus-transfection SA, Illkirch, France 
Kanamycin sulfate Gerbu Biotechnik GmbH, Gaiberg, Germany 
L-glutamine Biochrom AG, Berlin, Germany 
Lab-Tek Chambered Coverglass, 8-well Thermo Fisher Scientific, Rochester, USA 
Lab-Tek II Coverglass, 2-well  Thermo Fisher Scientific, Rochester, USA 
Lipid standards, PC and PI Avanti Polar Lipids Inc., Alabaster, USA 
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Magnesium acetate tetrahydrate 
((CH3COO)2Mgx4H2O) 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Magnesium chloride, anhydrous (MgCl2) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Methanol Applichem GmbH, Darmstadt, Germany 
Methyl cellulose Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Methylene blue Carl Roth GmbH, Karlsruhe, Germany 
Microfuge Tube Polyallomer, 1.5 ml Beckman Instruments Inc., Palo Alto, USA 
Milk powder Carl Roth GmbH, Karlsruhe, Germany 
Mycoplasma Removal Agent MP Biomedicals Inc., Solon, USA 
N,N,N′,N′-tetramethylethylenediamine (TEMED) Carl Roth GmbH, Karlsruhe, Germany 
NEBuffer 1 for restriction enzymes New England Biolabs, Frankfurt, Germany 
NuPAGE Antioxidant Invitrogen Ltd., Paisley, UK 
NuPAGE LDS Sample Buffer (4X) Invitrogen Ltd., Carlsbad, USA 
NuPAGE MOPS SDS Running Buffer (20X) Invitrogen Ltd., Carlsbad, USA 
NuPAGE Novex 4-12% and 10% Bis-Tris Gels Life Technologies, Carlsbad, USA 
NuPAGE Sample Reducing Agent (10X) Invitrogen Ltd., Carlsbad, USA 
Oligofectamine Reagent Invitrogen Ltd., Carlsbad, USA 
Oligonucleotides Thermo Fisher Scientific GmbH, Ulm, Germany 
Open-top polyclear centrifuge tubes, 11x60 mm 
(SW 60) 
Seton Scientific, Petaluma, USA 
Open-top polyclear centrifuge tubes, 14x89 mm 
(SW 41) 
Seton Scientific, Petaluma, USA 
Open-top polyclear centrifuge tubes, 25x89 mm 
(SW 32) 
Science Services GmbH, Munich, Germany 
Opti-MEM I + GlutaMAX-I Invitrogen Ltd., Paisley, UK 
OptiPrep Density Gradient Medium Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
PageRuler Prestained Protein Ladder Fermentas GmbH, St. Leon-Rot, Germany 
Parafilm M BRAND GMBH + CO KG, Wertheim, Germany 
PBS-powder without Ca2+, Mg2+ Biochrom AG, Berlin, Germany 
Penicillin/Streptomycin Biochrom AG, Berlin, Germany 
Pioloform (polyvinyl butyral)  Plano GmbH, Wetzlar, Germany 
Piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) Carl Roth GmbH, Karlsruhe, Germany 
Potassium chloride (KCl) Applichem GmbH, Darmstadt, Germany 
Potassium dihydrogen phosphate (KH2PO4) Applichem GmbH, Darmstadt, Germany 
Prestained SDS-PAGE Standards, Broad Range Bio-Rad Laboratories GmbH, Munich, Germany 
Roswell Park Memorial Institute medium (RPMI) Biochrom AG, Berlin, Germany 
Roti-Blue 5X Carl Roth GmbH, Karlsruhe, Germany 
Rotilabo syringe filters, 0.22 µm and 0.45 µm Carl Roth GmbH, Karlsruhe, Germany 
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Rotiphorese Gel 30 (37.5:1)  Carl Roth GmbH, Karlsruhe, Germany 
Serological pipettes Greiner Bio-One GmbH, Frickenhausen, Germany 
Silencer Negative Control siRNA #1 Ambion, Applied Biosystems, Darmstadt, Germany 
Sodium acetate (CH3COONa) Grüssing GmbH, Filsum, Germany 
Sodium azide (NaN3) Carl Roth GmbH, Karlsruhe, Germany 
Sodium chloride (NaCl) Applichem GmbH, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium hydroxide (NaOH) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium phosphate dibasic dihydrate 
(Na2HPO4x2H2O) 
Riedel de Haën, Seelze, Germany 
Sucrose ultrapure MB grade  Affymetrix, Cleveland, USA 
Surgical blades SCHREIBER GmbH, Fridingen, Germany 
Tris(hydroxymethyl)aminomethane (Tris) Carl Roth GmbH, Karlsruhe, Germany 
Triton X-100 Merck KGaA, Darmstadt, Germany 
Trypan blue 0.5% Biochrom AG, Berlin, Germany 
Trypsin/EDTA Biochrom AG, Berlin, Germany 
Tryptone Becton Dickinson, Le Pont de Claix, France 
Tubes 15 ml, 50 ml Sarstedt AG & Co., Nümbrecht, Germany 
Tween 20 Carl Roth GmbH, Karlsruhe, Germany 
Water HiPerSolv Chromanorm for HPLC VWR International, Leuven, Belgium 
Xylene cyanol FF Serva Electrophoresis GmbH, Heidelberg, Germany 
Yeast extract Carl Roth GmbH, Karlsruhe, Germany 
β-mercaptoethanol Merck Schuchardt OHG, Hohenbrunn, Germany 
µ-Dish 35 mm, glass bottom ibidi GmbH, Martinsried , Germany 
 
6.1.2 Enzymes 
AgeI restriction enzyme New England Biolabs, Frankfurt, Germany 
BamHI-HF restriction enzyme New England Biolabs, Frankfurt, Germany 
Tobacco etch virus (TEV) protease Research Group Prof. Dr. Walter Nickel 
 
6.1.3 Antibodies 
6.1.3.1  Primary antibodies  
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Antigen Antibody - primary Manufacturer/source Application Dilution  
Brain acid soluble 
protein 1 
Nap-22 antibody 
(H-100): sc-66994, 
rabbit polyclonal 
Santa Cruz 
Biotechnology Inc., 
Heidelberg, Germany 
Western blotting 
1:20, 
1:50 
Flotillin-1 
Flotillin-1 (H-104) 
antibody: sc-25506, 
rabbit polyclonal 
Santa Cruz 
Biotechnology Inc., 
Heidelberg, Germany 
Western blotting 1:200 
GFP 
Rabbit anti-GFP, 
polyclonal, affinity 
purified 
Research Group       
Prof. Dr. Walter Nickel 
Western blotting                    
Immunoelectron 
microscopy 
1:500
              
1:20 
GFP 
Living Colors anti-GFP, 
mouse monoclonal 
Clontech Laboratories 
Inc., Mountain View, 
USA 
Western blotting 
1:5000, 
1:10000 
GM130 
Anti-GOLGA2 antibody, 
rabbit polyclonal, 
HPA021799   
Sigma-Aldrich Chemie 
GmbH, Steinheim, 
Germany 
Western blotting        
Immunoelectron 
microscopy 
1:500   
                                                                                                                                                                                                                                                                                                                 
1:5 
mCherry, mRFP 
Anti-mRFP, rabbit 
polyclonal 
Research Group          
Dr. Barbara Müller, 
Department of 
Infectious Diseases, 
Virology, University 
Hospital of Heidelberg 
Immunoelectron 
microscopy 
 1:30, 
1:50 
Moesin 
Moesin antibody 
(38/87): sc-58806, 
mouse monoclonal 
Santa Cruz 
Biotechnology Inc., 
Heidelberg, Germany 
Western blotting 1:50 
Non-POU domain-
containing octamer-
binding protein 
P54/nrb antibody 
(C-16): sc-46220, goat 
polyclonal 
Santa Cruz 
Biotechnology Inc., 
Heidelberg, Germany 
Western blotting 
1:20, 
1:50 
Ras GTPase-activating-
like protein IQGAP1 
IQGAP1 antibody 
(H-109): sc-10792, 
rabbit polyclonal 
Santa Cruz 
Biotechnology Inc., 
Heidelberg, Germany 
Western blotting 1:500 
Ribophorin-1 
Ribophorin-1 (C-15) 
antibody: sc-12164, 
goat polyclonal 
Santa Cruz 
Biotechnology Inc., 
Heidelberg, Germany 
Western blotting 1:200 
Splicing factor, 
proline- and 
glutamine-rich 
Anti-SFPQ antibody 
(ab99357), rabbit 
polyclonal 
Abcam, Cambridge, UK Western blotting 
1:5000, 
1:10000 
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Antigen Antibody - primary Manufacturer/source Application Dilution  
TGN46 
Anti-TGOLN2 antibody, 
rabbit polyclonal, 
HPA012723 
Sigma-Aldrich Chemie 
GmbH, Steinheim, 
Germany 
Immunoelectron 
microscopy 
1:25 
Transferrin receptor 
Mouse anti-human 
transferrin receptor, 
monoclonal, clone 
H68.4 
Zymed Laboratories 
Inc., San Francisco, USA 
Western blotting 1:500 
Yes 
Purified mouse 
anti-Yes, monoclonal 
BD Transduction 
Laboratories, San 
Diego, USA 
Western blotting 1:500 
6.1.3.2  Secondary antibodies 
 
Antigen Antibody - secondary Manufacturer Application Dilution  
Goat IgG 
Alexa Fluor 680 donkey 
anti-goat IgG (H+L) 
Molecular Probes, 
Leiden, Germany 
Western blotting 1:10000 
Mouse IgG 
Alexa Fluor 680 goat 
anti-mouse IgG (H+L) 
Molecular Probes, 
Leiden, Germany 
Western blotting 1:10000 
Mouse IgG 
IRDye 800CW goat 
anti-mouse IgG (H+L) 
LI-COR Biosciences, Bad 
Homburg, Germany 
Western blotting 1:10000 
Rabbit IgG 
Alexa Fluor 680 goat 
anti-rabbit IgG (H+L) 
Molecular Probes, 
Leiden, Germany 
Western blotting 1:10000 
Rabbit IgG 
Mouse anti-rabbit IgG 
(conformation specific) 
(L27A9) mAb 
Cell Signaling 
Technology Inc., 
Danvers, USA 
Western blotting 1:2000 
6.1.3.3  Tertiary antibodies 
 
Antigen Antibody - tertiary Manufacturer Application Dilution  
Mouse IgG 
Alexa Fluor 680 goat 
anti-mouse IgG (H+L) 
Molecular Probes, 
Leiden, Germany 
Western blotting 1:20000 
Mouse IgG 
IRDye 800CW goat 
anti-mouse IgG (H+L) 
LI-COR Biosciences, Bad 
Homburg, Germany 
Western blotting 1:20000 
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6.1.4 Molecular biology and biochemical kits 
DNA Ligation Kit Ver.2.1 TaKaRa Biochemical, Berkeley, USA 
MBS Mammalian Transfection Kit Stratagene, La Jolla, USA 
NucleoBond PC 100 Macherey-Nagel, Düren, Germany 
NucleoSpin Plasmid  Macherey-Nagel, Düren, Germany 
QIAGEN Plasmid Midi Kit QIAGEN GmbH, Hilden, Germany 
QIAquick Gel Extraction Kit QIAGEN GmbH, Hilden, Germany 
 
6.1.5 Technical devices 
4639 Cell Disruption Vessel Parr Instrument Company, Moline, USA 
Agarose gel chamber Bio-Rad Laboratories GmbH, Munich, Germany 
BILATEST Separator M12+12 Bilatec AG, Viernheim, Germany 
Centrifuge 5415C Eppendorf AG, Hamburg, Germany 
Centrifuge 5417R Eppendorf AG, Hamburg, Germany 
Centrifuge 5804 Eppendorf AG, Hamburg, Germany 
Centrifuge 5804R Eppendorf AG, Hamburg, Germany 
CP64 Balance Sartorius AG, Göttingen, Germany 
Cryo-ultramicrotome EM UC6/EM FC6  Leica Mikrosysteme GmbH, Vienna, Austria 
Diamond cutting knife cryo immuno Diatome AG, Biel, Switzerland 
Diamond trimming knife cryotrim 45° Diatome AG, Biel, Switzerland 
DigestPro MS  Intavis AG, Cologne, Germany 
Dynal MPC-1 Magnetic Particle Concentrator Invitrogen Dynal AS, Oslo, Norway 
EM 10 transmission electron microscope Carl Zeiss, Göttingen, Germany 
ESI-LTQ-Orbitrap mass spectrometer  Thermo Fisher Scientific Inc., Dreiech, Germany 
FACSAria cell sorter Becton Dickinson, Le Pont de Claix, France 
FACSCalibur Becton Dickinson, Le Pont de Claix, France 
Function Line T12 Incubator Heraeus, Hanau, Germany 
Gel Doc 2000 Gel Documentation System Bio-Rad Laboratories GmbH, Munich, Germany 
HAAKE DC10 Water Bath Thermo Fisher Scientific GmbH, Ulm, Germany 
Heraeus Megafuge 40R Thermo Fisher Scientific GmbH, Ulm, Germany 
HERAsafe Microbiological Safety Cabinet Thermo Fisher Scientific GmbH, Ulm, Germany 
Inertsil C18 3 µm analytical column LC Packings-Dionex GmbH, Idstein, Germany 
Inertsil C18 trapping column  LC Packings-Dionex GmbH, Idstein, Germany 
Kern 474 Balance Gottl. Kern & Sohn GmbH, Albstadt, Germany 
Liebisch evaporator and heating device Liebisch GmbH & Co. KG, Bielefeld, Germany 
LSM 510 Confocal Laser Scanning Microscope Carl Zeiss, Göttingen, Germany 
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Magnetic Stirrers MR 3000 and 3001 
Heidolph Instruments GmbH & Co. KG, Schwabach, 
Germany 
Mini Trans-Blot System Bio-Rad Laboratories GmbH, Munich, Germany 
Mini-PROTEAN 3 Cell Bio-Rad Laboratories GmbH, Munich, Germany 
Multitron Incubator System Infors GmbH, Einsbach, Germany 
Nano-ESI emitter  New Objective Inc., Woburn, USA 
NanoDrop ND-1000 Spectrophotometer NanoDrop Technologies, Wilmington, USA 
Nano-HPLC system  Eksigent, Axel Semrau GmbH, Sprockhövel, Germany 
Odyssey Imaging System LI-COR Biosciences, Bad Homburg, Germany 
PH-Meter766 Calimatic Knick GmbH, Egelsbach, Germany 
PIPETBOY acu INTEGRA Biosciences GmbH, Fernwald, Germany 
Power Pac 200 and 300 Bio-Rad Laboratories GmbH, Munich, Germany 
Promax 2020 Platform Shaker 
Heidolph Instruments GmbH & Co. KG, Schwabach, 
Germany 
Quattro II (triple quadrupole mass spectrometer) Micromass, Manchester, UK 
Sonorex ultrasonic bath Bandelin Electronic, Berlin, Germany 
Sorvall Evolution RC Centrifuge 
Thermo Fisher Scientific, Kendro Laboratory 
Products, Hanau, Germany 
Sorvall SLC-6000 rotor 
Thermo Fisher Scientific, Kendro Laboratory 
Products, Hanau, Germany 
SpeedVac vacuum centrifuge Savant Instruments Inc., Holbrook, USA 
Steri-Cycle CO2 incubator Thermo Fisher Scientific GmbH, Ulm, Germany 
SW 60, SW 41 Ti and SW 32 Ti rotors Beckman Coulter, Fullerton, USA 
TC10 Automated Cell Counter Bio-Rad Laboratories GmbH, Munich, Germany 
Thermomixer 5436 Eppendorf AG, Hamburg, Germany 
Thermomixer comfort and compact Eppendorf AG, Hamburg, Germany 
TLA-55 rotor Beckman Coulter, Fullerton, USA 
Ultracentrifuge Optima L-90K Beckman Instruments GmbH, Munich, Germany 
Ultracentrifuge Optima LE-80K Beckman Instruments GmbH, Munich, Germany 
Ultracentrifuge Optima MAX Beckman Instruments GmbH, Munich, Germany 
Ultracentrifuge Optima TLX Beckman Instruments GmbH, Munich, Germany 
Vortex mixer Reax control 
Heidolph Instruments GmbH & Co. KG, Schwabach, 
Germany 
XCell SureLock Mini-Cell Electrophoresis System Invitrogen Ltd., Carlsbad, USA 
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6.2 Molecular biology methods 
6.2.1 Digestion of DNA with restriction enzymes 
Digestion of plasmid DNA with restriction endonucleases (New England Biolabs) was 
performed according to manufacturer’s instructions, using 2-5 µg of DNA for 
preparative, and 500 ng for control digests, at 37°C, for 1.5-3 hours. 
6.2.2 Agarose gel electrophoresis 
DNA was separated in 1% agarose gels, prepared in 1x TAE (Tris-acetate-EDTA) buffer, 
with ethidium bromide added to the final concentration of 0.5 µg/ml. Samples were 
loaded in 1x sample buffer. 1 kb DNA Ladder (New England Biolabs) was used as a 
molecular weight marker. Electrophoretic separation was performed in 1x TAE buffer at 
100 V for 30 minutes. Bands were visualized and documented using the gel 
documentation system Gel Doc 2000 (Bio-Rad). 
 
TAE buffer (50x):         
2 M Tris 
2 M acetic acid 
50 mM EDTA, pH 8.0 
 
Sample buffer (5x):   
0.25% (w/v) bromophenol blue 
0.25% (w/v) xylene cyanol FF 
30% (w/v) glycerol 
6.2.3 Extraction of DNA from agarose gels 
The DNA band of interest was cut out of the gel with a scalpel and processed using 
QIAquick Gel Extraction Kit (QIAGEN), according to manufacturer’s instructions. In the 
last step the DNA was eluted from the column with 30 µl of elution buffer (EB). 
6.2.4 Annealing of single-stranded oligonucleotides 
Complementary single-stranded oligonucleotides (0.1 pmol/µl, in water) were mixed 
together (10 µl of each), incubated at 95°C for 10 minutes, and then slowly cooled down 
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to room temperature. The annealed oligonucleotide inserts were used in a ligation 
reaction. 
6.2.5 Ligation of insert and vector 
Ligations were performed at 16°C for 1 hour with the TaKaRa DNA Ligation Kit Ver.2.1 
according to manufacturer’s instructions, using 50 ng of vector DNA, with 1:1, 1:3 and 
1:6 (or 1:10) molar ratios of vector to insert, and also without insert (vector self-ligation 
control). 
6.2.6 Transformation of plasmid DNA into Escherichia coli 
Chemocompetent Escherichia coli DH5α were mixed with DNA (an aliquot of ligation 
reaction or plasmid DNA in the case of retransformation). After a 30-minute incubation 
on ice, bacteria were subjected to a 20-second heat-shock at 37°C and further incubated 
on ice for 2 minutes, which was followed by the addition of LB (Luria-Bertani) medium 
(1% NaCl/1% tryptone/0.5% yeast extract; all w/v). Upon an 1-hour incubation at 37°C 
with shaking (600 rpm), cells were spread on LB agar plates containing appropriate 
antibiotics (100 μg/ml ampicillin or 30 μg/ml kanamycin), followed by overnight 
incubation at 37°C.   
6.2.7 Small-scale isolation of plasmid DNA 
5 ml of LB medium containing appropriate antibiotics was inoculated with a single 
colony and incubated overnight at 37°C with shaking (180 rpm). Plasmid DNA was 
isolated using the NucleoSpin Plasmid (Macherey-Nagel), according to manufacturer’s 
instructions. Concentration of the isolated DNA was determined using the NanoDrop 
ND-1000 spectrophotometer. 
Table 2 Oligonucleotides used to generate constructs utilized in this study. Nucleotides which upon 
annealing of oligonucleotides form AgeI or BamHI sticky ends are represented by lower case letters. 
Nucleotides shown in bold type encode tobacco etch virus (TEV) protease cleavage site (amino acid 
residues ENLYFQG). Nucleotides encoding the mutated residue are highlighted in red. 
. 
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6.2.8 Medium-scale isolation of plasmid DNA 
LB medium containing appropriate antibiotics was inoculated with a single colony and 
incubated overnight at 37°C with shaking (180 rpm). Plasmid DNA was isolated from 
125 ml of culture for low-copy and 40-50 ml for high-copy plasmids, with the use of the 
NucleoBond PC 100 (Macherey-Nagel) or QIAGEN Plasmid Midi (QIAGEN) kits, according 
to manufacturers’ instructions. DNA was reconstituted in water and its concentration 
and quality determined using the NanoDrop ND-1000 spectrophotometer and agarose 
gel electrophoresis. 
6.2.9 Sequencing of DNA 
The correctness of the DNA constructs was confirmed by DNA sequencing performed by 
GATC Biotech AG, Konstanz (20 µl samples, DNA concentration 30-100 ng/µl), using 
pRevTRE2 For or GFP Rev primers for pRevTRE2/GFP constructs, and standard CMV For 
primer in the case of pEGFP-N1, pmRFP-N1, or pIRES2-based constructs. 
6.3 Biochemical methods 
6.3.1 Electrophoresis in polyacrylamide gels 
Proteins were separated using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) in the Laemmli system (Laemmli, 1970). Samples (in 1x 
concentrated sample buffer) were incubated at 95°C for 5 minutes, stacked in 4% 
polyacrylamide stacking gel at 100 V, and resolved in 12% separating gel at 200 V. As 
protein molecular weight markers, Prestained SDS-PAGE Standards, Broad Range 
(Bio-Rad) or PageRuler Prestained Protein Ladder (Fermentas) were used. 
 
Sample buffer (4x):   
240 mM Tris, pH 6.8 
25% (v/v) glycerol 
8% (w/v) SDS 
0.04% (w/v) bromophenol blue 
5% (v/v) β-mercaptoethanol 
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Stacking gel:  
4% (w/v) acrylamide/bisacrylamide (37.5:1) 
125 mM Tris, pH 6.8 
0.1% (w/v) SDS 
0.075% (w/v) APS 
0.1% (v/v) TEMED  
 
Separating gel: 
12% (w/v) acrylamide/bisacrylamide (37.5:1)  
375 mM Tris, pH 8.8 
0.1% (w/v) SDS 
0.075% (w/v) APS 
0.05% (v/v) TEMED 
 
Running buffer:  
25 mM Tris, pH 8.3 
192 mM glycine 
0.1% (w/v) SDS 
 
When a good separation of a broad range of protein sizes was desirable, precast 
NuPAGE Novex 4-12% Bis-Tris Gels (Life Technologies) were used, together with 1x 
MOPS SDS Running Buffer. Samples (in 1x concentrated NuPAGE LDS Sample Buffer, 
with NuPAGE Sample Reducing Agent added) were incubated at 70°C for 10 minutes. 
Lysate samples were instead boiled at 95°C for 10 minutes, followed by a 10-minute 
incubation in an ultrasonic bath. Samples were loaded onto a gel and resolved at 200 V 
for 50-60 minutes. 
 
Samples to be analyzed by mass spectrometry were incubated at 70°C for 10 minutes in 
1x concentrated NuPAGE LDS Sample Buffer, with NuPAGE Sample Reducing Agent 
added. Pelleted TEV eluates were first incubated in 1x concentrated NuPAGE LDS 
Sample Buffer (with NuPAGE Sample Reducing Agent added) at 37°C for 30-60 minutes 
with shaking, followed by incubation at 70°C as above. Samples were partially resolved 
in precast NuPAGE Novex 10% Bis-Tris Gels (1 mm thick) at 200 V for 7-8 minutes, using 
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1x MOPS SDS Running Buffer. Before electrophoresis, the gel running chamber was 
incubated overnight in 100 mM NaOH, and subsequently rinsed with ultrapure water. 
6.3.2 Staining of polyacrylamide gels with Colloidal Coomassie 
Gels were placed in 15 cm cell culture dishes, washed 2 times for 5 minutes in ultrapure 
water on a platform shaker, and then fixed for 30-45 minutes in 2% (v/v) acetic acid/4% 
(v/v) methanol (50 ml/gel). Gels were then stained for 1.5 hours in 1x Roti-Blue (Carl 
Roth)/20% (v/v) methanol (50 ml/gel) (first 10 ml of 5x Roti-Blue and 10 ml of methanol 
were mixed and vortexed, then water was added and the solution was vortexed again). 
Gels were destained in ultrapure water. 
6.3.3 Western blotting 
After protein separation by PAGE, proteins were transferred to polyvinylidene fluoride 
(PVDF) membrane (Immobilon-FL, Millipore) by wet blotting at 100 V for 60 minutes (for 
0.75 mm and 1 mm gels) or 75 minutes (for 1.5 mm gels). 
 
Blotting buffer:  
25 mM  Tris, pH 8.4 
40 mM glycine 
20% (v/v) methanol 
 
After transfer, the membrane was blocked in 5% (w/v) milk in PBS (140 mM NaCl/2.7 
mM KCl/1.2 mM KH2PO4/10 mM Na2HPO4) for 1 hour at room temperature or overnight 
in the cold room, and then washed 2 times for 5 minutes with PBST (0.05% (w/v) 
Tween 20 in PBS) on a platform shaker. After an 1-hour incubation at room temperature 
with primary antibody (diluted in PBST containing 1.5% (w/v) bovine serum albumin, 
BSA), the membrane was washed 4 times for 4 minutes with PBST, and then incubated 
with shaking with Alexa Fluor 680 or IRDye 800CW-coupled secondary antibody (in PBST 
containing 1.5% BSA) for 30 minutes at room temperature in the dark. After 4 washes 
for 4 minutes with PBST and one with PBS, the membrane was scanned and the signals 
quantified with the use of the Odyssey Imaging System (LI-COR). 
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6.3.4 Isolation of detergent-resistant membranes (DRMs) 
A confluent 10 cm plate of HeLa or HeLa S3 cells was washed twice with cold PBS, and 
then scraped on ice with a cell scraper in 1-1.5 ml of PBS and transferred into a 
precooled Eppendorf tube. Cells were sedimented by centrifugation at 400 g at 4°C for 
3 minutes, and resuspended in 400 µl of cold MBS TX+ buffer. The cell suspension was 
incubated on ice for 45 minutes, while vortexing every 10 minutes, and then passed 10 
times through a precooled 27G needle, using a 1 ml syringe. The lysate was centrifuged 
(800 g, 4°C, 5 minutes), the supernatant collected (post-nuclear supernatant, PNS), and 
an aliquot saved for Western blotting. 350 µl of PNS was loaded on the bottom of a 
SW 60 centrifuge tube and mixed with 700 µl of OptiPrep (i.e. 60% iodixanol), resulting 
in a final concentration of 40% iodixanol. 2.35 ml of 28% iodixanol (in MBS TX+) was then 
layered on top, followed by 600 µl of MBS TX+. The gradient was centrifuged at 
35000 rpm at 4°C for 2 hours (SW 60 rotor, slow acceleration and deceleration). 
8 fractions of 500 µl each were collected from the top of the gradient. Before collecting 
the last fraction the centrifuge tube was vortexed. Equal aliquots of each fraction were 
analyzed by Western blotting. 
 
MBS TX+ buffer:   
20 mM MES, pH 6.5 
150 mM NaCl 
1% (w/v) Triton X-100 
Complete Protease Inhibitor Cocktail (EDTA-free) 
6.3.5 Disruption of human cells using nitrogen cavitation 
Cell disruption chamber (4639 Cell Disruption Vessel, Parr) was placed on ice on a 
magnetic stirrer (1400 rpm), with the collection valve closed. Suspension of HeLa S3 cells 
in homogenization buffer (HB+) was placed into the cell disruption chamber. Afterwards 
the chamber was attached to the filling hose, with the bomb inlet valve closed, and then 
the main valve was opened. The bomb inlet valve was gently opened until the desired 
pressure inside the chamber (2000 psi) was obtained. The nitrogen was allowed to 
dissolve within the cells during a 30-minute incubation, during which the bomb was 
repressurized several times in order to maintain the desired pressure level. A precooled 
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50 ml Falcon tube was placed at the base of the collection valve, which was then slowly 
opened to release the pressure and collect lysed cells. The pressure in the filling hose 
was then released by opening the bomb inlet valve. The lysate was rotated in the cold 
room to allow the foam to subside before centrifugation. Between different samples, 
the bomb was rinsed with water and then with homogenization buffer. After use the 
bomb was rinsed thoroughly with water and 70% ethanol. 
 
HB+ buffer: 
10 mM Tris, pH 7.4 
250 mM sucrose 
0.5 mM magnesium acetate 
Complete Protease Inhibitor Cocktail (EDTA-free) 
6.3.6 Immunoaffinity purification of detergent-resistant membranes 
containing SH4 domain fusion proteins 
HeLa S3 cells were grown on 10 cm plates in Dulbecco’s modiﬁed Eagle’s medium 
(DMEM). 4-5 days before immunoisolation, suspension culture was started: cells from 
6-8 plates were trypsinized and transferred to 3 l Erlenmeyer cell culture flasks 
(Corning), filling them up to 400-500 ml with Roswell Park Memorial Institute (RPMI) 
medium, so as to obtain the concentration of 5x104-1x105 cells/ml. The suspension was 
diluted after a couple of days, so as not to exceed the cell density of 8x105/ml. 
Expression of SH4-TEV-GFP fusion proteins was induced with doxycycline (1 μg/ml, 
added from a stock solution of 1000 μg/ml in PBS) for 48 hours. Cells were harvested by 
centrifugation (1500 rpm, 4°C, 15 minutes, rotor SLC-6000), washed 3 times with 50 ml 
of PBS (each centrifugation: 500 g, 4°C, 5 minutes), followed by 3 washes with HB (500 g, 
4°C, 5 minutes). Before the last centrifugation, cells were counted with trypan blue using 
a Bio-Rad TC10 automated cell counter. Pelleted cells were resuspended in HB+ at a 
density of 4-8x107 cells/ml) and disrupted by nitrogen cavitation (as described in section 
6.3.5). The lysates were subjected to differential centrifugation: at 3000 g at 4°C for 
10 minutes, followed by 2 times at 15000 g at 4°C for 10 minutes. The resulting 
post-mitochondrial supernatants (PMS) were transferred to SW 32 centrifuge tubes, 
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filled up to 38 ml with MBS buffer, and centrifuged at 28000 rpm at 4°C for 60 minutes 
(rotor SW 32 Ti).  
 
MBS buffer:   
20 mM MES, pH 6.5 
150 mM NaCl 
 
Microsomal pellets were weighed, and 1 ml of MBS TX+ was added for every 0.1 g of the 
pellet. Solubilization was carried out on ice for 60 minutes, while vortexing and pipetting 
every 10 minutes, and completed by passing 15 times through a precooled 27G needle, 
using a 1 ml syringe. Density gradients were prepared in SW 41 centrifuge tubes (1 or 2 
gradients for each cell line): 800-1350 µl of solubilized microsomes were loaded on the 
bottom of the tube and mixed with an appropriate amount of 60% iodixanol to obtain a 
final concentration of 40% iodixanol. 6.15-7.80 ml of 28% iodixanol were then layered 
on top, followed by 1.8 ml of MBS TX+. Gradients were centrifuged at 28000 rpm at 4°C 
overnight (14-16 hours, SW 41 Ti rotor, slow acceleration and deceleration). 8 fractions 
of 1.5 ml each were collected; before collecting the last fraction the centrifuge tube was 
vortexed. Protein G Dynabeads (Dynal) were washed 3 times with PBST (in a 15 ml 
Falcon tube, using Dynal MPC-1 magnet for retrieving beads), and incubated with 
affinity-purified anti-GFP antibodies (acidic fraction; Research Group Prof. Dr. Walter 
Nickel) in PBST, overnight in the cold room with rotation. The beads were then washed 2 
times with PBST and 2 times with MBS. Fractions 2 from density gradients (‘total DRMs’) 
were incubated with the washed magnetic beads for 2 hours in the cold room with 
rotation. Afterwards, the beads were washed 2 times with MBS TX and 4 times with 
MBS (each wash: a 5-minute incubation in the cold room with rotation), and then 
incubated with tobacco etch virus (TEV) protease in MBS for 3-3.5 hours in the cold 
room with rotation. Beforehand, the protease had been spun down at 55000 rpm at 4°C 
for 20 minutes (rotor TLA55). After the incubation, supernatants (i.e. TEV eluates) were 
collected, and the magnetic beads were washed 3 times with MBS. Each TEV eluate was 
transferred to 1 or 2 SW 60 tubes, which were then filled up to 4 ml with MBS, and 
centrifuged at 37200 rpm at 4°C for 1.5 hours. 
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6.3.7 Lipid mass spectrometry 
Lipid extractions were performed as described (Haag, 2010), with minor modifications: 
1.9 ml of chloroform/methanol/37% HCl (40:80:0.6, v/v/v) and x μl of sample were 
added to Teflon-sealed glass vials containing lipid standards: PC mix (13:0/13:0, 
14:0/14:0, 20:0/20:0, and 21:0/21:0), PE mix (14:1/14:1, 20:1/20:1, and 22:1/22:1), 
PS mix (14:1/14:1, 20:1/20:1, and 22:1/22:1), PG mix (14:1/14:1, 20:1/20:1, and 
22:1/22:1), PI 37:4, PA 37:4, Cer mix (14:0, 19:0 and 25:0), HexCer mix (14:0, 19:0 and 
25:0), and d6-cholesterol (CIS). PC and PI were purchased from Avanti Polar Lipids, all 
other standards were synthesized by Research Group Prof. Dr. Felix Wieland/Dr. Britta 
Brügger. Upon vortexing, water (500 μl – x μl of sample) was added. After vortexing 
again, 500 μl of chloroform and 500 μl of water were added, followed by vortexing and 
centrifugation (2000 rpm, room temperature, 2 minutes) to induce phase separation. 
The lower (chloroform) phase was transferred to a second vial, and then to both the 
aqueous phase and the chloroform phase 500 μl of chloroform and 500 μl of water were 
added, followed by vortexing and centrifugation. The chloroform phase of the second 
vial was transferred to a third vial. The chloroform phase of the first vial was transferred 
to the second vial (containing the aqueous phase), followed by re-extraction. After 
phase separation, the chloroform phase of the second vial was transferred to the third 
vial, followed by solvent evaporation by a gentle stream of argon at 37°C. Lipids were 
resuspended in 20 mM ammonium acetate in methanol. Nano-ESI-MS/MS analysis was 
performed using a Quattro II triple quadrupole mass spectrometer (Micromass), as 
described (Lorizate et al., 2013). Quantitative analyses were performed as described 
(Brügger et al., 1997; Brügger et al., 2000). Statistical significance of the differences in 
lipid composition between solubilized microsomes versus total DRMs, and total DRMs 
versus TEV eluates, was determined by a paired Student’s t-test using Prism 5 software 
(version 5.0c; GraphPad Software Inc.). 
6.3.8 Protein mass spectrometry        
6.3.8.1  Sample preparation and liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) 
Proteins were partially resolved in a precast NuPAGE Novex 10% Bis-Tris Gel and stained 
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with Colloidal Coomassie as described (sections 6.3.1 and 6.3.2, respectively). Each lane 
was cut into 3 slices of about 4 mm in length, which were then subjected to reduction 
with DTT, alkylation with iodoacetamide, and digestion with trypsin (Catrein et al., 
2005), performed with the automated system DigestPro MS (Intavis). Tryptic peptides 
were eluted from the gel slices with 50% (v/v) acetonitrile/0.1% (v/v) trifluoroacetic acid 
(TFA). The eluate was evaporated nearly to dryness using a SpeedVac vacuum 
concentrator (Savant), and diluted to 50 µl with 0.1% (v/v) TFA. 25 µl of the sample were 
analyzed by a nano-HPLC system (Eksigent) coupled to a nano-ESI-LTQ-Orbitrap mass 
spectrometer (Thermo Fisher Scientific). The sample was injected onto an Inertsil C18 
trapping column (LC Packings) using 0.1% TFA at a flow rate of 10 µl/min. Peptides were 
eluted, followed by separation on an Inertsil C18 3 µm analytical column (75 µm x 
150 mm; LC Packings) at a flow rate of 200 nl/min using a gradient of buffer A (0.1% 
(v/v) formic acid in water) and buffer B (0.1% formic acid in acetonitrile): 0-6 min, 3% B; 
6-60 min, 3-40% B; 60-65 min, 60-90% B. The column was connected to a nano-ESI 
emitter (New Objective). 1500 V were applied via liquid junction. One survey scan 
(resolution 60000) was followed by 5 information-dependent product ion scans in the 
LTQ. Only doubly and triply charged ions were selected for fragmentation. 
6.3.8.2  Protein identification 
MS/MS spectra were extracted by Mascot Daemon without grouping or smoothing and 
analyzed using Mascot software (version 2.2.04; Matrix Science; Perkins et al., 1999). 
The database was set to Swiss-Prot (taxonomy filter: Homo sapiens), the protease was 
set to trypsin, and the allowed number of missed cleavages was set to 1. Fixed 
modification was set to carbamidomethylation of cysteine. Variable modifications were 
set to: deamidation of asparagine and glutamine, and oxidation of methionine. 
Peptide and fragment mass tolerance were set to 100 ppm and 0.5 Da, respectively. 
MS/MS-based peptide and protein identifications were validated using Scaffold (version 
Scaffold_3_00_08; Proteome Software Inc.; Searle, 2010). The cut-offs in Scaffold were 
set to: 95% protein identification probability as specified by the ProteinProphet 
algorithm (Nesvizhskii et al., 2003), 95% peptide identification probability as assigned by 
the PeptideProphet algorithm (Keller et al., 2002), and a minimum of two peptides. 
Common contaminants were excluded from protein identification lists. Proteins that 
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were indistinguishable given the available mass spectrometry data were reported 
together in a group. Peptides shared between proteins were assigned to the one with 
the most evidence according to the ProteinProphet algorithm. Each protein 
identification was assigned a subcellular localization based on information available 
from the Swiss-Prot database. 
6.3.8.3  Quantification of relative protein amounts using exponentially 
modified protein abundance index (emPAI) 
Relative amounts of proteins in TEV eluates, as compared with total DRMs, were 
quantified using a label-free approach, the exponentially modified protein abundance 
index (emPAI) method (Ishihama et al., 2005). EmPAI values were calculated according 
to the equation: emPAI=10PAI–1, where PAI is the number of experimentally observed 
peptides per protein, normalized by the number of observable peptides per protein, 
PAI=nobserved/nobservable. Regarding the number of observed peptides per protein, unique 
parent ions (including different charge or modification states from the same peptide 
sequences) were counted, as this method was shown to give the best correlation 
between emPAI values and protein abundance (Ishihama et al., 2005). The number of 
observed unique parent ions (number of unique spectra) for each protein was exported 
from Scaffold 3. For each protein, the number of observable peptides in the mass range 
of 797-4060 Da was calculated using Protein Digestion Simulator (http://omics.pnl.gov/ 
software/ProteinDigestionSimulator.php), by performing in silico a tryptic digest with no 
missed cleavages of a protein database in FASTA format (composed of the identified 
proteins, exported from Scaffold 3), and filtering the resulting peptides to exclude 
peptides outside the mass spectrometer scan range. The resulting emPAI values were 
normalized by amounts of total lipid in each sample to correct for unequal protein 
amounts, based on the assumption that the lipid/protein ratio is constant. For each 
protein, enrichment factor was calculated as the ratio between normalized emPAI value 
in TEV eluate and normalized emPAI value in the respective total DRMs. For those 
proteins that were only detected in a TEV eluate (and not in the respective total DRMs), 
the missing values were replaced before normalization by minimal emPAI values 
(calculated for 1 observed unique parent ion), allowing us to calculate minimal 
enrichment factors. 
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6.3.8.4  Quantification of relative protein amounts based on integrated areas of 
LC-MS peaks 
Detection of peptide chromatographic peaks and quantification of the integrated peak 
area was performed using MaxQuant software, version 1.3.0.5 (Cox et al., 2008), 
followed by a search against the human International Protein Index database (IPI; 
version 3.68) using Andromeda, a peptide search engine integrated into the MaxQuant 
software (Cox et al., 2011). The protease was set to trypsin, the allowed number of 
missed cleavages was set to 1. Fixed modification was set to carbamidomethylation of 
cysteine. Variable modifications were set to: deamidation of asparagine and glutamine, 
and oxidation of methionine. The false discovery rate (FDR) was set to 0.05 for both 
peptides and proteins, the maximum peptide posterior error probability (PEP) to 0.01, 
the minimum peptide length was set to 7 amino acids, and the minimum score to 30. 
The ‘re-quantify’ and ‘label-free quantification’ options were enabled. For each protein 
identified in both TEV eluate and the respective total DRMs, we chose 2 or 3 peptides 
with the highest intensity in TEV eluate. For each of the peptides, ratios between their 
peak areas in TEV eluate and the respective total DRMs were calculated and then 
averaged, to obtain protein ratios. Only peptides with the Andromeda peptide score 
above 80 were taken into account. When it was possible, only peptides unique for a 
protein were used for quantification. Otherwise, also peptides shared between proteins 
were used. Shared peptides were assigned to the protein with the most evidence 
according to Scaffold 3 (section 6.3.8.2). The averaged peak area ratios were normalized 
using data on the yield of total lipid in each sample, acquired using lipid MS. 
6.4 Cell culture techniques 
6.4.1 Maintenance of human cell lines 
All cell lines were cultivated at 37°C in a humidified atmosphere containing 5% CO2. 
HeLa (human epithelial carcinoma) cells and adherently grown HeLa S3 cells (a clonal 
derivative of HeLa cell line, capable of suspension growth) were cultivated in DMEM 
containing 10% (v/v) fetal calf serum (FCS), 2 mM L-glutamine and 100 μg/ml 
penicillin/streptomycin. HeLa S3 cells were grown in suspension in RPMI medium 
containing 10% (v/v) FCS, 2 mM L-glutamine and 100 μg/ml penicillin/streptomycin, with 
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shaking (42-46 rpm). Human embryonic kidney 293T (HEK 293T) cells were cultivated in 
DMEM containing the above supplements, on collagen-coated plates (rinsed with a 
200 µg/ml collagen R solution in water and then left to dry). Adherent cells were 
passaged twice a week: the cultivation medium was aspirated, cells were washed with 
PBS and detached by trypsin/EDTA for 10 minutes at 37°C. Fresh medium was added, 
and then an aliquot of the cells was transferred into a new culture dish containing fresh 
growth medium. 
6.4.2 Freezing and thawing of cells 
Cells were grown on 10 cm dishes until subconfluency. Growth medium was discarded, 
cells washed with PBS and detached by incubation with trypsin/EDTA. Fresh medium 
was added, the cells were pelleted at 200 g for 3 minutes and resuspended in freezing 
medium at the density of 2-5x106 cells/ml, transferred into cryo tubes, and placed at 
-80°C for 24-48 hours in a Styrofoam box. For long-term storage, cells were transferred 
to liquid nitrogen. 
 
Freezing medium: 
20% (v/v) FCS 
10% (v/v) DMSO 
2 mM L-glutamine 
100 μg/ml penicillin/streptomycin 
in DMEM 
 
To thaw the cells, cryo tubes were incubated in a water bath at 37°C, and the thawed 
cell suspension transferred to prewarmed growth medium. Cells were then sedimented 
and resuspended in fresh prewarmed growth medium. After thawing, the cells were 
incubated for a week with Mycoplasma Removal Agent (MP Biomedicals), added to the 
culture medium at the dilution of 1:100. 
6.4.3 Generation of stable cell lines 
6.4.3.1  Retroviral transduction 
Stable cell lines were generated with the use of Moloney murine leukemia virus 
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(MMLV)-based retroviral expression vector pRevTRE2. The gene of interest (sequence 
encoding HASPB SH4-TEV-GFP, HASPB SH4 Δpal-TEV-GFP or Yes SH4-TEV-GFP) was 
located between the MMLV 5′ and 3′ long terminal repeat sequences (LTRs), under the 
control of the tetracycline-response element (TRE), to which reverse 
tetracycline-controlled transactivator protein, rtTA (Tet-On transactivator) can bind. The 
retroviral expression vector was transiently cotransfected into a packaging cell line, HEK 
293T, together with pVPack-GP (gag-pol-expressing vector) and pVPack-Eco 
(env-expressing vector), with the use of MBS Mammalian Transfection Kit (Stratagene), 
according to manufacturer’s instructions. Viral RNA encoding the gene of interest was 
encapsidated, and the resulting virus particles released into the supernatant of 
transfected cells. The supernatant was used to infect target cells - HeLa or HeLa S3 
MCAT-TAM2 cells, i.e. stably expressing receptor for retroviral particles, mouse cationic 
amino acid transporter 1 (MCAT1), and an optimized form of rtTA protein (rtTA-M2). 
Upon infection of target cells, the viral RNA is reverse transcribed and the cDNA of 
interest, flanked by the LTRs, integrated into the host DNA.  
6.4.3.2  Fluorescence-activated cell sorting 
Upon infection of target cells, cells expressing the SH4-TEV-GFP fusion protein in a 
doxycycline-dependent manner were selected by several rounds of sorting using 
FACSAria flow cytometer (Becton Dickinson). During the first round of sorting (‘bright 
sort’), transduced cells were selected (i.e. GFP-positive upon cultivation in the presence 
of doxycycline). After seven days, the second round of sorting was performed (‘dark 
sort’), selecting for cells that do not express the fusion protein without having been 
induced with doxycycline (i.e. GFP-negative cells upon cultivation in the absence of 
doxycycline). And finally, the third round isolated pools and single cells, in which the 
transduced fragment was integrated into the genome (GFP-positive cells after induction 
with doxycycline). 
 
Cells were cultivated in the presence of 1 μg/ml doxycycline for 48 hours (‘bright sort’), 
or in its absence (‘dark sort’), washed with PBS and detached by a 10-minute incubation 
at 37°C with Cell Dissociation Buffer (Invitrogen). Upon the addition of cold culture 
medium, cells were sedimented, resuspended in sorting medium, and the cell 
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suspension was passed through a 45 μm cell strainer cap into FACS tubes, which were 
then kept on ice until sorting. Cells were sorted into 6-well plates (pools during the three 
sorts) or 96-well plates (single cells during the last sort) containing DMEM or filtered 
conditioned DMEM (in the case of HeLa S3 cells). 
 
Sorting medium: 
5% (v/v) Cell Dissociation Buffer 
0.2% (v/v) FCS 
2 mM L‐glutamine 
100 μg/ml penicillin/streptomycin 
in DMEM 
6.4.4 Flow cytometry 
To characterize the inducibility and levels of expression of SH4-TEV-GFP fusion proteins, 
stable HeLa and HeLa S3 cell lines were cultivated for 16 hours without or in the 
presence of 4 μg/ml doxycycline. The cells were washed once with PBS, detached in 
PBS/0.5 mM EDTA for 15 minutes at 37°C, and analyzed using flow cytometry 
(FACSCalibur, Becton Dickinson) by detecting GFP fluorescence. Autofluorescence of 
HeLa and HeLa S3 MCAT-TAM2 cells was adjusted to 101. 
6.4.5 Transient transfection 
6.4.5.1  Transient transfection with DNA using FuGENE HD transfection reagent 
One day before transfection, HeLa cells were plated in 8-well Lab-Tek Chambered 
Coverglass plates, 2-well Lab-Tek II Coverglass plates, or 35 mm glass bottom dishes 
(µ-Dish 35 mm, ibidi). On the day of transfection, plasmid DNA was diluted in Opti-MEM 
medium to a concentration of 2 μg DNA/100 μl Opti-MEM. 6 μl of FuGENE were then 
added directly into the medium containing the diluted DNA. The transfection complex 
was mixed, incubated for 15 minutes at room temperature, and added to the cells 
(106 μl for a 35 mm plate). To prepare transfection complexes for smaller culture 
vessels, the quantity of all components was changed according to the surface area. 
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6.4.5.2  Transient transfection with DNA using jetPRIME transfection reagent 
HeLa cells to be processed for electron microcopy (HeLa HASPB SH4-mCherry), were 
plated one day before transfection in 6 cm plates in DMEM with L-glutamine, without 
antibiotics. On the day of transfection, plasmid DNA (pIRES2-EGFP/Arf1 WT or Q71L) 
was diluted to a concentration of 1.5 μg DNA/500 μl jetPRIME buffer. 10 μl of jetPRIME 
were then added directly into the buffer containing the diluted DNA. The transfection 
complex was mixed, incubated for 10 minutes at room temperature, and added to the 
cells. Beforehand, the medium was changed to DMEM with L-glutamine and doxycycline 
(2 μg/ml), without antibiotics. 15 hours after transfection the cells were fixed, followed 
by further processing for electron microscopy, as described in section 6.5.2 
6.4.5.3  Transient transfection with siRNA using Oligofectamine transfection 
reagent 
HeLa cells to be imaged by live-cell confocal microscopy were plated one day before 
transfection in 8-well Lab-Tek Chambered Coverglass plates or 2-well Lab-Tek II 
Coverglass plates. For one well of a 2-well Lab-Tek II, 100 pmol of siRNA (2 μl of a 50 μM 
stock) was added to 88 μl of Opti-MEM, and mixed with 24 μl of 5x diluted 
Oligofectamine (in Opti-MEM). The siRNAs used were: Silencer Negative Control siRNA 
#1 (Ambion) and COPB1 Silencer Pre-designed siRNA (ID: 24546, Ambion). After a 
20-minute incubation at room temperature, the transfection mixture was added to the 
cells. Beforehand, the medium was changed to Opti-MEM. 3-4 hours upon transfection, 
the medium was replaced by normal growth medium. To prepare transfection 
complexes for 8-well Lab-Tek Chambered Coverglass plates, the quantity of all 
components was changed according to the surface area. The cells were imaged by 
live-cell confocal microscopy 45-48 hours upon siRNA transfection, as described in 
section 6.5.1. 
 
HeLa cells to be processed for electron microcopy (HeLa HASPB SH4-TEV-GFP, clone 4), 
were transfected with siRNAs in 6-well plates (2 wells per condition). For each condition, 
600 pmol of siRNA (scrambled or COPB1) was added to 528 μl of Opti-MEM, and mixed 
with 72 μl of 5x diluted Oligofectamine. After a 20-minute incubation at room 
temperature, the transfection mixture was added to the cells. Beforehand, the medium 
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was changed to Opti-MEM. 3-4 hours upon transfection, the medium was replaced by 
normal growth medium. 24 hours after transfection, the cells were cells split onto two 
6 cm plates, induced with doxycycline (2 μg/ml) and incubated for additional 24 hours, 
fixed, and processed for electron microscopy, as described in section 6.5.2. 
6.4.6 Drug treatment 
Synthesis of HASPB SH4-TEV-GFP, HASPB SH4 Δpal-TEV-GFP, Yes SH4-TEV-GFP or HASPB 
SH4-mCherry in stable cell lines, or HASPB SH4-mCherry transiently expressed from 
pRevTRE2/HASPB SH4-mCherry in HeLa MCAT-TAM2 cells, was induced with 1-4 µg/ml 
doxycycline for 16-48 hours. To inhibit protein synthesis, cells were incubated in the 
presence of 100 μg/ml cycloheximide for 4 hours. To inhibit guanine nucleotide 
exchange factors (GEFs) responsible for activating Arf1, cells were incubated in the 
presence of 0.1 μg/ml brefeldin A (BFA) for 16 hours. 
6.5 Microscopy 
6.5.1 Fluorescence microscopy 
6.5.1.1  Live-cell confocal fluorescence microscopy 
Cells were grown in 8-well Lab-Tek Chambered Coverglass plates, 2-well Lab-Tek II 
Coverglass plates, or 35 mm glass bottom dishes. Live-cell laser scanning confocal 
imaging was performed using a Zeiss LSM 510 laser scanning confocal microscope 
(Zeiss), using either a Plan-Neofluar 40x/1.3 Oil DIC or a Plan-Apochromat 63x/1.4 Oil 
DIC objective. GFP fluorescence was excited using a 488 nm argon laser, and detected 
through a band pass (BP) 505-530 nm emission filter. The fluorescence of mCherry or 
mRFP was excited using the 563 nm laser line of a helium-neon laser, and detected using 
a long pass (LP) 560 nm emission filter. 12-bit, 1240x1240 pixel Z stack images were 
collected using the 40x objective, with the Z-step size of 0.43 µm. 
6.5.1.2  Intensity quantification of sum intensity projections of Z stack images 
Intensity quantification was performed using ImageJ software (version 1.43u). First, Z 
stacks of confocal images were projected into a single image using a sum intensity 
projection (excluding the top- and bottom-most Z stack images). For quantification of 
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subcellular localization (perinuclear or intracellular accumulation), first the perinuclear 
or intracellular signal was quantified: the sum of the pixel values (integrated density) of 
perinuclear or intracellular area was measured, and then integrated density of 
background area of the same size was subtracted. Total signal per cell was quantified by 
measuring the integrated density of the whole cell, and subtracting from it the 
integrated density of background area of the same size. Perinuclear or intracellular 
accumulation per cell was quantified by dividing the perinuclear or intracellular signal by 
the total signal for a cell, and expressing it as a percentage. Statistical significance of the 
differences in the magnitude of perinuclear or intracellular accumulation was 
determined by an unpaired Student’s t-test using Prism 5 software.  
6.5.2 Immunogold electron microscopy 
6.5.2.1  Fixation 
Cells were grown on 6 cm dishes. Some of the growth medium was removed, leaving 
2 ml per plate. An equal volume of fixative 1 was then added directly to the medium, 
followed by incubation for 1 hour at room temperature. The plates were drained, 
covered with 2 ml of fixative 2, wrapped with Parafilm and stored overnight at 4°C. 
 
Fixative 1:        
0.2 M PHEM buffer       
8% (w/v) formaldehyde       
0.2% (w/v) glutaraldehyde 
 
Fixative 2:  
0.1 M PHEM buffer 
4% (w/v) formaldehyde 
 
0.4 M PHEM buffer:  
240 mM PIPES    
100 mM HEPES 
8 mM MgCl2 
40 mM EGTA 
pH 6.9 
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6.5.2.2  Embedding in gelatin and sucrose infiltration 
After fixation, cells were washed twice with PBS for 5 minutes, and then with 
PBS/50 mM glycine for 10 minutes. Cells were then covered with 2 ml of 1% (w/v) 
gelatin in PBS, scraped, transferred to 1.5 ml Eppendorf tubes and spun down for 
5 minutes at 1000 rpm (Centrifuge 5804, Eppendorf). Supernatant was removed, the 
cells resuspended in 1 ml of 10-12% (w/v) gelatin in PBS (kept at 37°C to prevent it from 
solidifying), and incubated for 15 minutes at 37°C. Cells were spun down at full speed 
(14000 rpm) for 5 minutes, most of the supernatant removed, and the tube placed on 
ice for 45 minutes to 1.5 hours to solidify the gelatin. The pellet was pulled out of the 
tube with the use of a flattened toothpick, cut into slices, and then into cubic blocks of 
about 1 mm3. The blocks were transferred to tubes containing 2.3 M sucrose in PBS, and 
rotated overnight in the cold room. Flat-head aluminum rivets were prepared to be 
mounting pins: the surface of the head was roughened by scratching with a file, and 
then the pins were cleaned with 100% ethanol. The next day, the blocks were taken out 
from the sucrose, and the excess of it removed, leaving enough to glue the blocks onto 
the mounting pins. The blocks mounted onto pins were frozen in liquid nitrogen. 
6.5.2.3  Trimming and cutting 
The block was trimmed with the use of EM UC6/EM FC6 cryo-ultramicrotome (Leica), 
equipped with a diamond trimming knife (Diatome), at a chamber temperature of -90°C. 
First, the face of the block was trimmed at a speed of 10 mm/s, with the section 
thickness of 250 nm and the ionizer on. Sections were picked up with the ionizer 
switched off, with a droplet of pick-up solution (1:1 mixture of 2.3 M sucrose in PBS and 
2% (w/v) methyl cellulose) in a wire loop, transferred onto a glass slide, and stained with 
methylene blue to confirm the presence of cells in the sections using light microscopy. 
Afterwards, the block was trimmed at one side: 250 nm sections were cut at a speed of 
10-80 mm/s. When the sectioning was deep enough (60 μm), the other side was 
trimmed. Then, the specimen was turned 90°, and the procedure was repeated until all 
sides of the block were trimmed, forming a rectangular 60 μm high prism. Cutting was 
performed at -110°C using a diamond cutting knife (Diatome), at a speed of 0.8-1 mm/s, 
with the section thickness of 60 nm and the ionizer on. Ribbon formed by cut ultrathin 
sections was kept straight during sectioning with the use of a brush (cat whisker glued to 
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the tip of a wooden stick). Sections were picked up with the ionizer switched off, with a 
droplet of pick-up solution in a wire loop. The wire loop with sections was withdrawn 
from the cryochamber and after thawing, the sections were placed on copper grids 
(Hexagonal 100 meshes, Plano), which had been coated with a Pioloform (polyvinyl 
butyral) film and a thin (2.6 nm) layer of carbon. 
6.5.2.4  Double immunogold labeling of cryosections 
Grids with sections were placed on gelatin plates (2% (w/v) gelatin/0.001% (w/v) NaN3 in 
PBS), sections facing gelatin, and incubated at 37°C for 20 minutes. The grids were then 
washed on PBS at 37°C for 20 minutes, and blocked with 0.8% (w/v) BSA/0.1% (w/v) fish 
skin gelatin/50 mM glycine in PBS at room temperature for 30 minutes, by floating the 
grids on drops of the blocking solution placed on a Parafilm sheet, sections facing the 
drop. Then, the grids were labeled with primary antibody diluted in blocking solution, at 
room temperature for 30 minutes (7-10 μl for each grid). Afterwards, the grids were 
washed 5 times for 5 minutes in PBS/50 mM glycine at room temperature, and 
incubated for 30 minutes with 10 nm or 15 nm protein A-gold at room temperature, 
fixed for 5 minutes in 1% (w/v) glutaraldehyde in PBS, and washed in PBS/50 mM glycine 
as above. Then, the grids were blocked again, incubated with the second primary 
antibody, washed in PBS/50 mM glycine, incubated with 15 nm or 10 nm protein A-gold, 
fixed, and washed in PBS/50 mM glycine. After 10 washes for 2 minutes in water at 
room temperature, and 3 washes in water on ice, grids were passed over two drops of 
3:2 mixture of 4% (w/v) watery uranyl acetate and 2% (w/v) methyl cellulose on ice, and 
then incubated on fresh drops of this mixture for 10 minutes on ice. The grids were 
picked up with wire loops, the excess of uranyl acetate/methyl cellulose was removed 
by slowly dragging along filter paper, and the grids were dried at room temperature for 
10 minutes.  
6.5.2.5  Electron microscopy 
Grids were examined at 60 kV using a Zeiss EM10 electron microscope. Pictures were 
taken at magnifications of 20000-50000x. 
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7 Appendix 
7.1 Abbreviations 
1D-PAGE 1-dimensional polyacrylamide gel electrophoresis 
ADP adenosine diphosphate 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
APs adaptor protein complexes 
APT1 acyl-protein thioesterase 1  
Arf1 ADP‐ribosylation factor 1 
ATP adenosine triphosphate 
BARS brefeldin A-ribosylated substrate 
BASP1 brain acid soluble protein 1 
BCR B cell antigen receptor  
BFA brefeldin A 
BHK baby hamster kidney 
Bis-Tris bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane 
BP band pass 
BSA bovine serum albumin 
cAMP cyclic adenosine monophosphate 
cDNA complementary DNA 
Cer ceramide 
CHO Chinese hamster ovary  
Chol cholesterol 
COP coat protein complex 
COPB coat protein complex, subunit β 
CR cysteine-rich 
Da dalton 
DHHC aspartate-histidine-histidine-cysteine  
DIC differential interference contrast 
DMEM Dulbecco’s modiﬁed Eagle’s medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DRMs detergent-resistant membranes  
DTT dithiothreitol  
EDTA ethylenediaminetetraacetic acid 
EGFP enhanced green fluorescent protein 
EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
emPAI exponentially modified protein abundance index  
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eNOS endothelial nitric-oxide synthase 
ER endoplasmic reticulum 
ERGIC ER-Golgi intermediate compartment 
ESI electrospray ionization 
FACS fluorescence-activated cell sorting 
FCS fetal calf serum  
FRET fluorescence resonance energy transfer 
GalCer galactosylceramide 
GAP GTPase-activating protein 
GBF1 Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 
GDP guanosine diphosphate 
GEF guanine nucleotide exchange factor 
GFP green fluorescent protein 
GGAs Golgi-localized, γ-ear-containing, Arf-binding proteins 
GlcCer glucosylceramide 
GlcNH2 glucosamine  
GPCR G protein-coupled receptor 
GPI glycosyl-phosphatidylinositol 
GPI-APs glycosyl-phosphatidylinositol-anchored proteins 
GPMVs giant plasma membrane vesicles  
GTP guanosine triphosphate 
GTPase guanosine triphosphatase 
HA influenza hemagglutinin  
HASP hydrophilic acylated surface protein 
HASPB hydrophilic acylated surface protein B 
HB homogenization buffer 
HEK human embryonic kidney 
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
HexCer hexosylceramide 
HIV-1 human immunodeficiency virus type 1 
HPLC high-performance liquid chromatography 
IQGAP1 Ras GTPase-activating-like protein 
IRES internal ribosome entry site 
LB Luria-Bertani 
LC liquid chromatography 
ld liquid-disordered 
LDS lithium dodecyl sulfate 
lo liquid-ordered  
LP long pass 
LSM laser scanning microscope 
LTQ linear trap quadrupole 
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LTRs long terminal repeat sequences 
m/z mass-to-charge ratio 
Man mannose 
MARCKS myristoylated alanine‐rich C kinase substrate 
MBS MES buffered saline 
MBS  modified bovine serum 
MCAT1 mouse cationic amino acid transporter 1 
MDCK Madin-Darby canine kidney 
MES 2-(N-morpholino)ethanesulfonic acid (MES) 
MMLV Moloney murine leukemia virus  
MOPS 3-(N-morpholino)propanesulfonic acid 
MVD mevalonate-diphospho-dehydrogenase 
mRFP monomeric red fluorescent protein 
MS mass spectrometry 
MS/MS  tandem mass spectrometry 
MβCD methyl-β-cyclodextrin  
NMT N-myristoyltransferase 
NONO non-POU domain-containing octamer-binding protein 
NRK normal rat kidney 
ns not significant 
PA phosphatidic acid 
PAGE polyacrylamide gel electrophoresis 
PAI protein abundance index 
PAT palmitoyl transferase 
PBS phosphate buffered saline 
PBST PBS/Tween 
PC phosphatidylcholine 
PE phosphatidylethanolamine 
PI phosphatidylinositol 
PIP phosphatidylinositol-4-monophosphate 
PIP2 phosphatidylinositol-4,5-bisphosphate  
PIPES piperazine-N,N′-bis(2-ethanesulfonic acid) 
PKD protein kinase D 
PLAP placental alkaline phosphatase 
PMS post-mitochondrial supernatant 
PMS plasma membrane spheres  
PNS post-nuclear supernatant 
PP protein phosphatase 
ppm parts per million 
PrP prion protein 
PS phosphatidylserine 
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psi pound-force per square inch 
PVDF polyvinylidene fluoride  
RNA  ribonucleic acid 
RNAi RNA interference 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute medium 
rtTA reverse tetracycline-controlled transactivator protein  
SD standard deviation 
SDS sodium dodecyl sulfate  
SFKs Src family kinases 
SFPQ splicing factor, proline- and glutamine-rich 
SH Src homology 
SILAC stable isotope labeling with amino acids in cell culture 
siRNA small interfering RNA 
SM sphingomyelin 
SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptor  
SP spacer 
SR signal recognition particle receptor 
SRP signal recognition particle 
TAE Tris-acetate-EDTA 
TCR T cell antigen receptor  
TEV tobacco etch virus 
TFA trifluoroacetic acid 
TGN trans-Golgi network 
TRE tetracycline-response element 
Tris tris(hydroxymethyl)aminomethane 
VP4 viral protein 4 
VSVG vesicular stomatitis virus glycoprotein 
VTCs vesicular-tubular clusters 
WT wild-type 
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7.2 Supplementary tables 
 
Table S1 Proteins identified in Triton X-100 detergent-resistant membranes (DRMs) isolated from HeLa 
S3 cells. DRMs were isolated from HeLa S3 cell lines stably expressing HASPB SH4-TEV-GFP or Yes SH4-
TEV-GFP, as well as from HeLa S3 cells that do not express any SH4-TEV-GFP fusion protein. Listed are 
proteins identified in at least 3 out of 6 DRM preparations (2 experiments for the 3 cell lines each, 
considered together), their Swiss-Prot accession numbers, primary subcellular localizations, and 
classification according to Foster et al., 2003. Not identified - the protein was not identified in Triton X-100 
DRMs from HeLa cells in the study by Foster et al.; unable to quantify - the protein was identified in Triton 
X-100 DRMs from HeLa cells in the study by Foster et al., but was not quantifiable and thus was not 
classified.  
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Table S1 - continued. Caption on page 117. 
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Table S1 - continued. Caption on page 117. 
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Table S1 - continued. Caption on page 117.  
 
*all four proteins were identified with exactly the same set of peptides 
 
 
Caption for table on pages 121-122. Table S2 Proteins identified in TEV eluates. TEV eluates were 
obtained following the procedure for immunoisolation of detergent-resistant membranes (DRMs) 
containing SH4 domain fusion proteins. As input for immunoprecipitation served Triton X-100 DRMs 
prepared from HeLa S3 cell lines stably expressing HASPB SH4-TEV-GFP (denoted as HASPB), Yes SH4-
TEV-GFP (denoted as Yes), or from control cells (HeLa S3 cells that do not express any SH4-TEV-GFP fusion 
protein, denoted as ctrl). Listed are proteins that were identified in at least one TEV eluate sample (i.e. 
that met criteria for positive protein identification specified in Scaffold 3: 95% protein identification 
probability, 95% peptide identification probability, and a minimum of two peptides), their Swiss-Prot 
accession numbers, primary subcellular localizations, and classification according to Foster et al., 2003. 
The table lists also the number of unique spectra identified in TEV eluates and in total DRMs, the number 
of observable peptides, normalized exponentially modified protein abundance index (emPAI) values, and 
enrichment factors of proteins in TEV eluates relative to the respective total DRMs, calculated by the 
comparison of normalized emPAI values, and by the comparison of integrated areas of liquid 
chromatography-mass spectrometry (LC-MS) peptide peaks between samples. For those proteins that 
were only detected in a TEV eluate (and not in the respective total DRMs), the missing emPAI values were 
replaced by minimal emPAI values (calculated for 1 observed unique spectrum; underlined), allowing us to 
calculate minimal enrichment factors (underlined). Blank cells indicate normalized emPAI values that 
equal zero (no unique spectra identified), or they indicate that enrichment factors could not be calculated. 
Not identified - the protein was not identified in Triton X-100 DRMs from HeLa cells in the study by Foster 
et al.; unable to quantify - the protein was identified, but was not quantifiable and thus was not classified. 
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Table S2 Caption on page 120. 
                 
*all four proteins were identified with exactly the same set of peptides; emPAI values were calculated for each one of them and then 
averaged 
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Table S2 - continued. Caption on page 120. 
 
*all four proteins were identified with exactly the same set of peptides; emPAI values were calculated for each one of them and then 
averaged  
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